ug20210930_10q.htm

0001171843-21-007870.txt : 20211112 0001171843-21-007870.hdr.sgml : 20211112 20211112100429 ACCESSION NUMBER: 0001171843-21-007870 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211112 DATE AS OF CHANGE: 20211112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNITED GUARDIAN INC CENTRAL INDEX KEY: 0000101295 STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844] IRS NUMBER: 111719724 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-10526 FILM NUMBER: 211400843 BUSINESS ADDRESS: STREET 1: 230 MARCUS BLVD CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: 631-273-0900 MAIL ADDRESS: STREET 1: P.O. BOX 18050 STREET 2: 230 MARCUS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: UNITED INTERNATIONAL RESEARCH INC DATE OF NAME CHANGE: 19820422 10-Q 1 ug20210930_10q.htm FORM 10-Q ug20210930_10q.htm

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2021 .

☐	TRANSITION REPORT PURSUANT TO 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________

COMMISSION FILE NUMBER: 1-10526

UNITED-GUARDIAN, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware	11-1719724
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

230 Marcus Boulevard, Hauppauge, New York 11788

(Address of Principal Executive Offices)

(631) 273-0900

(Registrant’s Telephone Number)

N/A

(Former name, former address, and former fiscal year, if changed since last report)

Cover Page 1 of 2

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, $0.10 par value per share	UG	NASDAQ Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☑	Smaller reporting company ☑
	Emerging growth company ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes ☐ No ☑

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date:

As of November 1, 2021, the Registrant had issued and outstanding 4,594,319 shares of Common Stock, $.10 par value per share ("Common Stock").

Cover Page 2 of 2

UNITED-GUARDIAN, INC.

INDEX TO FINANCIAL STATEMENTS

	Page No.
Part I. FINANCIAL INFORMATION

Item 1 - Condensed Financial Statements (unaudited unless indicated otherwise)

Statements of Income - Three and Nine Months ended September 30, 2021 and 2020	2

Balance Sheets – September 30, 2021 (unaudited) and December 31, 2020 (audited)	3-4

Statements of Changes in Stockholders’ Equity – Three and Nine Months ended September 30, 2021 and 2020	5

Statements of Cash Flows - Nine Months ended September 30, 2021 and 2020	6

Notes to Condensed Financial Statements	7-15

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations	15-22

Item 3 - Quantitative and Qualitative Disclosures About Market Risk	22

Item 4 - Controls and Procedures	23

Part II. OTHER INFORMATION

Item 1 - Legal Proceedings	23

Item 1A - Risk Factors	23-24

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3 - Defaults Upon Senior Securities	24

Item 4 - Mine Safety Disclosures	24

Item 5 - Other Information	24

Item 6 - Exhibits	25

Signatures	25

1 of 25

UNITED-GUARDIAN, INC.

Part I. FINANCIAL INFORMATION

ITEM 1. Condensed Financial Statements

STATEMENTS OF INCOME
(UNAUDITED)

	THREE MONTHS ENDED SEPTEMBER 30,					NINE MONTHS ENDED SEPTEMBER 30,
	2021			2020		2021		2020

Net Sales	$	3,179,746		$	2,336,360	$	10,268,592	$	8,613,918

Costs and expenses:
Cost of sales		1,320,509			974,763		4,180,912		3,634,528
Operating expenses		458,582			493,204		1,428,721		1,520,114
Research and development		130,742			114,836		349,053		331,134
Total costs and expenses		1,909,833			1,582,803		5,958,686		5,485,776
Income from operations		1,269,913			753,557		4,309,906		3,128,142

Other Income:
Investment income		38,747			38,932		124,147		131,318
Net (loss) gain on marketable securities		(25,108	)		113,248		40,419		143,832
Total other income		13,639			152,180		164,566		275,150
Income before provision for income taxes		1,283,552			905,737		4,474,472		3,403,292

Provision for income taxes		267,046			188,205		932,240		708,842
Net Income	$	1,016,506		$	717,532	$	3,542,232	$	2,694,450

Earnings per common share (Basic and Diluted)	$	0.22		$	0.16	$	0.77	$	0.59

Weighted average shares – basic and diluted		4,594,319			4,594,319		4,594,319		4,594,319

See Notes to Condensed Financial Statements

2 of 25

UNITED-GUARDIAN, INC.

BALANCE SHEETS

ASSETS

	SEPTEMBER 30, DECEMBER 31,
	2021		2020
	(UNAUDITED)		(AUDITED)
Current assets:
Cash and cash equivalents	$	691,921	$	591,444
Marketable securities		8,893,454		7,591,381
Accounts receivable, net of allowance for doubtful accounts of $27,296 at September 30, 2021 and $14,017 at December 31, 2020		1,930,183		1,387,698
Inventories, net		1,287,234		1,415,773
Prepaid expenses and other current assets		159,361		161,208
Prepaid income taxes		---		99,107
Total current assets		12,962,153		11,246,611

Net property, plant, and equipment:
Land		69,000		69,000
Factory equipment and fixtures		4,571,364		4,516,335
Building and improvements		2,853,718		2,848,585
Total property, plant, and equipment		7,494,082		7,433,920
Less: Accumulated depreciation		6,830,549		6,760,255
Total property, plant, and equipment, net		663,533		673,665

TOTAL ASSETS	$	13,625,686	$	11,920,276

See Notes to Condensed Financial Statements

3 of 25

UNITED-GUARDIAN, INC.

BALANCE SHEETS

(continued)

LIABILITIES AND STOCKHOLDERS’ EQUITY

	SEPTEMBER 30, DECEMBER 31,
	2021		2020
	(UNAUDITED)		(AUDITED)
Current liabilities:
Accounts payable	$	87,158	$	31,800
Accrued expenses and other current liabilities		1,542,760		1,363,457
Income taxes payable		57,614		---
Dividends payable		19,685		19,028
Total current liabilities		1,707,217		1,414,285

Deferred income taxes		227,203		151,684

Commitments and contingencies

Stockholders’ equity:
Common stock (at $.10 par value) (10,000,000 shares authorized; 4,594,319 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively)		459,432		459,432
Retained earnings		11,231,834		9,894,875
Total stockholders’ equity		11,691,266		10,354,307

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	13,625,686	$	11,920,276

See Notes to Condensed Financial Statements

4 of 25

UNITED-GUARDIAN, INC.

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021

	Common stock				Retained
	Shares		Amount		Earnings			Total
Balance, January 1, 2021	4,594,319	$	459,432	$	9,894,875		$	10,354,307
Net income	---		---		1,181,202			1,181,202
Balance, March 31, 2021	4,594,319	$	459,432	$	11,076,077		$	11,535,509
Net income	---		---		1,344,524			1,344,524
Dividends declared and paid ($0.48 per share)	---		---		(2,204,616	)		(2,204,616	)
Dividends declared, not paid ($0.48 per share)	---		---		(657	)		(657	)
Balance, June 30, 2021	4,594,319	$	459,432	$	10,215,328		$	10,674,760
Net income	---		---		1,016,506			1,016,506
Balance, September 30, 2021	4,594,319	$	459,432	$	11,231,834		$	11,691,266

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2020

	Common stock				Retained
	Shares		Amount		Earnings			Total
Balance, January 1, 2020	4,594,319	$	459,432	$	10,173,466		$	10,632,898
Net income	---		---		790,307			790,307
Balance, March 31, 2020	4,594,319	$	459,432	$	10,963,773		$	11,423,505
Net income	---		---		1,186,611			1,186,611
Dividends declared and paid ($0.42 per share)	---		---		(1,928,969	)		(1,928,969	)
Dividends declared, not paid ($0.42 per share)	---		---		(645	)		(645	)
Balance, June 30, 2020	4,594,319	$	459,432	$	10,220,770		$	10,680,202
Net income	---		---		717,532			717,532
Balance, September 30, 2020	4,594,319	$	459,432	$	10,938,302		$	11,397,734

See Notes to Condensed Financial Statements

5 of 25

UNITED-GUARDIAN, INC.

STATEMENTS OF CASH FLOWS
(UNAUDITED)

	NINE MONTHS ENDED
	SEPTEMBER 30,
	2021			2020
Cash flows from operating activities:
Net income	$	3,542,232		$	2,694,450
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		106,928			121,669
Net gain on marketable securities		(40,419	)		(143,832	)
Gain on sale of asset		(14,799	)		---
Allowance for doubtful accounts		13,279			(992	)
Deferred income taxes		75,519			(155,127	)
(Increase) decrease in operating assets:
Accounts receivable		(555,764	)		815,808
Inventories		128,539			(327,542	)
Prepaid expenses and other current assets		1,847			4,185
Prepaid income taxes		99,107			38,969
Increase (decrease) in operating liabilities:
Accounts payable		55,358			(30,460	)
Accrued expenses and other current liabilities		179,303			29,233
Income taxes payable		57,614			---
Dividends payable		---			(124,657	)
Net cash provided by operating activities		3,648,744			2,921,704

Cash flows from investing activities:
Acquisition of property, plant and equipment		(81,997	)		(25,437	)
Proceeds from sale of marketable securities		1,832,829			3,802,205
Purchases of marketable securities		(3,094,483	)		(4,932,754	)
Net cash used in investing activities		(1,343,651	)		(1,155,986	)

Cash flows from financing activities:
Dividends paid		(2,204,616	)		(1,928,969	)
Net cash used in financing activities		(2,204,616	)		(1,928,969	)
Net increase (decrease) in cash and cash equivalents		100,477			(163,251	)

Cash and cash equivalents at beginning of period		591,444			1,048,311
Cash and cash equivalents at end of period	$	691,921		$	885,060

Supplemental disclosure of cash flow information:
Taxes paid	$	700,000		$	825,000
Supplemental disclosure of non-cash items:
Dividends payable	$	657		$	645
Trade-in received from sale of asset	$	29,000		$	---

See Notes to Condensed Financial Statements

6 of 25

UNITED-GUARDIAN, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)

1. Nature of Business

United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients, pharmaceuticals, medical products and proprietary specialty industrial products. The Company’s research and development department modifies, refines, and expands the uses for existing products for additional uses and markets. It also develops new products using natural and environmentally friendly raw materials, which is important to many of the Company's cosmetic customers.

2. Basis of Presentation

Interim condensed financial statements of the Company are prepared in accordance with United States Generally Accepted Accounting Principles (“US GAAP”) for interim financial information, pursuant to the requirements for reporting on Form 10-Q and Regulation S-X. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for the fair presentation of financial statements for the interim periods have been included. The results of operations for the three and nine months ended September 30, 2021 (also referred to as the "third quarter of 2021" and the "first nine months of 2021", respectively) are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2021. The interim unaudited condensed financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2020.

3. Impact of Coronavirus (COVID-19)

While the coronavirus pandemic (“pandemic”) continues to impact the Company’s operations, the substantial impact the pandemic had on Company sales in 2020 significantly lessened in the first nine months of 2021. The current impact is coming primarily from supply chain disruptions, which have resulted in increased packaging and shipping costs, and increases in the cost of some raw materials, although it has not significantly affected the ability of the Company to obtain raw materials. It has, however, resulted in some shipping delays due to the shortage of truck drivers. The Company has been able to maintain production throughout the pandemic.

Sales of the Company’s non-pharmaceutical medical products (“medical products”) had also been negatively impacted by the pandemic in 2020, but those impacts have lessened as well in the first three quarters of 2021. Sales of the Company’s pharmaceutical products were not impacted by the pandemic in 2020 or in the first nine months of 2021.

There continues to be some uncertainty in regard to the future impact of the pandemic on the Company’s operations or financial results and as a result it is difficult for the Company to provide an accurate estimate or projection as to what the future impact of the pandemic will be on the Company’s future operations or financial results. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic.

7 of 25

4. Use of Estimates

In preparing financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead.

5. Cash and Cash Equivalents

For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At September 30, 2021 and December 31, 2020, approximately $806,000 and $653,000 exceeded the FDIC limit.

6. Revenue Recognition

The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales.

The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (‘VA”), rebates in connection with the Company’s current participation in Medicare programs and its past participation in Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period.

During 2021 and 2020, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell its product at a discounted price. In addition, during 2020, the Company also participated in the Medicaid Drug Rebate Program (MDRP), which required the Company to pay a significant rebate to the various states where Renacidin was provided to Medicaid patients, as well as the Section 340B Drug Pricing Program (340B), which required the Company to sell Renacidin at a deeply discounted price. Due to the overly burdensome nature of the Medicaid rebates, and the deeply discounted pricing associated with the 340B Program, the Company terminated its participation in the MDRP and the 340B Programs, effective December 31, 2020. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized.

8 of 25

The Company recognizes revenue from sales of its cosmetic ingredients, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer and the Company’s performance obligation is satisfied. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment, which is when the risk of loss and responsibility for the shipment passes to the customer, and the performance obligation of the Company is satisfied. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on prior year historical returns of its pharmaceutical products.

The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party.

Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimated allowances and actual activity.

The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. As of September 30, 2021 and December 31, 2020, the allowance for doubtful accounts receivable was $27,296 and $14,017, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken.

At September 30, 2021, the Company recorded an advance payment from one of its customers in the amount of $128,636. The related performance obligation associated with this payment had not been satisfied as of the balance sheet date. The deferred revenue related to this payment is included in accrued expenses and other current liabilities.

The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitles them to distribution and service-related fees. The Company records distribution fees and estimates distribution fees as offsets to revenue.

9 of 25

Disaggregated sales by product class are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Cosmetic Ingredients	$	1,578,650	$	550,177	$	5,065,022	$	3,358,956
Pharmaceutical		1,216,747		1,232,586		3,509,235		3,463,738
Medical		343,884		517,036		1,580,657		1,683,682
Industrial products		40,465		36,561		113,678		107,542
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

The Company’s cosmetic ingredients are marketed worldwide by five marketing partners, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 16% of the Company’s total sales in the third quarter of 2021 were to customers located outside of the United States, compared with approximately 22% in the third quarter of 2020. For the nine months ended September 30, 2021, approximately 21% of the Company’s total sales were to customers located outside of the United States, compared with approximately 20% for the nine months ended September 30, 2020.

Disaggregated sales by geographic region are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
United States*	$	2,670,515	$	1,819,084	$	8,115,145	$	6,887,726
Other countries		509,231		517,276		2,153,447		1,726,192
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

* Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 76% of its sales of the Company’s products in the third quarter of 2021 were to foreign customers compared with 69% for the same period in 2020, with China representing approximately 29% of those foreign sales in the third quarter of 2021, compared with approximately 30% in the third quarter of 2020.

For the nine months ended September 30, 2021 approximately 72% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 35% of ASI’s sales of the Company’s products, as compared with approximately 69% of ASI’s sales going to customers in other countries for the nine months ended September 30, 2020, with China accounting for approximately 33% of ASI’s sales of the Company’s products during that period.

7. Marketable Securities

Marketable securities include investments in fixed income and equity mutual funds, and U.S. Government securities with maturities greater than 3 months, all of which are reported at their fair values.

10 of 25

The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows:

	Three months ended September 30,					Nine months ended September 30,
	2021			2020		2021			2020
Net (losses) gains recognized during the period on marketable securities	$	(25,108	)	$	113,248	$	40,419		$	143,832
Less: Net gains recognized during the period on marketable securities sold during the period		---			25,062		112,180			29,918
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date	$	(25,108	)	$	88,186	$	(71,761	)	$	113,914

The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows:

• Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets.

The following tables summarize the Company’s investments:

September 30, 2021(Unaudited)

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	8,050,443	$	8,172,762	$	122,319
Equity and other mutual funds		610,542		720,692		110,150
Total equity securities		8,660,985		8,893,454		232,469
Total marketable securities	$	8,660,985	$	8,893,454	$	232,469

11 of 25

December 31, 2020(Audited)

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

Investment income is recognized when earned and consists principally of interest income from fixed income mutual funds and U.S. Treasury Bills and dividend income from equity and other mutual funds. Realized gains and losses on sales of investments are determined on a specific identification basis.

Proceeds from the sale and redemption of marketable securities amounted to $1,832,829 for the nine months ended September 30, 2021, which included realized gains of $112,180. Proceeds from the sale and redemption of marketable securities amounted to $3,802,205 for the nine months ended September 30, 2020, which included realized gains of $29,918.

8. Inventories

	September 30,		December 31,
	2021		2020
	(UNAUDITED)		(AUDITED)
Inventories consist of the following:
Raw materials	$	434,178	$	415,415
Work in process		75,716		59,258
Finished products		777,340		941,100
Total inventories	$	1,287,234	$	1,415,773

Inventories are valued at the lower of cost and net realizable value. Cost is determined using the average cost method, which approximates cost determined by the first-in, first-out (“FIFO”) method. Finished product inventories at September 30, 2021 and December 31, 2020 are stated net of a reserve of $35,000 for slow moving and obsolete inventory. At September 30, 2021 and December 31, 2020, the Company had allowances of $311,311 and $302,713 respectively, for possible outdated material returns, which is included in accrued expenses.

As of the date of this report, the Covid-19 pandemic has not materially impacted the valuation of the Company’s finished products, work in process, or raw material inventories, but increases in the cost of some raw materials may impact future inventory valuations.

9. Income Taxes

The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of September 30, 2021 and December 31, 2020, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and nine months ended September 30 comprises the following:

12 of 25

	Three months ended September 30,					Nine months ended September 30,
	2021			2020		2021		2020
Provision for federal income taxes - current	$	340,981		$	81,323	$	856,621	$	863,819
Provision for state income taxes - current		---			---		100		150
(Benefit from) provision for federal income taxes – deferred		(73,935	)		106,882		75,519		(155,127	)
Total provision for income taxes	$	267,046		$	188,205	$	932,240	$	708,842

10. Defined Contribution Plan

The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions after one year of employment.

The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The Company accrued $87,000 in contributions to the DC Plan for the nine months ended September 30, 2021, and $108,750 for the nine months ended September 30, 2020. For the first three quarters of 2021 and 2020, the Company did not make any discretionary contributions to the DC Plan.

11. Related-Party Transactions

During the three months ended September 30, 2021, there were no payments made to related parties. For the nine months ended September 30, 2021, the Company made payments of $9,500, to the accounting firm PKF O’Connor Davies (“PKF”) for accounting and tax services. For the three and nine months ended September 30, 2020, the Company made payments of $9,500 for accounting and tax services to Bonamassa, Maietta and Cartelli, LLP “Bonamassa”). Lawrence Maietta, a partner at PKF O’Connor Davies, and previously a partner at Bonamassa before its combination with PKF, is a director of the Company.

12. Other Information

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

13 of 25

	September 30, 2021		December 31, 2020
Accrued Expenses	(Unaudited)		(Audited)

Bonuses	$	237,000	$	210,000
Distribution fees		362,315		325,792
Payroll and related expenses		225,328		245,521
Reserve for outdated material		311,311		302,713
Company 401(k) contribution		87,000		---
Deferred revenue		128,636		---
Audit fee		57,875		50,500
Annual report expenses		46,462		63,432
Sales rebates		51,428		149,346
Other		35,405		16,153
Total Accrued Expenses	$	1,542,760	$	1,363,457

13. Recent Accounting Pronouncements

On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, “Simplifying the Accounting for Income Taxes.” This standard modified ASU 740 and simplifies the accounting for income taxes. The Company has determined that these modifications did not have an impact on its financial statements.

In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. In November 2019, the FASB amended the effective date of implementation of this standard for smaller reporting companies. The new effective date is for fiscal years beginning after December 15, 2022. The Company is currently evaluating if this pronouncement will have a potential impact on its financial statements.

14. Concentrations of Credit Risk

Customer concentration - Accounts receivable potentially exposes the Company to concentrations of credit risk. The Company monitors the amount of credit it allows each of its customers, using the customer’s prior payment history and its overall credit worthiness to determine how much credit to allow or whether any credit should be given at all. It is the Company’s policy to discontinue shipments to any customer that is substantially past due on its payments. The Company sometimes requires payment in advance from customers whose payment record is questionable. As a result of its monitoring of the outstanding credit allowed for each customer, as well as the fact that the majority of the Company’s sales are to customers whose satisfactory credit and payment record has been established over a long period of time, the Company believes that its credit risk from accounts receivable is low.

For the three months ended September 30, 2021, one of the Company’s marketing partners, and three of its distributors, together accounted for 86% of the Company’s sales and 79% of its outstanding accounts receivable at September 30, 2021. During the three months ended September 30, 2020, the same marketing partner and three distributors together were responsible for 79% of the Company’s sales and 70% of its outstanding accounts receivable at September 30, 2020.

14 of 25

For the nine months ended September 30, 2021, one of the Company’s marketing partners, and three of its distributors, together accounted for 79% of the Company’s sales and 79% of its outstanding accounts receivable at September 30, 2021. During the nine months ended September 30, 2020, the same marketing partner and three distributors together were responsible for 79% of the Company’s sales and 70% of its outstanding accounts receivable at September 30, 2020.

15. Earnings Per Share

Basic earnings per share is computed by dividing net income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if the potentially dilutive securities had been issued.

Per share basic and diluted earnings were $0.22 and $0.16 for the three months ended September 30, 2021 and 2020, respectively, and $0.77 and $0.59 for the nine months ended September 30, 2021 and 2020, respectively.

17. Subsequent Events

The Company has evaluated all subsequent events from the date of the financial statements through the date of this report. As detailed in Note 3 above, the Covid-19 pandemic is an ongoing event, and as such, the Company is not able to project or quantify the impact of this event on the Company’s future operations and financial results.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

Statements made in this Form 10-Q which are not purely historical are forward-looking statements with respect to the goals, plans, objectives, intentions, expectations, financial condition, results of operations, future performance and business of the Company. Forward-looking statements may be identified by the use of such words as “believes”, “may”, “will”, “should”, “intends”, “plans”, “estimates”, “anticipates”, or other similar expressions.

Forward-looking statements involve inherent risks and uncertainties, and important factors (many of which are beyond the Company’s control) could cause actual results to differ materially from those set forth in the forward-looking statements. In addition to those specific risks and uncertainties set forth in the Company's reports currently on file with the SEC, some other factors that may affect the future results of operations of the Company are: the development of products that may be superior to those of the Company; changes in the quality or composition of the Company's products; lack of market acceptance of the Company's products; the Company's ability to develop new products; general economic or industry conditions; changes in intellectual property rights; changes in interest rates; new legislation or regulatory requirements; conditions of the securities markets; the Company's ability to raise capital; changes in accounting principles, policies or guidelines; financial or political instability; acts of war or terrorism; and other economic, competitive, governmental, regulatory and technical factors that may affect the Company's operations, products, services and prices. Accordingly, results achieved may differ materially from those anticipated as a result of such forward-looking statements, and those statements speak only as of the date they are made. The Company does not undertake, and specifically disclaims, any obligation to update any forward-looking statements to reflect events or circumstances occurring after the date of such statements.

15 of 25

OVERVIEW

The Company is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing, and marketing of cosmetic ingredients, personal and health care products, pharmaceuticals, non-pharmaceutical medical products, and proprietary specialty industrial products. All the products that the Company markets, with the exception of Renacidin, are produced at its facility in Hauppauge, New York. Renacidin, a urological product, is manufactured for the Company by an outside contract manufacturer.

The Company’s most important product line is its Lubrajel® line of water-based moisturizing and lubricating gels, which are used primarily as ingredients in cosmetic products but are also used in medical products, primarily catheter lubricants. These products are marketed worldwide for cosmetic uses by five marketing partners, each handling a different geographic area, with the largest being U.S.-based ASI. The Company’s research and development department is actively working on the development of new products to expand the Company’s line of cosmetic ingredients. Many of the Company’s products use proprietary manufacturing processes, and the company relies primarily on trade secret protection to protect its intellectual property.

Renacidin and the Company’s other pharmaceutical product, Clorpactin®, which is also used primarily in urology, are distributed through full-line drug wholesalers and marketed only in the United States. Those wholesalers in turn sell the products to pharmacies, hospitals, nursing homes, and other long-term care facilities, and to government agencies, primarily the VA. The Company promotes Renacidin through internet advertising as well as a dedicated website. Clorpactin and some of the Company’s other products are marketed through information provided on the Company’s corporate website.

The Company’s non-pharmaceutical medical products, such as its catheter lubricants, as well as its specialty industrial products, are sold directly to end-users, or to contract manufacturers utilized by those end-users. They are also available for marketing on a non-exclusive basis by the Company’s marketing partners.

While the Company does have competition in the marketplace for some of its products, particularly its cosmetic ingredients, some of its pharmaceutical and medical products have some unique characteristics, and do not have direct competitors. However, these products may have indirect competition from other products that are not marketed as direct competitors to the Company’s products but may have functionality or properties that are similar to the Company’s products.

16 of 25

The Company recognizes revenue when all of the following requirements are satisfied: (a) persuasive evidence of a sales arrangement exists; (b) products are shipped, which is when the performance obligation is satisfied and title and risk of loss pass to the customers; and (c) collections are reasonably assured. An allowance for returns, based on historical experience, is taken as a reduction of sales within the same period the revenue is recognized.

Over the years the Company has been issued many patents and trademarks, and it still maintains several registered trademarks, the two most important of which are “Lubrajel” and “Renacidin.” However, regarding the protection of the Company’s proprietary formulations and manufacturing technology, the Company currently relies primarily on trade secret protection rather than patent protection due to the current disclosure requirements needed to obtain patents, the limited protection they afford, and the difficulty and expense of enforcing them globally. However, the Company may, from time to time, seek patent protection when it believes it would be in the Company’s best interest to do so. All of the Company’s previously issued patents have expired; however, the Company does not believe that the expiration of those patents has had, or will have, any material impact on its sales, since in recent years protection for the Company’s most important products has been based on trade secrets and proprietary manufacturing methods rather than patent protection.

As discussed in Note 3 above, while the coronavirus pandemic (“pandemic”) continues to impact the Company’s operations, the substantial impact the pandemic had on Company sales in 2020 significantly lessened in the first nine months of 2021. While the Company believes that sales of its cosmetic ingredients are still being negatively impacted, the sales situation has improved substantially, and the current impact is coming more from increased shipping costs and some higher raw material costs, which could have some impact on the Company’s profit margins in upcoming quarters. It has also been more difficult to ship the Company’s products due to a shortage of truck drivers, which has meant some delays in having orders picked up, even though the Company’s products are available to ship. The shortage of truck drivers is expected to continue into 2022, and the Company is doing what it can to minimize the impact on customers by making customers aware of some longer lead times due to the trucking issues.

Sales of the Company’s non-pharmaceutical medical products (referred to herein as “medical products”) had also been negatively impacted by the pandemic in 2020, but those impacts have lessened as well in the first three quarters of 2021. There continues to be some impact on shipping schedules, with the shipping of some customers’ orders being delayed due to the shortage of truck drivers.

Sales of the Company’s pharmaceutical products were not impacted by the pandemic in 2020 or in the first nine months of 2021. However, the Company is beginning to see a small decrease in gross pharmaceutical sales due the termination of its participation in the Medicaid Drug Rebate Program. Please refer to the pharmaceutical sales section of the MD&A for further discussion.

The pandemic has not significantly affected the ability of the Company to obtain raw materials, but it has made some of those materials more expensive, which could impact the Company’s gross profit margins in the future. The Company has been able to maintain production throughout the pandemic.

There continues to be uncertainty in regard to the future impact of the pandemic on the Company’s operations or financial results. While the impact on the Company’s’ sales lessened considerably in 2021, the Company is still unable to provide an accurate estimate or projection as to what the future impact of the pandemic will be on the Company’s future operations or financial results. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic.

17 of 25

CRITICAL ACCOUNTING POLICIES

As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, the discussion and analysis of the Company’s financial condition and results of operations are based on its financial statements, which have been prepared in conformity with US GAAP. The preparation of those financial statements required the Company to make estimates and assumptions that affect the carrying value of assets, liabilities, revenues and expenses reported in those financial statements. Those estimates and assumptions can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition, concentration of credit risk, investments, inventory, and income taxes. Since December 31, 2020, there have been no significant changes to the assumptions and estimates related to those critical accounting policies.

The following discussion and analysis covers material changes in the financial condition of the Company since the year ended December 31, 2020, and a comparison of the results of operations for the third quarter of 2021 and 2020 and the first nine months of 2021 and 2020. This discussion and analysis should be read in conjunction with "Management's Discussion and Analysis or Plan of Operation" included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020. All references in this quarterly report to “sales” or “Sales” shall mean “net sales” unless specifically identified as “gross sales”.

The Company recognizes revenue from sales of its cosmetic ingredients, medical products, and industrial products when all of the following requirements are satisfied: (a) a valid purchase order has been received; (b) products are shipped, which is when the performance obligation is satisfied and title and risk of loss pass to the customers; and (c) future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective.

The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. The Company assumes responsibility for the shipment arriving at its intended destination. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on gross sales of its pharmaceutical products.

RESULTS OF OPERATIONS

Sales

Sales for the third quarter of 2021 increased by $843,386 (36%) when compared with the same period in 2020. Sales for the first nine months of 2021 increased by $1,654,674 (19%) as compared with the corresponding period in 2020. The increase in sales for both the third quarter of 2021 and the first nine months of 2021 were attributable to changes in sales of the following product lines:

18 of 25

Cosmetic ingredients:

Third quarter sales: For the third quarter of 2021, the Company’s sales of cosmetic ingredients increased by $1,028,473 (187%) when compared with the third quarter of 2020. The increase in third quarter sales was due primarily to an increase of $983,466 (308%) in sales of the Company’s personal care products to ASI. Based on information provided to the Company by ASI, the Company’s marketing partner in China, the increase was due primarily to the continued increase in shipments of the Company’s products to China by ASI.

Third quarter sales to the Company’s four other marketing partners, as well as to four small direct cosmetic ingredient customers, had a net increase of $45,007 (20%) compared with the third quarter of 2020. Sales to the Company’s marketing partners in the United Kingdom, Switzerland, and Italy increased by a total of $117,448 (112%), while sales to the Company’s marketing partner in France and four of the Company’s small direct cosmetic customers decreased by $72,440 (58%).

Nine-month sales: For the first nine months of 2021, the Company’s sales of cosmetic ingredients increased by $1,706,066 (51%) when compared with the same period in 2020. This increase was due primarily to an increase of $1,486,664 (58%) in shipments of the Company's extensive line of cosmetic ingredients to ASI. The primary reason for the increase in sales to ASI during the first nine months of 2021 was the same as for the increase in sales in the third quarter, which was due to the continued increase in shipments of the Company’s products to China by ASI.

Cosmetic ingredient sales for the first nine months of the year to the Company’s four other marketing partners, as well as to the four direct cosmetic customers, increased by a net of $219,402 (28%) compared with the same period in 2020. Nine-month sales to the Company’s marketing partners in the UK, France, Switzerland and Italy increased by $240,985 (32%), while sales to the four direct cosmetic customers, decreased by $21,583 (52%).

The Company believes that the increase in sales of the Company’s cosmetic ingredients in Europe was, at least in part, the result of global pandemic conditions improving.

Pharmaceuticals:

Because there are fees, rebates and allowances associated with sales of the Company’s two pharmaceutical products, Renacidin and Clorpactin, discussion of the Company’s pharmaceutical sales includes references to both gross sales (before fees, rebates and allowances) and net sales (after fees, rebates and allowances). Gross sales of the Company’s pharmaceutical products for the three- and nine-month periods ended September 30, 2021 decreased by $92,405 (6%) and $178,459 (4%), respectively, compared with the corresponding periods in 2020. These decreases were due primarily to decreases of $86,751 (6%) and $232,493 (6%) in gross sales of Renacidin for the three- and nine-month periods, respectively, ended September 30, 2021. The decrease in both periods was primarily due to the Company having terminated its participation in the Medicaid Drug Rebate Program on December 31, 2020. Gross sales of the Company’s other pharmaceutical product, Clorpactin, decreased by $5,654 (3%) for the three-month period ended September 30, 2021, and increased by $54,034 (12%) for the nine-month period ended September 30, 2021, compared with the corresponding periods in 2020. The Company believes the changes in sales of Clorpactin were most likely due to normal fluctuations in the sales of that product.

19 of 25

The decrease in gross sales for the three- and nine-month periods ended September 30, 2021 was partially offset by a decrease in pharmaceutical related fees, rebates and allowances of $76,567 (22%) and $223,957 (23%), respectively. The decreases in these fees, rebates and allowances were the result of the Company’s termination of its participation in the Medicaid Drug Rebate Program at the end of 2020. Due to the overly burdensome nature of the Medicaid rebates that the Company had to pay under this program, the Company determined that it was no longer profitable for the Company to continue to participate. Accordingly, on October 30, 2020 the Company informed the Centers for Medicare & Medicaid Services (CMS) of its intention to terminate its Medicaid Drug Rebate Agreement and its participation in the Medicaid Program, effective December 31, 2020. As the Company had anticipated, the discontinuation of its participation in this program resulted in the loss of some Renacidin sales, but that loss was more than offset by the elimination of the rebate payments, which resulted in an increase in net income from these sales.

As sales of the Company’s pharmaceutical products fluctuate there is typically a corresponding direct relationship in the related allowances, such as for distribution fees, VA chargebacks, Medicare rebates, sales rebates and discounts, outdated material returns, and Medicaid rebates. For the three- and nine-month periods ended September 30, 2021, these allowances decreased by $74,116 (21%) and $226,932 (24%), respectively, compared with the same periods in 2020. This was primarily the result of the Company’s termination of its participation in the Medicaid Program. Although the Company will no longer be incurring Medicaid-related rebate costs, it will continue to incur costs related to other allowances, including Medicare rebates, distribution fees, chargebacks on VA sales, and outdated material returns.

Medical (non-pharmaceutical) products:

Sales of the Company’s medical products decreased by $173,152 (33%) for the third quarter of 2021, and by $103,025 (6%) for the nine-month period ended September 30, 2021, compared with the same periods in 2020. The decrease in medical product sales for both periods was primarily attributable to the loss of one of the Company’s domestic medical product customers in 2020 due to the reformulation of its product, combined with a decrease in orders from two of the Company’s larger direct medical product customers located in China and India, which was partially the result of shipping delays. The Company believes that the other decreases were related to the impact of the coronavirus pandemic.

Industrial products:

Sales of the Company's industrial products increased by $3,904 (11%) and by $6,136 (6%) for the three and nine months, respectively, ended September 30, 2021, when compared with the corresponding periods in 2020.The increase in sales for both the three- and nine-month periods was primarily due to an increase in orders from one of the Company’s industrial product customers located in the northeastern United States.

20 of 25

Cost of Sales

Cost of sales as a percentage of sales remained the same for both the third quarter of 2021 and 2020, at 42%. For the first nine months of 2021, cost of sales as a percentage of sales decreased from 42% in 2020 to 41% in 2021.

Operating Expenses

Operating expenses, consisting of selling and general and administrative expenses, decreased by $34,622 (7%) for the third quarter of 2021, and by $91,393 (6%) for the first nine months of 2021, compared with the same periods in 2020. The decreases in operating expenses for both periods were primarily attributable to a decrease in payroll and payroll related expenses, combined with the recognition of a gain on the sale of an asset during the third quarter of 2021. Operating expenses are expected to remain relatively consistent for the remainder of the year.

Research and Development Expenses

Research and development expenses increased by $15,906 (14%) for the third quarter of 2021, and by $17,919 (5%) for the first nine months of 2021 compared with the same periods in 2020. The increases for both periods were mainly due to an increase in payroll and payroll related expenses.

Investment Income

Investment income decreased by $185 (less than 1%) for the third quarter of 2021 compared with the third quarter of 2020 and decreased by $7,171 (5%) for the first nine months of 2021 compared with the same period in 2020. The decreases in both periods were due to decreased interest income from U.S. Treasury Bills combined with lower dividend income from stock and bond mutual funds compared to the same periods in 2020.

Net gain on marketable securities

Net gain on marketable securities decreased by $138,356 (122%) for the third quarter of 2021 compared with the same period in 2020. The reason for the decrease was a combination of 1) a decrease in realized gains on the sales of marketable securities during the third quarter of 2021 compared with the same period in 2020 (the Company did not sell any securities during the equivalent three-month period in 2021) and 2) in the third quarter of 2020, the market began its recovery after the significant market value decline that occurred in the first and second quarters of 2020 due to the pandemic.

For the first nine months of 2021, the net gain on marketable securities decreased by $103,413 (72%) compared with the same period in 2020. The primary reason for the decrease was that during the first nine months of 2020 the Company recognized unrealized gains of $113,914, which represented the upward market adjustment due to improved economic conditions after the significant decline that occurred during the first part of the year due to the pandemic.

21 of 25

Provision for income taxes

The Company's effective income tax rate was approximately 21% for the first nine months of 2021 and 2020. The Company’s tax rate is expected to remain at 21% for the current fiscal year.

LIQUIDITY AND CAPITAL RESOURCES

Working capital increased from $9,832,326 at December 31, 2020 to $11,254,936 at September 30, 2021, an increase of $1,422,610. The current ratio decreased from 8.0 to 1 at December 31, 2020 to 7.6 to 1 at September 30, 2021. The increase in working capital was primarily due to an increase in marketable securities and accounts receivable. The decrease in the current ratio was primarily due to decreases in prepaid income taxes and inventory, and an increase in accrued expenses.

The Company believes that its working capital is, and will continue to be, sufficient to support its operating requirements for at least the next twelve months. The Company does not expect to incur any significant capital expenditures for the remainder of 2021.

The Company generated cash from operations of $3,648,744 and $2,921,704 for the nine months ended September 30, 2021 and September 30, 2020, respectively. The increase in cash from operations was primarily due to an increase in net income.

Cash used in investing activities for the nine-month period ended September 30, 2021 was $1,343,651. Cash used in investing activities for the nine-month period ended September 30, 2020 was $1,155,986. The increase was primarily due to an increase in the purchases of property, plant and equipment, and an increase in fixed income mutual fund purchases.

Cash used in financing activities was $2,204,616 and $1,928,969 for the nine months ended September 30, 2021 and September 30, 2020, respectively. The increase was due to an increase in the dividends paid per share from $0.42 per share in 2020 to $0.48 per share in 2021.

The Company expects to continue to use its cash to make dividend payments, to purchase marketable securities, and to take advantage of other opportunities that may arise that are in the best interest of the Company and its shareholders.

OFF BALANCE-SHEET ARRANGEMENTS

The Company has no off balance-sheet transactions that have, or are reasonably likely to have, a current or future effect on the Company’s financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

CONTRACTUAL OBLIGATIONS AND COMMITMENTS

The information to be reported under this item is not required of smaller reporting companies.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

The information to be reported under this item is not required of smaller reporting companies.

22 of 25

Item 4. CONTROLS AND PROCEDURES

	(a)	DISCLOSURE CONTROLS AND PROCEDURES

		The Company’s management, including its Principal Executive Officer and Chief Financial Officer, has evaluated the design, operation, and effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. Based upon the evaluation performed by the Company’s management, including its Principal Executive Officer and Chief Financial Officer, it was determined that, as of the end of the period covered by this quarterly report, the Company’s disclosure controls and procedures were effective in providing reasonable assurance that information required to be disclosed in the reports filed or submitted pursuant to the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding disclosures.

	(b)	CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

		The Company's Principal Executive Officer and Chief Financial Officer have determined that, during the period covered by this quarterly report, there were no changes in the Company's internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting. They have also concluded that there were no significant changes in the Company’s internal controls after the date of the evaluation.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

NONE

ITEM 1A. RISK FACTORS

IMPACT OF COVID-19

As a result of the pandemic, global consumer purchases of cosmetic products declined significantly in 2020, which resulted in a significant decline in sales of the Company’s cosmetic ingredients in the last three quarters of 2020. Sales of these products were particularly impacted in China, where prior to the pandemic the Company had significant sales. This resulted in an excess inventory situation in China, which severely impacted sales, and which was not resolved until the end of 2020.

23 of 25

The impact of the pandemic on the Company’s sales significantly lessened in 2021. Sales of its cosmetic ingredients in the first quarter of 2021 were slightly lower than in the first quarter of 2020 because the pandemic didn’t begin to significantly impact sales of the Company’s cosmetic ingredients until the latter part of the second quarter of 2020, and that impact continued into the first quarter of 2021.

With the pandemic beginning to abate, sales in the third quarter of 2021 increased significantly compared with the third quarter of 2020. While it is still too soon to predict what the impact of the pandemic will be on future sales, it is likely that there will continue to be some impact on sales of the Company’s cosmetic ingredients, but to a lesser degree than in 2020. The current impact of the pandemic is coming primarily from supply chain disruptions, which have resulted in increased packaging and shipping costs, and increases in the cost of some raw materials. Due to the uncertainty surrounding the duration of the pandemic and its impact in the various countries in which the Company does business, it is difficult for the Company to provide an accurate estimate or projection as to what the future impact of the pandemic will be on the Company’s future operations or financial results. Although the pandemic had some impact on sales of some of the Company’s medical products, it has not impacted sales of its pharmaceutical products.

The Company does not anticipate that the pandemic will affect its ability to obtain raw materials and maintain production, and the Company has multiple sources for many of its raw materials. However, some of the Company’s raw materials have experienced price increases, which could impact the manufacturing cost of some of the Company’s products in the future. The Company may or may not be able to pass along and recoup these price increases, depending on the product. The Company expects to be able to maintain production levels sufficient to ship orders on a timely basis, but the timely shipping of the Company’s products may continue to be impacted by the current shortage of truck drivers.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

NONE

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

NONE

ITEM 4. MINE SAFETY DISCLOSURES

NONE

ITEM 5. OTHER INFORMATION

NONE

24 of 25

ITEM 6. EXHIBITS

	31.1*	Certification of Ken Globus, President and Principal Executive Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

	31.2*	Certification of Andrea Young, Chief Financial Officer of the Company, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

	32*	Certifications of the Principal Executive Officer and Chief Financial Officer of the Company, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

	101.INS*	Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.
	101.SCH*	Inline XBRL Taxonomy Extension Schema Document.
	101.CAL*	Inline XBRL Taxonomy Extension Calculation Linkbase Document.
	101.DEF*	Inline XBRL Taxonomy Extension Definition Linkbase Document.
	101.LAB*	Inline XBRL Taxonomy Extension Label Linkbase Document.
	101.PRE*	Inline XBRL Taxonomy Extension Presentation Linkbase Document.
	104*	Cover Page Interactive Data File (Embedded within the inline XBRL document and included in Exhibit 101.1).

	* Filed herewith

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 9, 2021	UNITED-GUARDIAN, INC.
	(Registrant)


	By:	/S/ KEN GLOBUS
		Ken Globus
		President


	By:	/S/ ANDREA YOUNG
		Andrea Young
		Chief Financial Officer

25 of 25

EX-31.1 2 ex_303096.htm EXHIBIT 31.1 ex_303096.htm

EXHIBIT 31.1

SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Ken Globus, certify that:

	1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended September 30, 2021;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2021	By:	/s/ Ken Globus
		Ken Globus
		President and Principal Executive Officer

EX-31.2 3 ex_303097.htm EXHIBIT 31.2 ex_303097.htm

EXHIBIT 31.2

SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER

I, Andrea Young, certify that:

	1.	I have reviewed this Quarterly Report of United-Guardian, Inc. on Form 10-Q for the three-month period ended September 30, 2021;

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2021	By:	/s/ Andrea Young
		Andrea Young
		Chief Financial Officer

EX-32 4 ex_303098.htm EXHIBIT 32 ex_303098.htm

EXHIBIT 32

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of United-Guardian, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2021, as filed with the Securities and Exchange Commission (the "Report"), I, Ken Globus, President and Principal Executive Officer of the Company, and I, Andrea Young, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(i) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 9, 2021	By:	/s/ Ken Globus
		Ken Globus
		President & Principal Executive Officer

	By:	/s/ Andrea Young
		Andrea Young
		Chief Financial Officer

EX-101.SCH 5 ug-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Statements of Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Impact of Coronavirus (COVID-19) link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Use of Estimates link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Cash and cash Equivalents link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Inventories link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Defined Contribution Plan link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Related-party Transactions link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 12 - Other Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 13 - Recent Accounting Pronouncements link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 14 - Concentrations of Credit Risk link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 16 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 6 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 7 - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 8 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 9 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 12 - Other Information (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Cash and cash Equivalents (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 6 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 6 - Revenue Recognition - Disaggregated Revenue (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Marketable Securities - Summary of Investments (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 8 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 9 - Income Taxes - Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 10 - Defined Contribution Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 11 - Related-party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 12 - Other Information - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 14 - Concentrations of Credit Risk (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 6 ug-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 ug-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 ug-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Note 6 - Revenue Recognition ug_AccruedDistributionFeesCurrent Distribution fees Accrued distribution fees Use of Estimates Disclosure [Text Block] The entire disclosure for use of estimates. Note 7 - Marketable Securities Note 8 - Inventories Note 9 - Income Taxes Note 12 - Other Information Note 6 - Revenue Recognition - Disaggregated Revenue (Details) Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) Note 7 - Marketable Securities - Summary of Investments (Details) Income Tax Disclosure [Text Block] Note 8 - Inventories - Summary of Inventories (Details) Discretionary Contributions Vesting Each Additional Year [Member] Represents discretionary contributions vesting each additional year of employment. Note 9 - Income Taxes - Provision for Income Taxes (Details) Discretionary Contributions Vesting at Two Years [Member] Represents discretionary contributions vesting after two years of employment. Note 12 - Other Information - Summary of Accrued Expenses (Details) Notes To Financial Statements us-gaap_LiabilitiesCurrent Total current liabilities Notes To Financial Statements [Abstract] Equity securities, unrealized gain Accumulated amount of unrealized gain (loss) on equity securities. Trade-in received from sale of asset Amount of trade-in received from sale of assets. PKF [Member] Represents information pertaining to PKF O'Connor Davies. Proceeds from sale of marketable securities Proceeds from Sale and Maturity of Marketable Securities, Total Equity securities, cost Fixed Income Securities [Member] Depreciation and amortization us-gaap_AssetsCurrent Total current assets Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date Common stock (at $.10 par value) (10,000,000 shares authorized; 4,594,319 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively) us-gaap_PaymentsToAcquireMarketableSecurities Purchases of marketable securities Retirement Plan Name [Axis] Financial Instruments [Domain] Retirement Plan Name [Domain] Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Financial Instrument [Axis] Common stock, par value (in dollars per share) Accrued expenses and other current liabilities Total Accrued Expenses Income taxes payable Dividends payable Accounts payable Product and Service [Axis] Product and Service [Domain] us-gaap_AccruedBonusesCurrent Bonuses us-gaap_OtherAccruedLiabilitiesCurrent Other Prepaid income taxes us-gaap_AccruedSalariesCurrent Payroll and related expenses us-gaap_PolicyTextBlockAbstract Accounting Policies Geographical [Axis] Geographical [Domain] Impact of Coronavirus (COVID-19) [Text Block] The entire disclosure pertaining to impact of coronavirus (COVID-19). Inventories, net Total inventories us-gaap_AccruedProfessionalFeesCurrent Audit fee us-gaap_AccruedMarketingCostsCurrent Sales rebates Net Sales Net Sales us-gaap_InventoryValuationReserves Inventory Valuation Reserves, Ending Balance us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Acquisition of property, plant and equipment Supplemental disclosure of non-cash items: Customer [Axis] Customer [Domain] Taxes paid Net (losses) gains recognized during the period on marketable securities Current liabilities: Equity And Other Mutual Funds [Member] Equity And Other Mutual Funds Member us-gaap_Assets TOTAL ASSETS Supplemental disclosure of cash flow information: Pharmaceuticals [Member] Net property, plant, and equipment: Medical [Member] Cash flows from operating activities: Industrial And Other [Member] Statement [Line Items] Accounts receivable, allowance for doubtful accounts Accounts receivable, net of allowance for doubtful accounts of $27,296 at September 30, 2021 and $14,017 at December 31, 2020 us-gaap_MarketableSecuritiesCurrent Marketable securities Stockholders’ equity: us-gaap_NonoperatingIncomeExpense Total other income Current assets: Investment income Net income Net Income us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Commitments and contingencies Director [Member] us-gaap_OperatingIncomeLoss Income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Other Income: Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Cost of sales ug_DefinedContributionDiscretionaryContributionPlanVestingPeriod Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year) Represents the vesting period of discretionary contributions made under the defined contribution plan. us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities Company 401(k) contribution Deferred income taxes Less: Accumulated depreciation us-gaap_PropertyPlantAndEquipmentNet Total property, plant, and equipment, net us-gaap_PropertyPlantAndEquipmentGross Total property, plant, and equipment ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIUnrealizedGainLoss Marketable securities, unrealized gain Amount of accumulated unrealized gain (loss) in debt securities classified as held to maturity and equity securities. Land ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNIFairValue Marketable securities Fair value of investment in debt securities classified as held to maturity and equity securities. Dividends payable, noncash Dividends ug_DebtSecuritiesHeldToMaturityAndEquitySecuritiesFVNICost Marketable securities, cost Cost of investment in debt securities classified as held to maturity and equity securities. Building and improvements Factory equipment and fixtures Other Liabilities Disclosure [Text Block] us-gaap_PaymentsOfDividends Dividends paid us-gaap_CostsAndExpenses Total costs and expenses Cash flows from investing activities: Scenario [Domain] Retained Earnings [Member] Earnings Per Share [Text Block] us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty Related Party Transaction, Expenses from Transactions with Related Party Equity securities Net (loss) gain on marketable securities Provision for state income taxes - current Scenario [Axis] us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Income taxes payable Accounting and Tax Services [Member] Represents accounting and tax services. us-gaap_MarketableSecuritiesRealizedGainLoss Net gain on marketable securities Common Stock [Member] Provision for federal income taxes - current Related Party Transactions Disclosure [Text Block] (Benefit from) provision for federal income taxes – deferred us-gaap_IncomeTaxExpenseBenefit Total provision for income taxes Provision for income taxes Accrued expense and other current liabilities Equity Components [Axis] Equity Component [Domain] CHINA Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Gain (Loss) on Securities [Table Text Block] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before provision for income taxes us-gaap_DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost us-gaap_DeferredRevenueCurrent Deferred revenue us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Cash and cash equivalents Disaggregation of Revenue [Table Text Block] Revenue from Contract with Customer [Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Accounting Policies [Abstract] Distributors and Marketing Partners [Member] Represents distributors and marketing partners of the company. Document Transition Report City Area Code Concentration Risk Disclosure [Text Block] Entity Interactive Data Current Dividends declared per share (in dollars per share) us-gaap_IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date Increase (decrease) in operating liabilities: Less: Net gains recognized during the period on marketable securities sold during the period Debt and Equity Securities, Realized Gain (Loss), Total us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Basis of Accounting [Text Block] Document Fiscal Period Focus Document Fiscal Year Focus Marketing Partner [Member] Information pertaining to the marking partner. Document Period End Date Distributor [Member] Information pertaining to the distributor. Entity File Number us-gaap_IncreaseDecreaseInPrepaidTaxes Prepaid income taxes Entity Emerging Growth Company Document Type Cosmetic Ingredients [Member] Represents information related to cosmetic ingredients. Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status ug_IncreaseDecreaseInDividendsPayable Dividends payable The increase (decrease) during the reporting period in dividends payable. Weighted average shares – basic and diluted (in shares) us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Non-US [Member] Earnings per common share (Basic and Diluted) (in dollars per share) Earnings Per Share, Basic and Diluted, Total (in dollars per share) Entity Central Index Key Entity Registrant Name Entity [Domain] Customer Concentration Risk [Member] EX-101.PRE 9 ug-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 ug20210930_10q_htm.xml IDEA: XBRL DOCUMENT 0000101295 2021-01-01 2021-09-30 0000101295 2021-11-01 0000101295 2021-07-01 2021-09-30 0000101295 2020-07-01 2020-09-30 0000101295 2020-01-01 2020-09-30 0000101295 2021-09-30 0000101295 2020-12-31 0000101295 us-gaap:CommonStockMember 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2020-12-31 0000101295 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000101295 2021-01-01 2021-03-31 0000101295 us-gaap:CommonStockMember 2021-03-31 0000101295 us-gaap:RetainedEarningsMember 2021-03-31 0000101295 2021-03-31 0000101295 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 2021-04-01 2021-06-30 0000101295 us-gaap:DividendPaidMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendDeclaredMember 2021-04-01 2021-06-30 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000101295 us-gaap:CommonStockMember 2021-06-30 0000101295 us-gaap:RetainedEarningsMember 2021-06-30 0000101295 2021-06-30 0000101295 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000101295 us-gaap:CommonStockMember 2021-09-30 0000101295 us-gaap:RetainedEarningsMember 2021-09-30 0000101295 us-gaap:CommonStockMember 2019-12-31 0000101295 us-gaap:RetainedEarningsMember 2019-12-31 0000101295 2019-12-31 0000101295 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000101295 2020-01-01 2020-03-31 0000101295 us-gaap:CommonStockMember 2020-03-31 0000101295 us-gaap:RetainedEarningsMember 2020-03-31 0000101295 2020-03-31 0000101295 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 2020-04-01 2020-06-30 0000101295 us-gaap:DividendPaidMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendPaidMember us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendDeclaredMember 2020-04-01 2020-06-30 0000101295 us-gaap:DividendDeclaredMember us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000101295 us-gaap:CommonStockMember 2020-06-30 0000101295 us-gaap:RetainedEarningsMember 2020-06-30 0000101295 2020-06-30 0000101295 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000101295 us-gaap:CommonStockMember 2020-09-30 0000101295 us-gaap:RetainedEarningsMember 2020-09-30 0000101295 2020-09-30 0000101295 2021-09-30 2021-09-30 0000101295 ug:CosmeticIngredientsMember 2021-07-01 2021-09-30 0000101295 ug:CosmeticIngredientsMember 2020-07-01 2020-09-30 0000101295 ug:CosmeticIngredientsMember 2021-01-01 2021-09-30 0000101295 ug:CosmeticIngredientsMember 2020-01-01 2020-09-30 0000101295 ug:PharmaceuticalsMember 2021-07-01 2021-09-30 0000101295 ug:PharmaceuticalsMember 2020-07-01 2020-09-30 0000101295 ug:PharmaceuticalsMember 2021-01-01 2021-09-30 0000101295 ug:PharmaceuticalsMember 2020-01-01 2020-09-30 0000101295 ug:MedicalMember 2021-07-01 2021-09-30 0000101295 ug:MedicalMember 2020-07-01 2020-09-30 0000101295 ug:MedicalMember 2021-01-01 2021-09-30 0000101295 ug:MedicalMember 2020-01-01 2020-09-30 0000101295 ug:IndustrialAndOtherMember 2021-07-01 2021-09-30 0000101295 ug:IndustrialAndOtherMember 2020-07-01 2020-09-30 0000101295 ug:IndustrialAndOtherMember 2021-01-01 2021-09-30 0000101295 ug:IndustrialAndOtherMember 2020-01-01 2020-09-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000101295 ug:CosmeticIngredientsMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000101295 country:US 2021-07-01 2021-09-30 0000101295 country:US 2020-07-01 2020-09-30 0000101295 country:US 2021-01-01 2021-09-30 0000101295 country:US 2020-01-01 2020-09-30 0000101295 us-gaap:NonUsMember 2021-07-01 2021-09-30 0000101295 us-gaap:NonUsMember 2020-07-01 2020-09-30 0000101295 us-gaap:NonUsMember 2021-01-01 2021-09-30 0000101295 us-gaap:NonUsMember 2020-01-01 2020-09-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-07-01 2021-09-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-07-01 2020-09-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2021-01-01 2021-09-30 0000101295 ug:ASIMember us-gaap:NonUsMember us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000101295 ug:ASIMember country:CN us-gaap:SalesRevenueSegmentMember us-gaap:GeographicConcentrationRiskMember 2020-01-01 2020-09-30 0000101295 us-gaap:FixedIncomeSecuritiesMember 2021-09-30 0000101295 ug:EquityAndOtherMutualFundsMember 2021-09-30 0000101295 us-gaap:FixedIncomeSecuritiesMember 2020-12-31 0000101295 ug:EquityAndOtherMutualFundsMember 2020-12-31 0000101295 ug:DCPlanMember 2021-01-01 2021-09-30 0000101295 ug:DiscretionaryContributionsVestingAtTwoYearsMember ug:DCPlanMember 2021-01-01 2021-09-30 0000101295 ug:DiscretionaryContributionsVestingEachAdditionalYearMember ug:DCPlanMember 2021-01-01 2021-09-30 0000101295 ug:DCPlanMember 2020-01-01 2020-09-30 0000101295 ug:AccountingAndTaxServicesMember ug:PkfMember 2021-01-01 2021-09-30 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2020-07-01 2020-09-30 0000101295 ug:AccountingAndTaxServicesMember srt:DirectorMember 2020-01-01 2020-09-30 0000101295 ug:MarketingPartnerMember 2021-07-01 2021-09-30 0000101295 ug:DistributorMember 2021-07-01 2021-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000101295 ug:DistributorMember 2020-07-01 2020-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000101295 ug:MarketingPartnerMember 2021-01-01 2021-09-30 0000101295 ug:DistributorMember 2021-01-01 2021-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember 2020-01-01 2020-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 0000101295 ug:DistributorsAndMarketingPartnersMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-09-30 iso4217:USD iso4217:USD shares pure utr:Y 0000101295 UNITED GUARDIAN INC false --12-31 Q3 2021

27296

14017

0.10

10000000

4594319

0.48

0.42

35000

P1Y P2Y P6Y

9500

1 3 3 1 3 3 10-Q true 2021-09-30 false 1-10526 DE 11-1719724 230 Marcus Boulevard Hauppauge NY 11788 631 273-0900 Common Stock, $0.10 par value per share UG NASDAQ Yes Yes Non-accelerated Filer true false false 4594319

3179746

2336360

10268592

8613918

1320509

974763

4180912

3634528

458582

493204

1428721

1520114

130742

114836

349053

331134

1909833

1582803

5958686

5485776

1269913

753557

4309906

3128142

38747

38932

124147

131318

-25108

113248

40419

143832

13639

152180

164566

275150

1283552

905737

4474472

3403292

267046

188205

932240

708842

1016506

717532

3542232

2694450

0.22

0.16

0.77

0.59

4594319

691921

591444

8893454

7591381

1930183

1387698

1287234

1415773

159361

161208

99107

12962153

11246611

69000

4571364

4516335

2853718

2848585

7494082

7433920

6830549

6760255

663533

673665

13625686

11920276

87158

31800

1542760

1363457

57614

19685

19028

1707217

1414285

227203

151684

459432

11231834

9894875

11691266

10354307

13625686

11920276

4594319

459432

9894875

10354307

1181202

4594319

459432

11076077

11535509

1344524

2204616

657

4594319

459432

10215328

10674760

1016506

4594319

459432

11231834

11691266

4594319

459432

10173466

10632898

790307

4594319

459432

10963773

11423505

1186611

1928969

645

4594319

459432

10220770

10680202

717532

4594319

459432

10938302

11397734

3542232

2694450

106928

121669

40419

143832

14799

13279

-992

75519

-155127

555764

-815808

-128539

327542

-1847

-4185

-99107

-38969

55358

-30460

179303

29233

57614

-124657

3648744

2921704

81997

25437

1832829

3802205

3094483

4932754

-1343651

-1155986

2204616

1928969

-2204616

-1928969

100477

-163251

591444

1048311

691921

885060

700000

825000

657

645

29000

1. Nature of Business United-Guardian, Inc. (the “Company”) is a Delaware corporation that, through its Guardian Laboratories division, conducts research, product development, manufacturing and marketing of cosmetic ingredients, pharmaceuticals, medical products and proprietary specialty industrial products. The Company’s research and development department modifies, refines, and expands the uses for existing products for additional uses and markets. It also develops new products using natural and environmentally friendly raw materials, which is important to many of the Company's cosmetic customers.

3. Impact of Coronavirus (COVID-19) While the coronavirus pandemic (“pandemic”) continues to impact the Company’s operations, the substantial impact the pandemic had on Company sales in 2020 significantly lessened in the first nine months of 2021. The current impact is coming primarily from supply chain disruptions, which have resulted in increased packaging and shipping costs, and increases in the cost of some raw materials, although it has not significantly affected the ability of the Company to obtain raw materials. It has, however, resulted in some shipping delays due to the shortage of truck drivers. The Company has been able to maintain production throughout the pandemic. Sales of the Company’s non-pharmaceutical medical products (“medical products”) had also been negatively impacted by the pandemic in 2020, but those impacts have lessened as well in the first three quarters of 2021. Sales of the Company’s pharmaceutical products were not impacted by the pandemic in 2020 or in the first nine months of 2021. There continues to be some uncertainty in regard to the future impact of the pandemic on the Company’s operations or financial results and as a result it is difficult for the Company to provide an accurate estimate or projection as to what the future impact of the pandemic will be on the Company’s future operations or financial results. The Company does not expect the carrying value of its assets or its liquidity to be impaired by the coronavirus pandemic. 4. Use of Estimates In preparing financial statements in conformity with US GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Such estimated items include the allowance for bad debts, reserve for inventory obsolescence, accrued distribution fees, outdated material returns, possible impairment of marketable securities, and the allocation of overhead.

5. Cash and Cash Equivalents For financial statement purposes, the Company considers as cash equivalents all highly liquid investments with an original maturity of three months or less at the time of purchase. The Company deposits cash and cash equivalents with high credit quality financial institutions and believes that any amounts in excess of insurance limitations to be at minimal risk. Cash and cash equivalents held in these accounts are currently insured by the Federal Deposit Insurance Corporation (“FDIC”) up to a maximum of $250,000. At September 30, 2021 and December 31, 2020, approximately $806,000 and $653,000 exceeded the FDIC limit.

806000

653000

6. Revenue Recognition The Company records revenue in accordance with ASC Topic 606 “Revenue from Contracts with Customers.” Under this guidance, revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration expected to be received in exchange for those goods or services. The Company’s principal source of revenue is product sales. The Company’s sales, as reported, are subject to a variety of deductions, some of which are estimated. These deductions are recorded in the same period in which the revenue is recognized. Such deductions, primarily related to the sale of the Company’s pharmaceutical products, include chargebacks from the United States Department of Veterans Affairs (‘VA”), rebates in connection with the Company’s current participation in Medicare programs and its past participation in Medicaid programs, distribution fees, discounts, and outdated product returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on sales for a reporting period. During 2021 and 2020, the Company participated in various government drug rebate programs related to the sale of Renacidin®, its most important pharmaceutical product. These programs include the Veterans Affairs Federal Supply Schedule (FSS), and the Medicare Part D Coverage Gap Discount Program (CGDP). These programs require the Company to sell its product at a discounted price. In addition, during 2020, the Company also participated in the Medicaid Drug Rebate Program (MDRP), which required the Company to pay a significant rebate to the various states where Renacidin was provided to Medicaid patients, as well as the Section 340B Drug Pricing Program (340B), which required the Company to sell Renacidin at a deeply discounted price. Due to the overly burdensome nature of the Medicaid rebates, and the deeply discounted pricing associated with the 340B Program, the Company terminated its participation in the MDRP and the 340B Programs, effective December 31, 2020. The Company’s sales, as reported, are net of these rebates, some of which are estimated and are recorded in the same period that the revenue is recognized. The Company recognizes revenue from sales of its cosmetic ingredients, medical, and industrial products when those products are shipped, as long as a valid purchase order has been received and future collection of the sale amount is reasonably assured. These products are shipped “Ex-Works” from the Company’s facility in Hauppauge, NY, and it is at this time that risk of loss and responsibility for the shipment passes to the customer and the Company’s performance obligation is satisfied. Sales of these products are deemed final, and there is no obligation on the part of the Company to repurchase or allow the return of these goods unless they are defective. The Company’s pharmaceutical products are shipped via common carrier upon receipt of a valid purchase order, with, in most cases, the Company paying the shipping costs. Sales of pharmaceutical products are final, and revenue is recognized at the time of shipment, which is when the risk of loss and responsibility for the shipment passes to the customer, and the performance obligation of the Company is satisfied. Pharmaceutical products are returnable only at the discretion of the Company unless (a) they are found to be defective; (b) the product is damaged in shipping; or (c) the product is outdated (but not more than one year after their expiration date, which is a return policy which conforms to standard pharmaceutical industry practice). The Company estimates an allowance for outdated material returns based on prior year historical returns of its pharmaceutical products. The Company does not make sales on consignment, and the collection of the proceeds of the sale of any of the Company’s products is not contingent upon the customer being able to sell the goods to a third party. Any allowances for returns are taken as a reduction of sales within the same period the revenue is recognized. Such allowances are determined based on historical experience under ASC Topic 606-10-32-8. The Company has not experienced significant fluctuations between estimated allowances and actual activity. The timing between recognition of revenue for product sales and the receipt of payment is not significant. The Company’s standard credit terms, which vary depending on the customer, range between 30 and 60 days. The Company uses its judgment on a case-by-case basis to determine its ability to collect outstanding receivables and provides allowances for any receivables for which collection has become doubtful. As of September 30, 2021 and December 31, 2020, the allowance for doubtful accounts receivable was $27,296 and $14,017, respectively. Prompt-pay discounts are offered to some customers; however, due to the uncertainty of the customers taking the discounts, the discounts are recorded when they are taken. At September 30, 2021, the Company recorded an advance payment from one of its customers in the amount of $128,636. The related performance obligation associated with this payment had not been satisfied as of the balance sheet date. The deferred revenue related to this payment is included in accrued expenses and other current liabilities. The Company has distribution fee contracts with certain distributors of its pharmaceutical products that entitles them to distribution and service-related fees. The Company records distribution fees and estimates distribution fees as offsets to revenue. Disaggregated sales by product class are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" style="text-align: center;">Three months ended September 30,</td><td> </td><td> </td><td colspan="6" style="text-align: center;">Nine months ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2020</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2020</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 44%;"> Cosmetic Ingredients </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,578,650</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">550,177</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,065,022</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,358,956</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,216,747</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,232,586</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,509,235</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,463,738</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">343,884</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">517,036</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,580,657</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,683,682</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Industrial products </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,465</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,561</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,678</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 2pt; border-bottom: 1px solid rgb(0, 0, 0);">107,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,179,746</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,336,360</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,268,592</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,613,918</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> The Company’s cosmetic ingredients are marketed worldwide by five marketing partners, of which U.S.-based Ashland Specialty Ingredients (“ASI”) purchases the largest volume. Approximately 16% of the Company’s total sales in the third quarter of 2021 were to customers located outside of the United States, compared with approximately 22% in the third quarter of 2020. For the nine months ended September 30, 2021, approximately 21% of the Company’s total sales were to customers located outside of the United States, compared with approximately 20% for the nine months ended September 30, 2020. Disaggregated sales by geographic region are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" style="text-align: center;">Three months ended September 30,</td><td> </td><td> </td><td colspan="6" style="text-align: center;">Nine months ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">2020 </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">2021 </td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0);">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 44%;"> United States* </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,670,515</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,819,084</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,115,145</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,887,726</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Other countries </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">509,231</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">517,276</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,153,447</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,726,192</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,179,746</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,336,360</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,268,592</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,613,918</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> * Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 76% of its sales of the Company’s products in the third quarter of 2021 were to foreign customers compared with 69% for the same period in 2020, with China representing approximately 29% of those foreign sales in the third quarter of 2021, compared with approximately 30% in the third quarter of 2020. For the nine months ended September 30, 2021 approximately 72% of ASI’s sales of the Company’s products were to customers in other countries, with China accounting for approximately 35% of ASI’s sales of the Company’s products, as compared with approximately 69% of ASI’s sales going to customers in other countries for the nine months ended September 30, 2020, with China accounting for approximately 33% of ASI’s sales of the Company’s products during that period.

27296

14017

128636

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="6" style="text-align: center;">Three months ended September 30,</td><td> </td><td> </td><td colspan="6" style="text-align: center;">Nine months ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2020</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2021</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">2020</td><td style="padding-bottom: 1px; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 44%;"> Cosmetic Ingredients </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,578,650</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">550,177</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5,065,022</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,358,956</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Pharmaceutical </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,216,747</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,232,586</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,509,235</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,463,738</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Medical </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">343,884</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">517,036</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,580,657</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,683,682</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Industrial products </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,465</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">36,561</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">113,678</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 2pt; border-bottom: 1px solid rgb(0, 0, 0);">107,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid black;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total Sales </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">3,179,746</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">2,336,360</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10,268,592</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,613,918</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

1578650

550177

5065022

3358956

1216747

1232586

3509235

3463738

343884

517036

1580657

1683682

40465

36561

113678

107542

3179746

2336360

10268592

8613918

0.16

0.22

0.21

0.20

2670515

1819084

8115145

6887726

509231

517276

2153447

1726192

3179746

2336360

10268592

8613918

0.76

0.69

0.29

0.30

0.72

0.35

0.69

0.33

7. Marketable Securities Marketable securities include investments in fixed income and equity mutual funds, and U.S. Government securities with maturities greater than 3 months, all of which are reported at their fair values. The disaggregated net gains and losses on the marketable securities recognized in the income statements for the three and nine months ended September 30, 2021 and 2020, respectively, are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Three months ended September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Nine months ended September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 44%;"> Net (losses) gains recognized during the period on marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(25,108</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> ) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">113,248</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">40,419</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">143,832</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Less: Net gains recognized during the period on marketable securities sold during the period </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">---</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,062</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">112,180</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">29,918</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(25,108</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> ) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">88,186</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(71,761</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> ) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 11%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">113,914</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> The fair values of the Company’s marketable securities are determined in accordance with US GAAP, with fair value being defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the Company utilizes the three-tier value hierarchy, as prescribed by US GAAP, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. • Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. • Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement. The Company’s marketable equity securities, which are considered available for sale securities, are re-measured to fair value on a recurring basis and are valued using Level 1 inputs using quoted prices (unadjusted) for identical assets in active markets. The following tables summarize the Company’s investments: September 30, 2021(Unaudited) <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="width: 49%;">Equity Securities</td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair Value</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized Gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,050,443</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,172,762</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">122,319</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">610,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">720,692</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,150</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,660,985</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,893,454</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">232,469</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,660,985</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,893,454</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">232,469</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> December 31, 2020(Audited) <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="width: 49%;">Equity Securities</td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair Value</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized Gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,703,107</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,907,270</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">204,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">584,044</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">684,111</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,067</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> Investment income is recognized when earned and consists principally of interest income from fixed income mutual funds and U.S. Treasury Bills and dividend income from equity and other mutual funds. Realized gains and losses on sales of investments are determined on a specific identification basis. Proceeds from the sale and redemption of marketable securities amounted to $1,832,829 for the nine months ended September 30, 2021, which included realized gains of $112,180. Proceeds from the sale and redemption of marketable securities amounted to $3,802,205 for the nine months ended September 30, 2020, which included realized gains of $29,918.

-25108

113248

40419

143832

25062

112180

29918

-25108

88186

-71761

113914

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="width: 49%;">Equity Securities</td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair Value</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized Gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,050,443</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8,172,762</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">122,319</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">610,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">720,692</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">110,150</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,660,985</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,893,454</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">232,469</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,660,985</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8,893,454</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">232,469</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="width: 49%;">Equity Securities</td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Cost</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Fair Value</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); text-align: center;">Unrealized Gain</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Fixed income mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,703,107</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,907,270</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">204,163</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Equity and other mutual funds </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">584,044</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">684,111</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,067</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total equity securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total marketable securities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,287,151</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7,591,381</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 14%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">304,230</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

8050443

8172762

122319

610542

720692

110150

8660985

8893454

232469 8660985 8893454 232469

6703107

6907270

204163

584044

684111

100067

7287151

7591381

304230 7287151 7591381 304230

1832829

112180

3802205

29918

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2021 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2020 </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> (UNAUDITED) </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> (AUDITED) </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 62%;"> Inventories consist of the following: </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Raw materials </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">434,178</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">415,415</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Work in process </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">75,716</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">59,258</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Finished products </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">777,340</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">941,100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total inventories </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,287,234</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,415,773</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

434178

415415

75716

59258

777340

941100

1287234

1415773

35000

311311 302713

9. Income Taxes The Company’s tax provision is based on its estimated annual effective tax rate. The Company continues to fully recognize its tax benefits, and as of September 30, 2021 and December 31, 2020, the Company did not have any unrecognized tax benefits. The Company’s provision for income taxes for the three and nine months ended September 30 comprises the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Three months ended September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td> </td><td colspan="6" style="text-align: center;">Nine months ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 48%;"> Provision for federal income taxes - current </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">340,981</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">81,323</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">856,621</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">863,819</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Provision for state income taxes - current </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">---</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">150</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> (Benefit from) provision for federal income taxes – deferred </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73,935</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">106,882</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">75,519</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">(155,127</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total provision for income taxes </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">267,046</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">188,205</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">932,240</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">708,842</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Three months ended September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td> </td><td colspan="6" style="text-align: center;">Nine months ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2021</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td><td> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); padding: 0pt; text-align: center;">2020</td><td style="border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 48%;"> Provision for federal income taxes - current </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">340,981</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">81,323</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">856,621</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">863,819</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Provision for state income taxes - current </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">---</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">100</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt;">150</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> (Benefit from) provision for federal income taxes – deferred </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(73,935</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">106,882</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">75,519</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);">(155,127</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> ) </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total provision for income taxes </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">267,046</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">188,205</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">932,240</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 10%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">708,842</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

340981

81323

856621

863819

100

150

-73935

106882

75519

-155127

267046

188205

932240

708842

10. Defined Contribution Plan The Company sponsors a 401(k) defined contribution plan (“DC Plan”) that provides for a dollar-for-dollar employer matching contribution of the first 4% of each employee’s pay that is deferred by the employee. Employees become fully vested in employer matching contributions after one year of employment. The Company also makes discretionary contributions to each employee's account based on a "pay-to-pay" safe-harbor formula that qualifies the 401(k) Plan under current IRS regulations. Employees become vested in the discretionary contributions as follows: 20% after two years of employment, and 20% for each year of employment thereafter until the employee becomes fully vested after six years of employment. The Company accrued $87,000 in contributions to the DC Plan for the nine months ended September 30, 2021, and $108,750 for the nine months ended September 30, 2020. For the first three quarters of 2021 and 2020, the Company did not make any discretionary contributions to the DC Plan.

0.04

0.20

87000

108750

11. Related-Party Transactions During the three months ended September 30, 2021, there were no payments made to related parties. For the nine months ended September 30, 2021, the Company made payments of $9,500, to the accounting firm PKF O’Connor Davies (“PKF”) for accounting and tax services. For the three and nine months ended September 30, 2020, the Company made payments of $9,500 for accounting and tax services to Bonamassa, Maietta and Cartelli, LLP “Bonamassa”). Lawrence Maietta, a partner at PKF O’Connor Davies, and previously a partner at Bonamassa before its combination with PKF, is a director of the Company.

9500

12. Other Information Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-size: 10pt; width: 62%;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2021 </td><td style="font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2020 </td><td style="font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-size: 10pt; width: 62%;">Accrued Expenses</td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;">(Unaudited)</td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;">(Audited)</td><td style="font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Bonuses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">237,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">210,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Distribution fees </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">362,315</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">325,792</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Payroll and related expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">225,328</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">245,521</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Reserve for outdated material </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">311,311</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">302,713</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Company 401(k) contribution </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">87,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Deferred revenue </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">128,636</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Audit fee </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">57,875</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">50,500</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Annual report expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">46,462</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">63,432</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Sales rebates </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">51,428</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">149,346</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Other </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,405</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,153</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Total Accrued Expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,542,760</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,363,457</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-size: 10pt; width: 62%;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2021 </td><td style="font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> December 31, 2020 </td><td style="font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr><td style="font-size: 10pt; width: 62%;">Accrued Expenses</td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;">(Unaudited)</td><td style="font-size: 10pt;"> </td><td style="font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-size: 10pt; margin-left: 0pt;">(Audited)</td><td style="font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom;"><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Bonuses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">237,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">210,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Distribution fees </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">362,315</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">325,792</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Payroll and related expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">225,328</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">245,521</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Reserve for outdated material </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">311,311</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">302,713</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Company 401(k) contribution </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">87,000</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Deferred revenue </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">128,636</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">---</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Audit fee </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">57,875</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">50,500</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Annual report expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">46,462</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">63,432</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Sales rebates </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">51,428</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt;">149,346</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-size: 10pt;"> Other </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,405</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,153</td><td style="width: 1%; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-size: 10pt;"> Total Accrued Expenses </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,542,760</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td><td style="width: 1%; font-size: 10pt;"> </td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 16%; text-align: right; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">1,363,457</td><td style="width: 1%; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;"> </td></tr> </tbody></table>

237000

210000

362315 325792

225328

245521

311311 302713

87000

128636

57875

50500

46462 63432

51428

149346

35405

16153

1542760

1363457

13. Recent Accounting Pronouncements On January 1, 2021, the Company adopted Accounting Standards Update (ASU) 2019-12, “Simplifying the Accounting for Income Taxes.” This standard modified ASU 740 and simplifies the accounting for income taxes. The Company has determined that these modifications did not have an impact on its financial statements. In June 2016, the FASB issued ASU-2016-13 “Financial Instruments – Credit Losses”. This guidance affects organizations that hold financial assets and net investments in leases that are not accounted for at fair value with changes in fair value reported in net income. The guidance requires organizations to measure all expected credit losses for financial instruments at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. In November 2019, the FASB amended the effective date of implementation of this standard for smaller reporting companies. The new effective date is for fiscal years beginning after December 15, 2022. The Company is currently evaluating if this pronouncement will have a potential impact on its financial statements.

0.86

0.79

0.70

0.79

0.70

0.22

0.16

0.77

0.59

Since substantially all purchases by ASI are shipped to ASI’s warehouses in the U.S., all sales to ASI are reported as U.S. sales for financial reporting purposes, even though a significant quantity of those purchases will be shipped by ASI to foreign customers. ASI has reported to the Company that approximately 76% of its sales of the Company’s products in the third quarter of 2021 were to foreign customers compared with 69% for the same period in 2020, with China representing approximately 29% of those foreign sales in the third quarter of 2021, compared with approximately 30% in the third quarter of 2020.

XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2021	Nov. 01, 2021
Document Information [Line Items]
Entity Central Index Key	0000101295
Entity Registrant Name	UNITED GUARDIAN INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	1-10526
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-1719724
Entity Address, Address Line One	230 Marcus Boulevard
Entity Address, City or Town	Hauppauge
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11788
City Area Code	631
Local Phone Number	273-0900
Title of 12(b) Security	Common Stock, $0.10 par value per share
Trading Symbol	UG
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,594,319

XML 12 R2.htm IDEA: XBRL DOCUMENT

Statements of Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Income (Unaudited) - USD ($)	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net Sales	$ 3,179,746	$ 2,336,360	$ 10,268,592	$ 8,613,918
Costs and expenses:
Cost of sales	1,320,509	974,763	4,180,912	3,634,528
Operating expenses	458,582	493,204	1,428,721	1,520,114
Research and development	130,742	114,836	349,053	331,134
Total costs and expenses	1,909,833	1,582,803	5,958,686	5,485,776
Income from operations	1,269,913	753,557	4,309,906	3,128,142
Other Income:
Investment income	38,747	38,932	124,147	131,318
Net (loss) gain on marketable securities	(25,108)	113,248	40,419	143,832
Total other income	13,639	152,180	164,566	275,150
Income before provision for income taxes	1,283,552	905,737	4,474,472	3,403,292
Provision for income taxes	267,046	188,205	932,240	708,842
Net Income	$ 1,016,506	$ 717,532	$ 3,542,232	$ 2,694,450
Earnings per common share (Basic and Diluted) (in dollars per share)	$ 0.22	$ 0.16	$ 0.77	$ 0.59
Weighted average shares – basic and diluted (in shares)	4,594,319	4,594,319	4,594,319	4,594,319

XML 13 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 691,921	$ 591,444
Marketable securities	8,893,454	7,591,381
Accounts receivable, net of allowance for doubtful accounts of $27,296 at September 30, 2021 and $14,017 at December 31, 2020	1,930,183	1,387,698
Inventories, net	1,287,234	1,415,773
Prepaid expenses and other current assets	159,361	161,208
Prepaid income taxes		99,107
Total current assets	12,962,153	11,246,611
Net property, plant, and equipment:
Land	69,000	69,000
Factory equipment and fixtures	4,571,364	4,516,335
Building and improvements	2,853,718	2,848,585
Total property, plant, and equipment	7,494,082	7,433,920
Less: Accumulated depreciation	6,830,549	6,760,255
Total property, plant, and equipment, net	663,533	673,665
TOTAL ASSETS	13,625,686	11,920,276
Current liabilities:
Accounts payable	87,158	31,800
Accrued expenses and other current liabilities	1,542,760	1,363,457
Income taxes payable	57,614
Dividends payable	19,685	19,028
Total current liabilities	1,707,217	1,414,285
Deferred income taxes	227,203	151,684
Commitments and contingencies
Stockholders’ equity:
Common stock (at $.10 par value) (10,000,000 shares authorized; 4,594,319 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively)	459,432	459,432
Retained earnings	11,231,834	9,894,875
Total stockholders’ equity	11,691,266	10,354,307
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 13,625,686	$ 11,920,276

XML 14 R4.htm IDEA: XBRL DOCUMENT

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accounts receivable, allowance for doubtful accounts	$ 27,296	$ 14,017
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, shares issued (in shares)	4,594,319	4,594,319
Common stock, shares outstanding (in shares)	4,594,319	4,594,319

XML 15 R5.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Dividend Paid [Member] Retained Earnings [Member]	Dividend Paid [Member]	Dividend Declared [Member] Retained Earnings [Member]	Dividend Declared [Member]	Common Stock [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019					4,594,319
Balance at Dec. 31, 2019					$ 459,432	$ 10,173,466	$ 10,632,898
Net income						790,307	790,307
Balance (in shares) at Mar. 31, 2020					4,594,319
Balance at Mar. 31, 2020					$ 459,432	10,963,773	11,423,505
Balance (in shares) at Dec. 31, 2019					4,594,319
Balance at Dec. 31, 2019					$ 459,432	10,173,466	10,632,898
Net income							2,694,450
Dividends							(645)
Balance (in shares) at Sep. 30, 2020					4,594,319
Balance at Sep. 30, 2020					$ 459,432	10,938,302	11,397,734
Balance (in shares) at Mar. 31, 2020					4,594,319
Balance at Mar. 31, 2020					$ 459,432	10,963,773	11,423,505
Net income						1,186,611	1,186,611
Dividends	$ (1,928,969)	$ (1,928,969)	$ (645)	$ (645)
Balance (in shares) at Jun. 30, 2020					4,594,319
Balance at Jun. 30, 2020					$ 459,432	10,220,770	10,680,202
Net income						717,532	717,532
Balance (in shares) at Sep. 30, 2020					4,594,319
Balance at Sep. 30, 2020					$ 459,432	10,938,302	11,397,734
Balance (in shares) at Dec. 31, 2020					4,594,319
Balance at Dec. 31, 2020					$ 459,432	9,894,875	10,354,307
Net income						1,181,202	1,181,202
Balance (in shares) at Mar. 31, 2021					4,594,319
Balance at Mar. 31, 2021					$ 459,432	11,076,077	11,535,509
Balance (in shares) at Dec. 31, 2020					4,594,319
Balance at Dec. 31, 2020					$ 459,432	9,894,875	10,354,307
Net income							3,542,232
Dividends							(657)
Balance (in shares) at Sep. 30, 2021					4,594,319
Balance at Sep. 30, 2021					$ 459,432	11,231,834	11,691,266
Balance (in shares) at Mar. 31, 2021					4,594,319
Balance at Mar. 31, 2021					$ 459,432	11,076,077	11,535,509
Net income						1,344,524	1,344,524
Dividends	$ (2,204,616)	$ (2,204,616)	$ (657)	$ (657)
Balance (in shares) at Jun. 30, 2021					4,594,319
Balance at Jun. 30, 2021					$ 459,432	10,215,328	10,674,760
Net income						1,016,506	1,016,506
Balance (in shares) at Sep. 30, 2021					4,594,319
Balance at Sep. 30, 2021					$ 459,432	$ 11,231,834	$ 11,691,266

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Statements of Changes in Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Dividend Paid [Member]
Dividends declared per share (in dollars per share)	$ 0.48	$ 0.42
Dividend Declared [Member]
Dividends declared per share (in dollars per share)	$ 0.48	$ 0.42

XML 17 R7.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net income	$ 3,542,232	$ 2,694,450
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	106,928	121,669
Net gain on marketable securities	(40,419)	(143,832)
Gain on sale of asset	(14,799)
Allowance for doubtful accounts	13,279	(992)
Deferred income taxes	75,519	(155,127)
(Increase) decrease in operating assets:
Accounts receivable	(555,764)	815,808
Inventories	128,539	(327,542)
Prepaid expenses and other current assets	1,847	4,185
Prepaid income taxes	99,107	38,969
Increase (decrease) in operating liabilities:
Accounts payable	55,358	(30,460)
Accrued expense and other current liabilities	179,303	29,233
Income taxes payable	(57,614)
Dividends payable		(124,657)
Net cash provided by operating activities	3,648,744	2,921,704
Cash flows from investing activities:
Acquisition of property, plant and equipment	(81,997)	(25,437)
Proceeds from sale of marketable securities	1,832,829	3,802,205
Purchases of marketable securities	(3,094,483)	(4,932,754)
Net cash used in investing activities	(1,343,651)	(1,155,986)
Cash flows from financing activities:
Dividends paid	(2,204,616)	(1,928,969)
Net cash used in financing activities	(2,204,616)	(1,928,969)
Net increase (decrease) in cash and cash equivalents	100,477	(163,251)
Cash and cash equivalents at beginning of period	591,444	1,048,311
Cash and cash equivalents at end of period	691,921	885,060
Supplemental disclosure of cash flow information:
Taxes paid	700,000	825,000
Supplemental disclosure of non-cash items:
Dividends payable, noncash	657	$ 645
Trade-in received from sale of asset	$ 29,000

XML 18 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Business

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]

1. Nature of Business

XML 19 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Basis of Accounting [Text Block]

2. Basis of Presentation

XML 20 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Impact of Coronavirus (COVID-19)

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Impact of Coronavirus (COVID-19) [Text Block]

3. Impact of Coronavirus (COVID-19)

XML 21 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Use of Estimates

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Use of Estimates Disclosure [Text Block]

4. Use of Estimates

XML 22 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Cash and cash Equivalents

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Cash and Cash Equivalents Disclosure [Text Block]

5. Cash and Cash Equivalents

XML 23 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Revenue from Contract with Customer [Text Block]

6. Revenue Recognition

Disaggregated sales by product class are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Cosmetic Ingredients	$	1,578,650	$	550,177	$	5,065,022	$	3,358,956
Pharmaceutical		1,216,747		1,232,586		3,509,235		3,463,738
Medical		343,884		517,036		1,580,657		1,683,682
Industrial products		40,465		36,561		113,678		107,542
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

Disaggregated sales by geographic region are as follows:

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
United States*	$	2,670,515	$	1,819,084	$	8,115,145	$	6,887,726
Other countries		509,231		517,276		2,153,447		1,726,192
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

7. Marketable Securities

	Three months ended September 30,					Nine months ended September 30,
	2021			2020		2021			2020
Net (losses) gains recognized during the period on marketable securities	$	(25,108	)	$	113,248	$	40,419		$	143,832
Less: Net gains recognized during the period on marketable securities sold during the period		---			25,062		112,180			29,918
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date	$	(25,108	)	$	88,186	$	(71,761	)	$	113,914

• Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

• Level 3 – inputs to the valuation methodology are unobservable and significant to the fair value measurement.

The following tables summarize the Company’s investments:

September 30, 2021(Unaudited)

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	8,050,443	$	8,172,762	$	122,319
Equity and other mutual funds		610,542		720,692		110,150
Total equity securities		8,660,985		8,893,454		232,469
Total marketable securities	$	8,660,985	$	8,893,454	$	232,469

December 31, 2020(Audited)

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

XML 25 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Inventory Disclosure [Text Block]

8. Inventories

	September 30,		December 31,
	2021		2020
	(UNAUDITED)		(AUDITED)
Inventories consist of the following:
Raw materials	$	434,178	$	415,415
Work in process		75,716		59,258
Finished products		777,340		941,100
Total inventories	$	1,287,234	$	1,415,773

XML 26 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Income Tax Disclosure [Text Block]

9. Income Taxes

Three months ended September 30,
Nine months ended September 30,

2021 2020 2021 2020

Provision for federal income taxes - current
$ 340,981 $ 81,323 $ 856,621 $ 863,819

Provision for state income taxes - current
--- --- 100 150

(Benefit from) provision for federal income taxes – deferred
(73,935
)
106,882 75,519 (155,127
)

Total provision for income taxes
$ 267,046 $ 188,205 $ 932,240 $ 708,842

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 27 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Defined Contribution Plan

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Retirement Benefits [Text Block]

10. Defined Contribution Plan

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

XML 28 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Related-party Transactions

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

11. Related-Party Transactions

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Other Information

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Other Liabilities Disclosure [Text Block]

12. Other Information

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following:

	September 30, 2021		December 31, 2020
Accrued Expenses	(Unaudited)		(Audited)

Bonuses	$	237,000	$	210,000
Distribution fees		362,315		325,792
Payroll and related expenses		225,328		245,521
Reserve for outdated material		311,311		302,713
Company 401(k) contribution		87,000		---
Deferred revenue		128,636		---
Audit fee		57,875		50,500
Annual report expenses		46,462		63,432
Sales rebates		51,428		149,346
Other		35,405		16,153
Total Accrued Expenses	$	1,542,760	$	1,363,457

XML 30 R20.htm IDEA: XBRL DOCUMENT

Note 13 - Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Accounting Standards Update and Change in Accounting Principle [Text Block]

13. Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (g)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (i)(2)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (g)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Publisher FASB
-Subparagraph (c)

+ Details

XML 31 R21.htm IDEA: XBRL DOCUMENT

Note 14 - Concentrations of Credit Risk

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

14. Concentrations of Credit Risk

XML 32 R22.htm IDEA: XBRL DOCUMENT

Note 15 - Earnings Per Share

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Earnings Per Share [Text Block]

15. Earnings Per Share

XML 33 R23.htm IDEA: XBRL DOCUMENT

Note 16 - Subsequent Events

9 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Subsequent Events [Text Block]

17. Subsequent Events

XML 34 R24.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
Cosmetic Ingredients	$	1,578,650	$	550,177	$	5,065,022	$	3,358,956
Pharmaceutical		1,216,747		1,232,586		3,509,235		3,463,738
Medical		343,884		517,036		1,580,657		1,683,682
Industrial products		40,465		36,561		113,678		107,542
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

Revenue from External Customers by Geographic Areas [Table Text Block]

	Three months ended September 30,				Nine months ended September 30,
	2021		2020		2021		2020
United States*	$	2,670,515	$	1,819,084	$	8,115,145	$	6,887,726
Other countries		509,231		517,276		2,153,447		1,726,192
Total Sales	$	3,179,746	$	2,336,360	$	10,268,592	$	8,613,918

XML 35 R25.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Gain (Loss) on Securities [Table Text Block]

	Three months ended September 30,					Nine months ended September 30,
	2021			2020		2021			2020
Net (losses) gains recognized during the period on marketable securities	$	(25,108	)	$	113,248	$	40,419		$	143,832
Less: Net gains recognized during the period on marketable securities sold during the period		---			25,062		112,180			29,918
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date	$	(25,108	)	$	88,186	$	(71,761	)	$	113,914

Marketable Securities [Table Text Block]

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	8,050,443	$	8,172,762	$	122,319
Equity and other mutual funds		610,542		720,692		110,150
Total equity securities		8,660,985		8,893,454		232,469
Total marketable securities	$	8,660,985	$	8,893,454	$	232,469

Equity Securities	Cost		Fair Value		Unrealized Gain
Fixed income mutual funds	$	6,703,107	$	6,907,270	$	204,163
Equity and other mutual funds		584,044		684,111		100,067
Total equity securities		7,287,151		7,591,381		304,230
Total marketable securities	$	7,287,151	$	7,591,381	$	304,230

XML 36 R26.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	September 30,		December 31,
	2021		2020
	(UNAUDITED)		(AUDITED)
Inventories consist of the following:
Raw materials	$	434,178	$	415,415
Work in process		75,716		59,258
Finished products		777,340		941,100
Total inventories	$	1,287,234	$	1,415,773

XML 37 R27.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Three months ended September 30,					Nine months ended September 30,
	2021			2020		2021		2020
Provision for federal income taxes - current	$	340,981		$	81,323	$	856,621	$	863,819
Provision for state income taxes - current		---			---		100		150
(Benefit from) provision for federal income taxes – deferred		(73,935	)		106,882		75,519		(155,127	)
Total provision for income taxes	$	267,046		$	188,205	$	932,240	$	708,842

XML 38 R28.htm IDEA: XBRL DOCUMENT

Note 12 - Other Information (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2021		December 31, 2020
Accrued Expenses	(Unaudited)		(Audited)

Bonuses	$	237,000	$	210,000
Distribution fees		362,315		325,792
Payroll and related expenses		225,328		245,521
Reserve for outdated material		311,311		302,713
Company 401(k) contribution		87,000		---
Deferred revenue		128,636		---
Audit fee		57,875		50,500
Annual report expenses		46,462		63,432
Sales rebates		51,428		149,346
Other		35,405		16,153
Total Accrued Expenses	$	1,542,760	$	1,363,457

XML 39 R29.htm IDEA: XBRL DOCUMENT

Note 5 - Cash and cash Equivalents (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Cash, Uninsured Amount	$ 806,000	$ 653,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition (Details Textual) - USD ($)		3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accounts Receivable, Allowance for Credit Loss, Ending Balance	$ 27,296	$ 27,296		$ 27,296		$ 14,017
Increase (Decrease) in Contract with Customer, Liability	$ 128,636
Cosmetic Ingredients [Member] \| Non-US [Member] \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage		16.00%	22.00%	21.00%	20.00%
ASI [Member] \| Non-US [Member] \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage		76.00%	69.00%	72.00%	69.00%
ASI [Member] \| CHINA \| Revenue, Segment Benchmark [Member] \| Geographic Concentration Risk [Member]
Concentration Risk, Percentage		29.00%	30.00%	35.00%	33.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition - Disaggregated Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net Sales	$ 3,179,746	$ 2,336,360	$ 10,268,592	$ 8,613,918
Cosmetic Ingredients [Member]
Net Sales	1,578,650	550,177	5,065,022	3,358,956
Pharmaceuticals [Member]
Net Sales	1,216,747	1,232,586	3,509,235	3,463,738
Medical [Member]
Net Sales	343,884	517,036	1,580,657	1,683,682
Industrial And Other [Member]
Net Sales	$ 40,465	$ 36,561	$ 113,678	$ 107,542

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 42 R32.htm IDEA: XBRL DOCUMENT

Note 6 - Revenue Recognition - Revenue by Geographic Region (Details) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Net Sales

$ 3,179,746

$ 2,336,360

$ 10,268,592

$ 8,613,918

UNITED STATES

Net Sales

^[1]

2,670,515

1,819,084

8,115,145

6,887,726

Non-US [Member]

Net Sales

$ 509,231

$ 517,276

$ 2,153,447

$ 1,726,192

[1]

- Definition

+ References

+ Details

XML 43 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Proceeds from Sale and Maturity of Marketable Securities, Total		$ 1,832,829	$ 3,802,205
Debt and Equity Securities, Realized Gain (Loss), Total	$ 25,062	$ 112,180	$ 29,918

XML 44 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities - Net Gains and Losses on Marketable Securities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net (losses) gains recognized during the period on marketable securities	$ (25,108)	$ 113,248	$ 40,419	$ 143,832
Less: Net gains recognized during the period on marketable securities sold during the period		25,062	112,180	29,918
Unrealized (losses) gains recognized during the reporting period on marketable securities still held at the reporting date	$ (25,108)	$ 88,186	$ (71,761)	$ 113,914

XML 45 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Marketable Securities - Summary of Investments (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Equity securities, cost	$ 8,660,985	$ 7,287,151
Equity securities	8,893,454	7,591,381
Equity securities, unrealized gain	232,469	304,230
Marketable securities, cost	8,660,985	7,287,151
Marketable securities	8,893,454	7,591,381
Marketable securities, unrealized gain	232,469	304,230
Fixed Income Securities [Member]
Equity securities, cost	8,050,443	6,703,107
Equity securities	8,172,762	6,907,270
Equity securities, unrealized gain	122,319	204,163
Equity And Other Mutual Funds [Member]
Equity securities, cost	610,542	584,044
Equity securities	720,692	684,111
Equity securities, unrealized gain	$ 110,150	$ 100,067

XML 46 R36.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Inventory Valuation Reserves, Ending Balance	$ 35,000	$ 35,000
Accrued Reserve for Outdated Material	$ 311,311	$ 302,713

XML 47 R37.htm IDEA: XBRL DOCUMENT

Note 8 - Inventories - Summary of Inventories (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Raw materials	$ 434,178	$ 415,415
Work in process	75,716	59,258
Finished products	777,340	941,100
Total inventories	$ 1,287,234	$ 1,415,773

XML 48 R38.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0

XML 49 R39.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Provision for federal income taxes - current	$ 340,981	$ 81,323	$ 856,621	$ 863,819
Provision for state income taxes - current			100	150
(Benefit from) provision for federal income taxes – deferred	(73,935)	106,882	75,519	(155,127)
Total provision for income taxes	$ 267,046	$ 188,205	$ 932,240	$ 708,842

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 50 R40.htm IDEA: XBRL DOCUMENT

Note 10 - Defined Contribution Plan (Details Textual) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Defined Contribution Plan, Cost	$ 87,000	$ 108,750
DC Plan [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	1 year
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0
DC Plan [Member] \| Discretionary Contributions Vesting at Two Years [Member]
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	2 years
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%
DC Plan [Member] \| Discretionary Contributions Vesting Each Additional Year [Member]
Defined Contribution, Discretionary Contribution Plan, Vesting Period (Year)	6 years
Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage	20.00%

XML 51 R41.htm IDEA: XBRL DOCUMENT

Note 11 - Related-party Transactions (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction, Expenses from Transactions with Related Party	$ 0
PKF [Member] \| Accounting and Tax Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party			$ 9,500
Director [Member] \| Accounting and Tax Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party		$ 9,500		$ 9,500

XML 52 R42.htm IDEA: XBRL DOCUMENT

Note 12 - Other Information - Summary of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Bonuses	$ 237,000	$ 210,000
Distribution fees	362,315	325,792
Payroll and related expenses	225,328	245,521
Accrued Reserve for Outdated Material	311,311	302,713
Company 401(k) contribution	87,000
Deferred revenue	128,636
Audit fee	57,875	50,500
Annual report expenses	46,462	63,432
Sales rebates	51,428	149,346
Other	35,405	16,153
Total Accrued Expenses	$ 1,542,760	$ 1,363,457

XML 53 R43.htm IDEA: XBRL DOCUMENT

Note 14 - Concentrations of Credit Risk (Details Textual)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Marketing Partner [Member]
Number of Customers	1		1
Distributor [Member]
Number of Customers	3	3	3
Distributors and Marketing Partners [Member]
Number of Customers				3
Distributors and Marketing Partners [Member] \| Revenue Benchmark [Member] \| Customer Concentration Risk [Member]
Concentration Risk, Percentage	86.00%	79.00%	79.00%	79.00%
Distributors and Marketing Partners [Member] \| Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk, Percentage	79.00%	70.00%	79.00%	70.00%

XML 54 R44.htm IDEA: XBRL DOCUMENT

Note 15 - Earnings Per Share (Details Textual) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share, Basic and Diluted, Total (in dollars per share)	$ 0.22	$ 0.16	$ 0.77	$ 0.59

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

#SE.ZCN6-2!..1'1&+Z2[V4\:.:9,.R>2!+(%Z9&#ZA1(H=LW3N^0UUL6$WD?G8K#393 .\'<53-#<=JY7;_UJ_'$=[3$JA&.B"ZVKD[ M4(/J>8XQ L!>7*#;>Q2A]-194G]]8D$-.#4-L[?CZ869V=L#P/JS',]F;P=% M(YJ]HXQWB-F[+@E"C]O.ATA3,GW[I!#T_FB:05+JK)YZ_<8.FG(5*E*\8"I0 M>TO4J3/H"7X-KL1@/PBTX& MV+Z'+A,OP#)O15\TF$K-.37@L?TY640)$2,Q(X\V?[@]!:U_8#Z3/,I>B8%X W8"6%J$G)$=HCF;:3,'EH;RGJS9M^(>@>?^K7;)*@?P0J1?V[$J:-">>PY'6SD4B5Y+P.[SBJ@8X]C:Z/<,R*Y]GD2CO^CFEX3G4JTB*4 MPSHE"?LEYX17)GXCPZWLA#<:8.@!<# !KLSNX92"Z@-YX ] .9_1U1HG6_3[ M=R>OO[[9TQM^CLWCR36U-QG.4^DO"",HK#/\-PB3ORK2[ 5.I=\+W?K%:HF^ M?%B"?#TV4R#OW"<5V:PV,:\_=LX-DR 2U@S[/1;;+5M#LQ5-\^B? MXG/3>G1C@X#MR?64>&7<&J>UIF4H"5[FJUNDR M=MI6!TI:AP:0;37JF, /Z_N3T8H$1--*2"O9CO39.965]#&51P?I=1I[-0G@ MWM>3H&+4%04\W)2L#M?(8"'.W1'0.W'RCD"GL3_3"V\ J[DS\=<1VM34B/IG MOX[AP]RZS%#=)$4&PH;Y?L" HAR<>/D4LL$U>(6"&&=9M(A82YRA)1LLRBE: ME<.M]2+[==?)@Y=W3%U!;)&S'XPC1,\?( M=[VHF0_J?\SNUE[9X$U-,G^N[QXB'N>4A-*"O8??0^\3*CCVGV25B- :;\M, MT4P*<+:$')PA9'\HR$[($S<)#8,I*GQ^[CI:DTV5K'"[3_,8JE&VZ"8@)[LS M1SC-C9E39G^[@HU_O*-I,.%1PO;C*O[Q?^9.O+> P9MP>[X<[[^GFRCFR3IX M2.C5BC_]$D$+69\+7*L/<)_NA6U;?U7(A51&#>Q>=D,]-E,0[QQ+V67TPI8! MR70O693M@=(EA6M;LBXQ?P:_W5TU"!%;E.1X$2\UCZDQXUR_Z>?15HW@EO.Z MD/"$$Y%P?3#@Z X,?0XBDST1J Q9=KG<) =;DT MV8?)L&K'&H"L/U3V5>VXZ^GNI*H=ZTP.Z VOC3P06@G1'@*2X#2BGY-L30+A MGCFG*QPE!U*KU1:0)DT*T[;L58C1EP*?^XQI:G92(QXY5H3W),?\/5T][S#B"3RW-F>M=Z_#^[ODFDFU8/4VA>U4'2.O;U.'%K)^-J8^9U(1# MC@6FJ\BS[%V$01>@ /6!MBU(/%M7&8HNPM)I@E:3+MW=&3MNS$C7CM@BKT8]CU&@>Z"#FNO S<7+X;47ES)B]1(>Z3]D.XE_J@N?.M\2Q>? L]3*1 M:G/&L=IJ%Q":!4&Z:>2O(-E=$4LK45X "$ 59H#)U#_!(B"1F&*@MDMQ=7M[UY ',_7-M+9X== MW(0R_*@B0-.K:WU @W/]X?TQLM7"[.R")N?AM9I21(TY.8$#W;WBP3N@ZX@' MO$,4KC8E'5H@N]'(8QRR#?$S[:_C,"N5,\6AMI^QSJ.,5BN:/.0T^-I[Y2AM M!XXS.H!G/ZTT1X@$1K]WC')64FW^^'&!7)*0I,;.#U6O86X/&72W#H]%0<4$ M71Y*[K>='7HLG<8EI$%P.@#"N)>+/H+5I3=ETXI:A\R-^OYK6""V'XDMJ7V=8E'7.*^*4JG]>O:WW[WT_N3DS_R5.J"?J])935G MJ".WK G;W?L3#835CG1Z$D<%>J#_;YR1#,G9UUA4^@F9;8_'/!KD#C@2>_Y+ MW64_T77>[3]5ESBT7EZ!I"7DF:2/ MU-38KK#JA0@X&POX0-=/R'2LMTY14IEN-W!*-E$ MR=-M446>)MDI6="4-"*$+E[R%-,TC'BEPBMFJ&8WC&F\SAJ-8U%W/B=L?OO= M7U8Q#G*A6:',K1O.RA#@KJ^)9D3G@ODG@3T*>$!*?)[)_V^\&LG-0Y7^D6+&%#:83NC'*FZT^>2;(A99R%XIZWN_' >]U]H Y75 =VX!(:91RP-5,4 M+TT+W%ZOF"7"T7&EW,>I:>Q"%ZMU3+=L0C[A/%BR+;/98)8D&QSO:H,'/'K[ M2>:%L8!AW!T-0HGG?0]"\HB[HQN.C;N'UC2CBNB]5D>HH!N5A"-=QKG=>0>M M&O7^/'QBIZ6^>+!9*@K>LH/ WEA$33&8QM($:D=)*9!/1"\IJ+2@BD;GBQWM M@_;HW&^IPQL_VD97XO45C-%T34NG=*G&4AO"](D&0#NZI ?Q1/1(#X46=,BH M_+"D/R3&2TDF+U)2-B79[Y#(6X_NL)^D2B.(O;Y"T9X[U\]T<+:<)2'_P>,B MGG$LXFGR,YRF6T9O9RE$2%_HDQT='$[2Y/*0/5X\3%2.*.GP\TK'B.UT$"]= M;VU1AI^>4OX(E*V/VT7IB!#WFZJK7Z.^T U+!X=M:=PG@JO4DHRI7 2;S00= MQ%[G3\H$1=5-#\\8S3/CG6VRG*Y(JGY/9M8=_)A,#XW]EV2%7(J\BA4E14[% MBI8IO",SG!,ZE-&#H@M#$A7BRG[9116R/_YQ7B:J^(\-3IEU%V_OR9JFAT:_ M1DM#J>N!:%T5EFA1C1<5B)U*D@Y+J0&?+,G'C"$..?++&#]U2$7G]P!9V(-C M_6%%A0QQ;,ZGO9MG5,D(2U-\D>11ON61!BD3*[&+BICYLR)0]HR&A[:\82^ M.&A MQZH+DA >S0<(4$%HBDJ*4&<%.<29,)\"N2H8R/IAXF>S2:]W1. K4!8O4'8"+10[88?ZW"C7Z4B'W>9 /?@.O"$U%<)'5].!*D*@F01M#7!P M1L'P<,RK>LSK:LQT@?(E00%=K7&R=5_'VTSX*)CAE@_3(C5,Q"=*>9J6-1UP MG#X$Z>P\O4/L^T MY2HU894E*3GC]>13@B4'JZZO =+0!&/]JH,?E#@R/Z>A M3HY1%1N<)T!,^+U=S%CTG7X?E?I2CLGS:JVN0A"6+,0_O7)$69*!SX.DI02&/V M<;;[](WOA+'JZ>C.(:O)8^^Y%KHNWJK<0[)"@D HH^5AZ,7F+Y-!+UGC9&T8 M>>0 GV9%$WI=4?4&L87;?3U]A#3'[RRO@YZ@]F9Y,)@#U[FZN)[);C=YEF/A M7Y:L7VD[:$ZN0WBNUF +,625C4 ]VZXB&C[D.,W-5E/I_Q=[G]CO,L6&9WD( M%XEA\0#C =A*AB85::K-)DNGC3+5R/;B)5@RUI$;O.KR=O0U YPNNL#97I85 M3E0A11RK\\-$+R>I+GO\'1YTU;A.E^&'!>?*O:P;D7'D1Z52072'W[NNT>)[ M]ZG KP8Z>?\XC_)60K6^)@,T3P7*MKP()/S"YN3]Z\([(^QYT__GS,9TEX6&%=L_:=86_PLTXM++8E]YIDV<^H*@Z7H48H6\A( M8J++ R2*8Z.T=!S*:-S1'O:ZTQ);0$\Y'W,1.5+F<-Z1HNY2L<116V7C*0@]L'+>\8L LRX@TF'88L-$V+!VD_MS< M.M2-X^T>F0]#BF26I%05*+*.$A188^3.]G CN>W=R\TGP;$&.,59E-TN=J&D MDL4M;0=D0,@/NHVP7^_!('*N4FU660Y"+$Y4=\+RN&2?'6I_K;8# MPA!;,)W%(9;GWP(U$KB]12+*.4N-V.5$6/CQ6T]46BT'"TH-T;68"#?)%(2D MS=-.$9$P:L!;@<.0:=G;@/YVYF\!NN'9GO]6J#\TTG\L\F&1_5?)@J:K(E:2 M'2]S=BH1ITTJ#IS\6-J(['<>R:\0%:K-0,MZ[ZZZ_Y5XAWO;#=!Y>_"<:;QR M1_3F$^[G)M5FT3COHC2>0(WXVLGYPZ81'C!-2:,UGB_Y?)>D>H+D4(<5$<&7 M44QN-AV2W-<$'+>] ^4H5ILC1 5&3^'9'=RC.BR9BD=0%(\P]?SM=1K;PR> M>_?DS0>4(!YG7&-XYJ90.$5'A'2<;1W\LZHZ+U8D?6);S,>4?LN79\6C5ZD6 M[6T-5JB=4!WIU@HW*I"C$KLG/=O/7VK(--LO?!GXGN-"\^LA+WE95W>O=UE+ M?P]VFPP[?*3;XL( ^_^,9BMVY@RNDJ>4A!%_&2\[!RB;FI\'I"#M1Q<6B%$# M,_2 ,.(@!B\U MG:T&N2]K: X]F"FJD'IT8K;9V/)C2GAC50[*!P!% B9FK_.LI)T1"#K-P9+1 M#=:1B%0/-VKLJ$#O25@4+*:F?!MP7&_["G<9)O"V8W,QZF-^@%?#MN[7UB'" M\$1O8U20^/(Z3\IZ,L. >2CF2\(]\ZTW,(TG 6F]ULO'!#P/S"$#G/LL#-8. M!?'<\:W8WTCTM,Q).'LF*7XJ[^EN%^)!:N,]*H_4#&9)>![%FUQ:H'P8,. M M&@RI;2U4485P05;U8/FWW_WT_N3DC^B1DR.BQ<."(._/EP=.'AUW1GPG']Q5 M.CV1"+M.E[&2#39 N[H6[J,!^*1[W*_6B+4ERE1RD/OL15E M3']V3P(2/7?9H8"NH\59M%'XB[9HTS).S,6@,0Z)O*@0\Z>A6B-R%GC1(UF] MX1)F,?O=^@-Q67J3'K M'*OL&YI\EMSLRUL %7 #DFUQ8:C83\V;>TN*IXMQ5(,;CB7@ J<\?KC.1*IW MQM/L!904!73KRJ9$+Q+-!F7"J2(+[6E]8"MI>0/*3.MHV #[N!X[(P()*HY0 M:]!EQH(I)>75%4@*9+==W[XPY^.K)"0O?R7R6QY).[@W?Q^>*S=^@14)M(CA M]>6_EW"3:K/(JE#WIM=8U>T$]DOW0 M[2?N*^M:=Y1 \6KJZW*= EEI2;-XFZ8@DD+0#ZY0"2_?QD#!VJ M% W'Z%[-R)A'-3CB6-F($K?B$4&/C[:[$5"5[ .SGGNZPN8EXDS!0*K'%:OF MQ2P,&?NR\L=UE+0NO+3:@@V/#IB.K) 2Y5'U"^+(T6WBRPKMXRXU8IDO'7*[ MN(P2G 01CN]H4390D0+6I.M0?=.#PIT6H@M44X$J,GP7YS6:A2ZEI?TF_S0)&TY5(WM(+I68J+$)$T1Q^U7@75PM4M]R5CE6'E])/0IQ>ME M%)B=M[3[ =66$KYM =L1,+E3ES[O*9BA+C05TY4YCO]/M)94NE4W'JJO]H"Z M5ED%+L75PS,70B,VW=OT+J7/41(HQ4;2?*C@'(!U+3H"/=_N M*@+\"H^,R5WBT\LYWV&/IUN>3*##)V308ZR@QQUD^X__6_L;1^W#?63"Y[[( M0!GS' O8+([I-UX)[I*FYW3SF"\VL79HH%EGH-CI(7$5'JA'#23$P-8X 9$& M=8#@#N\1JNE#"Z;6SWBBAQSQ,@)'/!TC?P92UA3TLAP-19$.X[OO78"KCLYK M1X,>8^T".\C>=@$?MY4FG.[;!V3L\^[77\*%MJ-G](OCVG6"1Y9Y;%$9A5F500N/A25,@LJD'8U9'M1 M5YKU,2&\=*W.<,SK'3V39$,>R!-?![W.0F5[J"*3P;4M:25.)ET%5G1*DF#) MDZK[]0RJ&4V-N>=OJQ22OZ1QR&SLHMJ6_IZI[CM\\Y3C<+J+-LGX755[;3K[ MJ<9,=&^LNNQU_MCOF60Y)S&[2LI:<)_J*G^'5>'8EV=%KO)YBKGB+DI#G4=9 M$--LDQ)>J4@4*I+(M&UTX$>%=LBRO7(:=/.,"G7)PAWM[>J%Z#5O40X E2- MQ1#>H-T@_)>=LBXLU+4$#,@-,PN"=$/">Y*1])G['YCY%/+WG)_8/VF$X\,5 M9]#%/#.,$K2#Q#!*&@P3JE@8$\R?QJE )1G"@581@J8S,EBFF#.V;8W1 MV!,;FV$12(I\;W5Z7*<@5KI/'T%7I+9\U67C^UK#DT1T0;5OCHGR%(TP9;_G M%A5SJ2''AILOLR39X+C(GU=6FO^;+3[2[ =,;S!@DK464ZCP 1*(H#,+L26"XWJ"(.U=2AQRUJ!"<+ M J=BE(\QG]3")+D.^VH%N/2J6E5S:&B7!*QM^>V(;_*K ^*P].+:%O+HD+; YC[CJYAE5,L)WY/'IMCZEFCU" MZ>PVWDN4/? > I$;9_=)O4GI9GO_PY0>7GH7OXHTL^AW2;?1Q&\?O%_QFU0P MO(SQO0+8QTUOYQI>QY F/);D=E%??(PQNSP* M[8CC?Y77;SR[=$D@>EV2^&9Z)R3XE'8>F0;.DZW<9$SPXKLE(TR:Z%S6!)*= M[ "4]?1D'!\2"'TE,)=RC^JPQ+&&O$V?A^&.6A'=%D6OQ M9R,#37TCW0BN8ZT?HJ=$)&!/\M+'Q6S@.P8OT AQ\44&4!>[)M?VJFF.YPCM MC4@$KS;'M)]B:3>L9IPJ[],8&=H-#55C\Q_+ZDWFZ%0$R;&NT3*P1K69W)I! MW5@AGK:A= ,"1&YHSA:E0.S'LZ:VK";D9$\-#H#!>'',RQ^TG-I2=#%,9 QZOH MAGQK[%4I3=BO0;&W\><<2S8%)*O+0XDV$=L#U[':H!P3-'!%CD&"HZOTLN)S M$N(TS-#G-8^7%T9<025_R-0TX2HZ_=MPHTXSM3EWSD.I8J[F[G":;^+K]G)'P*BE]2LG3C.T0 MS\4SZOZW87! 8"/:%*'UZUN>4VHAS*&P9-#Q^.XZPN, M->%WS\G3&_QM^JQ>,:6P^VB?$PN#R75[3@@&4H_ NL6+/Y6IP#P%7FIS60*YYQCD3N/ MN))-PG,2Q#@E8>\SCO[&0-'J!FI;G"JLJ$+K]P&'@K/4C%V.9:@1DL_O 5M) MK232I-L-*%E\<>6\ZK/9@>F^>U\=HVNKV:G5]=7\ZN+!S2[ M.4%I2UD%,I=3PK[#D=Z MRKK=<*"BW@%TIJ0YRFDHZ YN=BAG&8MEI" M@YS;$%UIW [4$"4[R@@ CBB.]PC5F)'."&S%8_>(!37@E*]SU&641-F2A!\I M#0T]2<@RVUTF%&:U3&FX"3[Y-$U9WG:=T^>=+]OY&TZ]7R5U* Y*9 MR9ZZYU#9DV.P+7L<,[_-7Q>X_4J>!J.[)$^7>X/BYX73/MT6@E?^L8NC+S_X M!V/I_E2WOS"4E1T VZ+P^>9J?L$/#+/YQ8-30>A@$I6/?!J!$^:1$O9"(]S' M0C203S NPC 0PGOD0W5,R7J$JK/-P)-CYD)P:F0^!:6;>QTGQ0Z6#,BH>'YV MQWC1[1;H_M8\2V(3BO6Y/$,;1?V1288D![\FZ>#:1(4;]FGWG/*E?YSQ3 M!4>FLP5,TFKHKN=&B!K[ MGD^AD?&P:^^;@&"TL^/4H0'% P5UKFJS_J,E=)+@L2UFKRM*WJ"PI(6?YVD= M!"*>IG@*0#*?C=Y$25HL=KYQ\A(C)+S :<(HRV8!LU(V0N^>DT441#))U>\( MWD)5".SOHP4%B)0D>-HVM1E-X=QS+G898VJPG/'(@V<2TS4WC..DB K(111P3. MJL.VYZZ,69XY[HDV4[<%G&0ESMHBYSU?;5 M2)N8^VQ:H*R;D1TX#7TX(] ,,10%5I% VQ_=\%J<24U^4)>1PXL%"8H[R:1T M0OTN0\%>]OLTRKXZ]SS)!9SJ<-+#*R*>\.-+" MXR1!ATA>QW]IT#(I ]E\6NA@7KO.VD22K$AE?)LO27I'V;F1Y%$J=K@R ;Z! M( \%!\WV!$3KX+:]) )55/B7ZL%S1,=FO&O+>_.8D?_>\!M=?CI0YBE5MH=: MWC*XUD^ -6)48/8OE&H>4V/&N?82\WN^E.=AZBPC(O,4Z_6">HO[H3OS&/>3 M ?(:CSTRP(&@H@%%10F='+]XRNRD*T44R,##I=0<0989_\ M/U!+ P04 " ",4&Q3YS=G7P4K !Q[0, $P '5G+3(P,C$P.3,P7W!R M92YX;6SM?6USW+:2[O>MNO_!U_N9L67'29PZV2U9+U[5VI*N)"=[]DN*(C$S M/.80$X"4I?SZ"Y#SYAD":)!#@H2ZRF5),PVPNXF7?KH;C7_\Y^,\??% &$]H M]MO+HQ]>OWQ!LHC&23;][>67V^#X]N3BXN4+GH=9'*8T([^]S.C+__R/__-O M__B_0?"19(2%.8E?W#^]N)L564S8*9V3%__SX>;3B^#%ZY]^??/+\><77^Y. M7KQY_>8H.!+_7@?!?_PC3;*OO\K_[D-.7@@F,E[^^=O+69XO?GWUZMNW;S\\ MWK/T!\JFK]Z\?OWVU8KZY9)55^N2?>Z_O:VI#UZ__[]J_+; M-2E/Z@A%IT>O_N?SI]MH1N9AD&12(Y'DA2>_\O+#3S0*\U*-1A%>*"GD7\&* M+) ?!4=O@K='/SSR^*70^HL7E>H83O),$KP6Q.YB3+@XSF)#CZ*>#%/2=_%?(C\B#^YX$0I>QYQLCDMY?%-%AU M(1_][S8]Y$\+,4QX,E^DY.6K+:87C'!!66KID_A@22]9/* U>/)8T[$<%PJ M;<5!2J/OQ)0/Y:O!PTGTPY0^O(I)4CY>_E)JH=2 ^.//LRQ/\B])^MM+U=<5-ZD<&Y0MM7$@;CZ1:9A6SSQ^3'@-0PH*&YYV!T(Q_?-2O )^ M1\^33$R!)$QO5R^'']_SG(51OL.*59O&"IN$_+Z<2 4/IF&XJ+1&TIRO/BDE M"5X?+>?3OR\__O,TX5%*><'(G1@V'\13OJHD@;<8NQS!&X>2K(>'6";(A?AU M=W2;"5UR?1?>I\3$\7=$+KA=KZ!GY0*Z'@$JQDWT.AFVE_YC%KV@3)@*O[T4 MYH;X9D(8(_&GZG'*K;'<"$J>Q /+[?U7.79)_-O+G!5K388L^FY#V>]H2?%J M$3*Y?42S)(U7K2>,SFT7+ I[N>*Q'2DE%_8;^=2/9LSSCC9:7KK33C]#1K?= M4I-Y,';A#<.? JP1L J.QJH"Z);ERV" V$C4>GO9:.7W\W MS8^S^&069E/"+[)MFD2,*['\&%'!(;M&H.D6:([,SD"0AB -01J"- 1IO8&T MP^_V_>&Y-P'-9X0%23:A;%[V;P?@-!WT@-B,3T>(AA -(=I8(=J5G-R?DO ^ M29,\(;R&3X5$%BT18"' 0H"% L!%@(L!%A#!%C6FWEO^.G'H. DH). \#P1 M^(-8I@QJVG>/GHP/1_#T#,!3#7-?.+F:G*T&!<#HMF@R=CSDBQR8R8CX!_$/ MXA_$/ZZ-?\0_B'\4^,?:KNH-^+P-!#"1:Y6 #Q%E- L?$B;$B^A#$A^]MP)! MP+ZZ!T16C" XZ@P<791OX6IRLGD')]4KT" 0BT;>8+A&:#GHX;F1\.B(A1$*(*L:**J[8-,R2O\N%XH1F MG*9)7&T,67R]M8A<36I&U$8H07V;3+-DDD1AEF\=^Q3]18FY>H0K-A#'(8Y# M'(=0D8K'CH!CL?B M\;%DX3P-=^,LRN\[A(XG+D=1]>QKPA(:GXO/ZH"WD;8W/J6.8%SN4?; X\5F%JIP!Y2\ M7V[K\ :$M 0X%CLU7_Z0L_-(Z2'5T/;%I]SAKM@=_:;VXRHI M^^+QF@H3)OW?9*'8ID&DB'399?AG.U:JM)^N9BF M'W:"Z/NLU5%USMM=^'@12X^-=)#)N6!8? ST8P_&V_)$I?-A1C/UFJTBZ9"K M6Q(53"CAZ,W]79+7HF@520]/P>KAI/S%MH&@9<,9Y8N^HL4K@J/+%Q]6$6 MN#H\L6_U\1VXL\T3NU83O8'KPA.CUAQ@@ZO$*RL6DC,%5XU71BPD\02N&J_L M6$W2$UPC7MFPFD06N$:\,ET!*85PS7ABNYX9\K'@"O'$@CVS3#;NXXCB?9B& M G\&?$9(SH.H6O>#1>E(#HHL+.(D)W%0:6%&\D18X> R-^UZ[_1 XR%8PP(Y M'>3D-:]D<9RF])M\J>>4G=+B/I\4Z?(\,+\A$4D>9)I+?0INJSXZN%Z>K=D-$JRMH"AGLJ/%./WJ &JV6@GO*6:JFST<$J&:B'O*5* MG+JRUK^5%[Q4H2\>))GX0C XHZE0/ _(7X6L7=76LW70AW7JZ.J TP9^KX,@ MT=/D(8G%D_EJF3X)^>PZ3 "PVMC42:WABJ=3$J6"H_@SJ3EA"B-VR+U4(HCS M?4*'7/,:;Z:6QB6OMPK2$B%#\"^ZH^XN,X%Q@OL9A\C6>PX5&9['\ M<;894#4E[E6^!]OV8[_LR!,BOTOGDW%PAB4@-DR:R M?CGE\@:QBHGZ2!N(MB>>;\E4SLV/A$Y9N)C)X+R29R-M7SRO5I1M3A3#PDC; MTD]Q?'M1'ZRN^:KEHTXHG\OTB8ML*C;;1.Y,JD<;2=$[LYL4DD5$EE\M"WLE M_.L'DD6S>2S MDX+G=$Z8R;UOV]R%5U:@8;[D@/1W\X^L/1']Z%\$:G"+7R M1/B@#K,S@%IY.L:N$QN<1!O $8_U4P^*=4K2N@9\T90Z\@3ST8X] @=9=.'^ MN;%K S8J@"[:L2L#O $9<:TOB=#F,+6=-W+L(Z3-=@,$V]X=L;89.O6^7X]' MC3 YKF1S6S$7?6V[8 MSX&T#T@NWVK JY+M"0$7H(#TT7UV&(@!/':#QVXP2#W6(/5%]D!X7HZ/B^R4 MW.?'6?QY/>FKT_.WZYDOLW$)R\6L6][(<>FVVXAD(4OH MEXPO2)1,$A*KBXN9:/LN+K9BR%18K(ZN)40]/;D6PUE5W*ONV[8/%,L5(W(B MA>SI9&M>\=\)SV40/+_[1O])0J8L.=:XBZY9/PNCV7$3TQ(/@7ELXSD2.'B7T**%'"3U*Z%'JVIAS6&\'_U%@HX"1E+Q42PTD3\%0JZ,"]'DW+>+! $ZZB$2!.8" M(T'.(T&G8E9$X@FUKGU^-W1'OBQQ. PHWU1)\+9=@@RM:1>B8Z[O-OJ&-!!A;#$<.\(M0MAF. M+/S#T_8W]J](T\& I(3'W!KT@&$>#/-@F ?#/!CFZ=9A;;W_4+A]Y+F6(&HQ M6"N^: @2!FIFZ8P]%-!RIBDQK"]Z:3QRGMU0J2O];>'\\27ZT6PBF?QUOF@' M8T,8&VI>++PA2N\O'/2C/$&SN?F!!W021/(ZHCQ@"5^S!0L) 3OK(2QDQ0F& MAIR'ACZ'_Z)L542?*T[;J(EZXE+F'UU-OF-#>93)2-O^R$N5M:&(I^E(#O=H MOBZC*4PFNU4^"+'$YS([;O9+PDN79<:6DQ?HOQ6XS?8OP6 MX[==G9S0^!>H%:@?NS)LK&K=;;LJ$\]C_1CO:+8#DKYH2G^ S>38&WLN@AR<7\>,QLP1M$,'0TUM#1V7)V7Q-V*^>V*69LI,<0 M$H:0,(2$(20,(8T=+PW<(X-XJ2%> F[AO8&DGP)6>57%SXA.L[(@7)#+MVI7 M+@K24?>0"4*Z3)LK=J MZZ2@2,A!PD\0%Z1+3C%NUTQ"UH M^ QF1#3@%N9S&)DYU':]1GBI@I?ZP3-V.QH1)2)*1)3;FE!L;;25M>C+,#$K MYV"&96\8_.=@7B9D2%X" >L*)G9(PIN@<%A7W>-P&SX0B?>/Q&'O!X#%;5YT MKW;Y1_%F/U'.K[*+[('PO QJF.QT6",'TGQ>*_EVK6.3,* VB*$10SL?$8BA MC1@:N,XBBD84C2@:432B:#-0M#'V?!D?9JU86(V] >1?@D2\H4SL[PUAL:Z# M[L&P^>D(@?N'P+JW @"^YI?:+SR)9B0N4G(UN5BR]712,+;:"4S&M6USA(T( M&YV/"(2-1MBH7:40+")81+"(8!'!HAD6-3.0>D-([\4Z+XB(6.(?FT$D;0_= M8R3 XQ$D]0^2M*\%@)( K]413#JA\P7-I,M'3FG)XUWX>/:X(!DGRUN=+9%3 MXQX13"&8DP2T$\/A66@3"#DZA]R 5X. 'B!7[$C^'4<16+UB3\EX7V25D%F.[0% M[0#!%8(KYR,"P9417$$6+(18"+$08B'$0HAE ['L+*7>$-6[( KY+ BSN/J% M_%4D#V$JH6 0DSQ,4A[D@LGU?NX^_YU M?%_D$][.@;5Y(D;8ERS)9%&J^'@N*UDK3,X:2K=WJ2%R&NW.9#TQG%OS:+P. MP')#XW4 QNM@<2U@@^K-8*TO8]3&5+7JT57QQ*[,T_*&#?94;;/+/S:&X?*# M/T\N=_;3_2\Z-$V?H:%<;Q-QEF_90^*O75M(7D-SS6A<1/D5NR7L(8GJKO,V MD?7+J;P+9\D$KWW)(-J>>+XE4SE5-P5LPE3)LY&V+YY7"\PV)XIA8:1M"?>. M;R_J[V:N^:KEHTXHGY,\B2ZRJ=BV$HGR58\VDB+(K0==QVE*OPGFR#EEI[2X MSR=%NG]MDP*,P1H[A<+0:T1W$;W5[:..):J_B,LHD>Z21-<2W3TMZO8]BQ9# MD..:,/E!."5'4$&VF@QKWDC]VDV9_18NZE>M=T'#-8:[):R@[1S(=)%%LN@> M.275SXM,\%B6RO\CR6>K*GVK0,630D++7IR.QDN:?5'L_6H*%R[,K?M5E\:C MEFLC/3J/T7F,SF-T'K<1WN@LH%8(W0=UF$$RM?( C%TG-G:U[M92EU3Y 6 %_#A,!?292?5NK"K 3"IE)E6SD&=W6\M@%=4RO-#=0CM8C=G$ GO+ MUE-=F- F7\^RS^XS]AHQA$=*\$B);93JE-SGQUE\]E3NJ+X"EFM^\$#-Q@SQ9@I MQDS'!Q,'[DY"F-C EF^]?3U#Q-C0O.D-"GU_"4 ; 3JJ7O88\$&@IW.P,ZR MKL2->*GL0;J5KHH\%N])+AB$)74XQ]BDF3'\G)#8NOS\[V%:5!Z72ILJRUW= M )$'(@]$'H@\$'D@\G!O1<$,1K83+WABIUZ^&V !:RKWJ^A06B!<12T M>D=6&OA+MBQ?\C>)[\+'915YE:(5U)Z6WT6['>UVM-O1;C^@W0Y<0'NS2H]> M"[-M(CB.@T@F;B7W15G':I&&[:IU->FXA[L\&G.%]JOSBEFW$1J6UTR[U MH$''/:0>-.8*4P^B] MB\#6,'G]=:)2TMY73L(AY4)P+1<"0R!$1>B8Z[O-ZJ6-0QE;#$<.\(M0MAF. M+&>/"Y)Q4A8FV/J8RZ)LVTWLI(7VZCA06LL[__"T_8W]H-5T@.%(#$=B.!+# MD8<)K%BO/A1N+WBN)8A:#+NW+QJ"A"N;[7-C#UFUG&E*!.&+7AJ/G&$>S!;M6C*YV[N**3W=F;5\+-+XM3)O'\7C/8"JOT3-*I+MS MT+5$NU>\F879;3$$.;:NO($*HKDEQZTL4K]V4V:_A0LYENNHX3; 75E@K5R$ MEK8NQ+PDN58*+2T&\S"8A\$\#.:U/>ZA@8K4"I^-71DVMHGNGCS5MNFQ?HS7 M0-N9X[YH2G_JSN2C&7M0RKRX 'T*8X^P@!1A\$"-?3# 0RQV.-<7O3195 'P M8.Q3I]6PJ?#QBM&:*#2(>>T#7=L4%^]A]F4]-EAN8H:GC@;^\?Y2/]X%)&296.MYL" LX#,A;;M\#YL>>TCR ML&<',SOPWA-;S_K91,*5.D[3(E55@#:WP_D*,<&"$ R,< MXS/G!^XP0'.^@?UJN5GU9L+^',S7U[8'?'-O.R_FXHLGF=0K;]/FN6RRKMMA M9=.V>T3W1NXA^$.KMS.K]Y32$K)NV;P0T["MZZ$^0\3)B\\'3/%FO7FTN1Y(5082HK67T4X_83Y36YKP?I M]F!"5H\3S[W*9X1]+J3M=UYDL3+I&MC@(&QM:>$A2XZCJ)@7Y:$8B)X;=]&2 M]"-81P]P 8WW7M%EHL+#&M*!<%ZW, /)'4BP!H 7&1?6HQP2FE1D M [43_A])?%'>6+S1JS91%- "G2E>7HM;'JV[%OJGGH]_RK0+T3[FHR_*-'NZ0)N^+XX_B[$%-B1\282! MZ,82&?HR;/IPF0]\= S99>Y($WIO.0@,>C=!K'7B^6RIUT=KOU5WJ84YS<-T M4.&G@[F]NTM&]$1I2N\Z6'/OGJGFS+[[/L*AZ]^J2D:S,)L*B)UDX@L:?9W1 M-):9F*3D/RBRL(B3K=PD4R2T7>^=!D$/P5J#^&>;D@3S.JNV&'0U$N M<(V-ZXL2ZD6LT8$*/_GB\@8K0@>!?5&&173(; #Y,E5@(E.PM\>[P0+5"P1M M^1(Y B\K[=)6!JX%ZR$"\'QXIYL!1N(7Y;7RXODL'U10!^K]Z&Z)';IFC/#, MN^FCU8?&*]E![/U]I8B,3&7P?XCC0QUHZ"ZJ7DV9LVR0"C&Z)+N+F0];+T9_ M26\'@W\*6%414/R,Z#1+Y ."..'A=,JJJ;:F:'(JN$7_W1\);LT57;'DEH>*&(QU9OYQN\O!)?7@51-OR:.8)Y7.2)]%%-I5W>4G4H#KF M:B1MRRLF*8KA.F%9R8*%LR\EE(%X6I\CJCNJ];/O):;)#S,")%+KM6 MO@(M65>'=%LLCH 3NJV7WI[CWB4G\G+"$YJ5#GYY,>&J"!T%&&H(4846J,C MQW[3U6?W3\&4T"D+%[,D$I].2_OZ8.Y3F\>X\J+:\]C"F5K>-,&>*HBX_&/C MQEQ^\.>7VQTLN/]%AXY4=.O:.$MOR52.L(_KH1.F2F>ID;8OGE?S8IL3A3_: M2-NO6\]FMC;V[MDO"?T>Q*'9%_V)EAH*=$:B,Q*=D8=W1EJM%>B3?!X^2?.F M2:TL@K'K!.:8!)H:8W<[@ >(RNH?N],!K "C.3/VH8 >*/1 >>^!4E6+S4@N M1$DR'H19' BE"D8#83354Q_RIH]63W9W <@!V,8\P,[N!;&NEMSJ=0)\&QT. MHWYKO)#[O*92E^H:";M6PY'GQG ]1K/6PY'/? %(T_;HXD$7SV%CU M\=_KTR>2&RV81217IPTK2\6[0=)$-7ICQSN/2!,5P6M.=XS^WP=)>?0VR,-' ML3G MH$:<0+>CVZ/-!B#0..HS('D5^'3W+W7B[ "CB@)W;(_0V)2/(@>;HD.4P& M71,WDH@5,UXO7(0;Q=#3NY/A4Q+>)VGIHP;)H*9W(\/J4L=3(A;)*"F72/%[ M2LKM,HN/YY3ER=_EY]>,BN4N?[H6*^'*2;^8:T4^:/9*7:I9L4F%W9%.216+! M54ED;N%(CF6]?>WK4) Y=-VOM^FMO4Z8'0:?O:&5R\OX0.:B@=H!_^?)8UX( MY+.]E>I6*R.]DX#)@^""LB?U *HC<<#IIS"+%1QN?^6"L\V$D@7#H)=+F9HY MM23 9O<^X<#X-IA!Y@8.I/B\SA/=9.CH7X.F1?#&H237C"S")%YZSE;5H2!6 MM45+=W*56%DOP'4EY4HX#>E&IOZDW#2&;?-+QQUFXQD M?;]NFTMU1QZGA\P4S.;!;![,YL%L'D6J < I[XM"]*+25@[Q[J9/+C8VTF^2 M"EA1%CX 7_*V?%:6T72X>A+W8,7.PM7>U'K'P9*XW4 8R,^F*U--*1 M1:Z+5SG:C91EY^OWQV4[-1F%MJJ;DYU^ MS,EMOCB +,>-34YQ=\;-D%4$3GKW9>6!V3C0! %?;!R O#N#1GW8P!?KQDXG MMFEAW9DY3@ZHVZC*G#WDE6?(3CFVZ?8;575WG'_]&P_H)(A"/@LF*?W&[4_R MPWOJ]!"_+1MX?K^SJH7"-F,DY.245#\OLEUK?X<54)MFAPEJV+MCH9 ]J^+Q M));WDMR&*;F:E)Z@?=9@]"[.W,;_*GAEZ-U1P1X5-EZ975 9Q[*4ZAV5R2O7 MLN:7&.L?GKYP:3I?+0@+I55X'.5"R^7"9#BRV^&C')V2W5A^I'18B%:B+^CTMH6J'\I-\V41U-[9"'X$77=FZ[? MC577UV6]F_V%>"G^V6,T"P60O!'[[-ED0I1K1;],.,U2W_-&6-4R555W*_=WO'?"XJH!^E56+39G)OS0T^)&"<7VC(/O%H4!;SN_K M,(EU1[U5A&ZXWEE^=D) :B'T[8*C04JU24VU%FS3U/E V^=P)_S2X.75]Q , M4M(M-X.MB#5-!R'9*D'81J2M-D,;DALP5*[-!LQEW7Y8,FY[O1H+JNED$-(N MDY)7%EUM^C98:DAG0QO2@&H$^D9N!:H[N *\WA#2U*UP\IQ)C4MF>51TVR6C M$!'>@5,4!F?3L! U[V@X4LOMC^8EJ*-UN\BN&[NAQ]%>1,%)GEQB$T;8=F'BVE8KA'3@6E-&(D)BOPHN" ML\]A+M_!T]7$YITV[<>-S-5=1.>4G=+B/I\4Z M8<$C13YX6\#HB[9:Z(&"T*IW$TP[K+K/E/-EX'6JJ>^.#-GFI70P8M]7&L[$ M3I0O:;U3=*.(2 >')IZ#KBV3?CH\?>&@+%U/.K;Q-71X5-5?!5LF0OIRC!Q\ M]V>3](\.K .7ZZF]%K0J!*2M>;;Y'UB!NNPJS[;R VNN479/!_NV?RJMSR-Z M7J?;V^30=0P:;55H3D3W"N:U MT&23\\1>%1MJ/PJ;YX]UI\@A;KQMLPH]PVLMU+'M>6F>M./+5GP@1;;+!O)L M;^YH<(*RYKRJ?W,8139/0 !C"<]CBX&HHV86ZQ)YN]M+AC-G M+=76_$A0=][[T2K3;:6,[G:D12\O2/-V!I^JEG&6C7*U=5O ! MOY*!5Y$%EDEMDEOL2TJ2K?#?>^VT!4S *OIYX"J"F:S-#GWY,H[LQ:\KC>ZI M8Z.1;NS*,&YTU5<%U:2<_FVKIZIZZ;%RJIX%K)IZF*JIAZKW1WE^-?E(:5Q6 M%B;L(8D(OZ6;N;=;F\_8P)$4Y05L54J$LHKC#IG3<^NKFN "A=W.Q)KW(>1) M5)J4:;$U:W9$ +9R5JA-9O;)A;6Z-* 0K&[,X@]$V$%DR\PY>Q3+M-ASQ.+- MGLJ56R[MHJ587U*YF&P.U2 I+;,( M]/,=U,:)+ \D*\C*?))CXH\DGYT4/!>J9FNWIP3(XI_,DU5*:-T3%MMHSO4H M2E3\09+I3("2XP8S+,9R@$W;N_&C59BE1>W+^@(7F]H[BGT908V4!(2;W64^ MC4!'%N#)JQ39QK-.%^+PZHQ*NRFG]B?X,MW F18V[CM?-C6XV-_EZ!C<_;[L M9HVT X\E^)7*VT17X!" 5WM:PTG76YRWP^VQ?Q#80MF'JZ1C?7YF+*-2&WWT M)>.WD6:L^4V)C =Y2*=YC@?D$-,@.[L\?EGKXCC+BC"](0O*5LX" M?E(P.8]W0TR0-@>[/'[YJ--$GC6Y+^3P.2=FUA3TAV9+.EO8 SFG3*P_L3R: M^5G\QY(P57*F;G(PYFI2C0\S&3?"=/8(!X'7Y8OY0+-"/>AUM$Y#\_OE?D 2 M[-,[31-9$RW*F8:I9LD"-AB#/;9B&##J\=H@= M7[%>F<'+^)V>_WIBI_Q7]0HMI[F^D5-YKL7"7U4$+YF\%O.6B1G,REU$Z#_) MQ );X6A9?F;%L_FZY?8=8Y+54)*L1N8E[](BPMPDS$W"W"3,3=+>@@+!)=V- MD.'IQ=83T&&(;7"ZL3+5.PRH#4XQ#9PT7H7 8./F\&9VA^&QH2H1AC.["XP- M5C%VCI#NXF'#4U 3OSM8/[^,7S\-_()@];SW1CUVCB&XR6AO2_>?N6 U@,P> M\MYBR;\$R=8U,%N^@^V/F\2/FW3WIWU5G"EL3=U>VU*!N[O;L*>XP]L^>\]!(H,9H2$JV++_/K M3T2F) 0($"! PMFKJPJ0E,K+%]>,C/AUZ(U,\C8R+?>WDZ'GC<_/SEY?7T]? MRZ>V\WRF-)O-LS>\YX3?=.[0P=2-;SW'9+>JLEP[@ZOAC7A!-Z)[I^_C%\-; M+;+QY)7CUU -A5PS+-"SZ?U\?OIUYCF:Y ]L9:9YA6]"64BW)C5)Y MTDFX]P8?J)5F)==)U MO$5/19<2'O,]ASXO7(#F&5R?C&W1?4HY-K[8*!S;7# *=B5I%-[82<8.7IF" MSMRB3",'+_. M;H_HU-,/5S?7!G3_V3WMVZ/80J5;IK=$VE_1%YT:R=,.%Z9FW9^ Q2\]8P?9 M9;E9EL-;^K[C4*O_GMQ@>'6J5=?H+UAUHS]U(WWK#Y/OQ"M3MSH+@.0@C)3& M-.[ZMF]YSJ(N\XO3\^"6GC5MG ANO,!NGJ/01-I,N%7WG!EBGEIRN'R&E_%) M&9^$?EW\C?PZI)H._Y)?/<,SZ87_'"[-GXK\URDP_E_/^!6\Y_\IE<@-M:BC M>50GO7?RR/%X!7@D][;C:28I$44Y:[(.DO)YM7PNR^3^.RF56 LCZFD$^U>B M?_G&RV\GE[;E438#_ M .XMN<9_Z3E1Y+'WA; ?!MK(,-_/R?_\Y=O>ET=C1%W2H:_DP1YI%O_Q"QEK MN@[$,][. ML4?4X1\-7:?6Q=_P,]S1\4?4,?I\+&_> \I+_<]PP60E^-@L(?PM#2D9*.:\ M;<$\OU_"Z!W-O(59??N#OI\0 X17C.I+R;==R/"?(BMJL_KKV50WLNG6 WTV M7!1"7@>N+.K5S%T73YW;Q_85N7EJ/5S=MCKDMG.9<>]:(VKI\,>[-K7G$\(E MY&\G(%+/>S;("\T::"8P] OV3\8OOV1LR;LVW+YF_IMJ3MO2KX R3BY*)44% MTLSX?5=VWQ]%+[R')FS]&GYS3R[^4=[INW!PP9OP]D7ONG:T/NHG#![]>J/> MK-14^63JW<;4"WW+X#\_=:_"UP?<\+QEFO8K"IQK&QB,W_,&OMGJ,\;J/M ^ M-5ZTGDF#13@AV$]X6IY&@>6/=-O3:=\8: M>U!TSBW#!'[A^$ :ZW6NL>ED[Z-SS;0S!Z3:'6H.3>JD;74]N__C7G/NG*Z' M([6W*ABN-]09>WV;@5[1O0I^+.OA9&:1SY$:# MEXNSZNIZ Z]N,_# MP_C^\X%ZAD/18KDW-0L=*)PT+O%K2!#!()[/KZ"[%F6&C6/T?'SK%9CJ#L5/ MFO,>OX -_).Z: %QI\%)?-VKZM10==S#Y0?7+P*V09F1_,G,!;^GV M*?3?L .^L&!(;C">EO?X:J-WPMWE#%67S)":\QEJ:_UA2]<-=@MSY.QRINI+ M9JJVAMNH6JLERQ%E(D?24\TR1I P>'RT/1J;]CMU%DY$:X2.FWWPN"158E/^ M4=B9:*BR4EN@5,UCPD3?P[WF>.^/N''*FV+3$3CZU8X_B;_N7X0WCCVRF S2EZIHJ0*.1 M#+7Z#-2^:_^QG4O?]6P@9*[!?=><'Y1Q!>BP1>=GY=Z/J6[/Y\ #X/K=(&IE M0]?$>N-K;CR^*]S80, G+/ANAE9>:VC-)#-3G@Q-+O#0%JS:+ ,L*"IKLKSQ M^'*^=#6YDHYC+Q\:>O!G5](]['@'MNU9MD=Q[_T MU-2&6E*;/:54T6O]4K.G5DJ#>J76JPY4N4H;)Q==P^I3XOH]]$MYAF::[P3^ M(F/?Z0\UD NXP][JWA*P9(D[-,9CJA//QI_^YZ[#8MX M0TJ>3KNG$FO(A?&ZP1.L$8>.;0>W[C67W1;< =-!0/9K5A\Z$=P$4XT=&=O0 MLD0HF*?0N.T_#XE&7 ,,IX'1AUZ3OWR-[?T2>X WN#36_5<#.M&;]#T8#G0( MWDBA$=(/5^>478'')GV$VW X8-^/->L=/FL>T<9CQWZ#!?(H3%:]]C.^%NRV M8""L#]$CDTF"AW2_[T53Y T-1\>NPXLZR\!^@,<+"ULZ' M+ +0?RZ%D2*G;RZ8 ?PBAIC\=N(:H#2R_;3I%OCKIE[!OKLV8(9]9<%]YP'/ M8,2T:+/Z(KB7,OB%W]#_XP$V8<3LK30QDN_R]H_ID(G9AR_"GZ9;YPL=?@.R M=3S<\+^8]#!\;G(MZJ8>NQ5','D%OQ)^#U]R-C47T=P@PV,3P[UA8?LCJKG M 2^"US.7=]A$>"W\CDTDSG7@\U%P)#F88!YQYEU,.A4U%%Q9=\Y0-Y^=L2"& M[QRNK3UA"S3(',S=+#CK>P'GW-S,JZ!YFQLY_=S(F<^-DONY2) U4PPUI>>YY_/&*6O8(9'9"LVF9ZE039].]3\E[\X*# M*=X[M;1K\MZY,8;^^5R-40XC]C(=X\1IV_[+Q[!-T-QLBP4EH8T3V[H*S)D= MSTF 8_J,7>)?=7C9V]@T^H;'^T!T ZZZ8.I,_%=+AW%RD; 5Q]OZ]2SQ%=$\ M1CTIP&(]4$]#_VA;5.Z7+<$F*(L5W-$*;F'FE&/+O:VV-+_< M.9 @AY\;(SW^A;C9C&_-+-:VXD8PJ_V(F]TL6PZ8SD[&N"@\3Z!T#R*UDEYL MU#)T0,PO=P[0G=NY61VLF5/83_5[ O/Y 7P(B*]=NOO>"NNX;>3-1S M,9$T/0BQG/0#W%6H;;',* VIN9OX-ERX$AM),Q M+@IY%2C=@]C8?PR&D7Z-A=C8F/]DN3LN"')O8B/#95.:8L-_=XL5SNY^%TO0 M6#Z7+5>J689C3(@)%/N$>U'-U@MSS#*H87ZYZX M8%;[BJ';Q;+E@.GL9(R+LL\(E.Y!I*9UDLO9[M/,+W<.T)W;N1%!#4V%[/<'1<&U-[,_!TL6PX, MH9V,<5&R*X'2/8B-_2=/,-*OL1 ;&_.?;(_\"X+.=) M(P!R?3Y?.(J=2<\\I642*UMXO6A1XE"QL@=+@+';=&%B90\7!70(.7L_U)R1 MUJ<^S(MF%G%5$T?P@>6K6-%CDZMB18]-GHH5/38Y^AT4"IB( J[D5,\_L-P4 M*UAT.2E6L.AR4:Q@T>7@K:7[6&5%,UN6?N<-HP(Y15K,18/XP-)1K.MQRDRQ MKL;S]A M$LXQ:1E6'Y_IV-933CTEDU":Y9,\">%8.-L+H;U-)\+EFKQ_Y;IMWH^,MV!2 MO6\A:B8CCL'G8ZAQ@N(%Q0N*_T@*OJ!X0?&"XC^2Z2NGDCH!5KV+=]0.C[^5/W8QAD8ND*JUF+I2NLBB26[@AE78ZUQAPI+@61 M?F(QCT@>BL4\(@DI%K-P,C-?'J%6]U9X@#Z"!RA:Z*/P^.1*<1(4+2A:4'21 MM>?BR^C+CB!D0=G"Z)X]"LDLB#DG$GDP^U#'05%"XDL"/G0-O+^Z7>J0/RU86E6 MW]#,6\OU'!^'P4CCVGBC^JW5MT> JK[O&)Y!=_S-?/:M_3"+MSS^8HA%6/=Y*!2O""V72Z:G&F=^)6+)H@M=^NV MR%?T0#W#85+^WM2LCC;B*N+5)7[-]W(E=YVM5KS[Q?<91.E1_DTU9RX]BN\Y MY_\.'UT[,\H&>)A8#5U0:C7H.K_%?U/4,Z[GE M/;[:.(2>Q^ _,##;6G_8TG6#W6+BS J ;@/01?-Y MA$!-\/4(B5HLFW\QPS&A1?T>^O#^Z&B6J_41T-R#UF<>$&3&EOZHO04>F/" M_X)'W:_O\2NLI?L?@[QC8N$T<&?3TJG8WM.6?BYY)O9P/H^3VG7NQ6!RDHH2=GM4C##9*%(X"KP*O^54"9H/3OVO_L9U+W_7L$75X$=7O MFO.#XJK@]%AYSB0[WWF>G#UQ +N4EP<*5DZWGF#.< LFK_QBR5+.]?UCK.): MV^D=FF8K/9S;11OIRX'C H>>):N<>[DVVT:/)G-/6^@KEF4[%\=JHEJRKH+2 MXDH;X*-/C1>M9U)!;-L0VZ+Y%/1V?/268,\+_:2(5NY61^*$?B+TDR+QRV)1 MFM!/A'XBZ&UC>V!V4TSXPPJ\?Y1N/86^6;A5%/JFT#>/5OX5B]*$OBGT34%O M&]MWL_$"1X/\_*YW<0_*"DU&:#*"TG9%:4*3$9J,H+<5]&:\G3L8+(=Q?Y3)7E\ID#E\_POA.B.7UG^^5!K;M6;9' M3XAG/]"!^]O)H-?4FYK:4$MJLZ>4*GJM7VKVU$II4*_4>M6!*E=IXX0,''O$ M'^C7&_5FI:Q62?BI%GVJ1Y\:0&UG,T,+?W%MW^E3%\:.WX=4T]E2Z<;+!?D; M(;_B!_B7_,]/;YK\!7^9OO;KF+C>.PYZ +-8&F@CPWP_?P0\N:1#7\F#/=*L M+^R::_R7GBORV.-?7S3'T"SOW+*=D69^P14H::;Q;)TCH*GS!6CNV;#.\0$8 M0._BZ;1[2KKMRZ>'V\?;=I>T.E>D_7^7O[??]^VVW>WO7^?6L!P,8 M0Q?WV+=_M;J_WW9N'N\Z$KDZO3PEL%25YJJN_#+3EU_2=&;JU7Q9-ARNNO%P MK^\>OA.D%LNV.CXP":-/+ W9M4Z-\RN[ST[;(M]"E5T/WAO!"^>'K;U0Q\-L)@%H/7O\ M)7A!@SU%=C47*TG@'SX(*>J8[P]T;#L>\&YLQ?OMQ 2 WWFO&?;9D\S31L& M]I:26& %U)JB?)DG&%B37\\\?<7<+)R0#)#XCZ?6PV/[X=N_R4/[_N[AD=P_ M/72?6IU'\GB'S/L1.#11RN3N@2C53_IG.*9Z_A*3^Y]IVB#>DY*\0D(0K001T(ZH3 M-K_P/Y"J%?:8B0&=]FVN7)X3'VX%?:0ZV4T._2L<=5UK(L$;PR2P3D% :#P]BW_!"L<(4V@&=2V"'B['FA MG$M>R.'Q^-#J=&\9WTM@B4M9(6\@7_R0<07#0EO[O+D_#6=3?N=%J L9'EI/ MY,_@/S"]HL]"W]S" )K87^3Z]EN;=)Z^?VT_G&0$ONRT>+S?;+F"CQU;A_;5Z4;4.6N;EM@T=YV+D^GIBOXN&>, M?6J_:7V/8"(#8@_( WU&AQ0T0327=,>TC\X_G1@6N?5<0))R]MG,7;L%VPGM69X14WM%33)I60^K0[L M=Q8>M;?;P$/=9X^OQ\2 B]659EVMK!P@5P:F%WS1\#ZQY2 @+%DB-/*_OF.X MNL%.#B.-32T=N\UYUBSCO^S[YZ1)7?BFV],'=."U1V/3?H=734\&Z=BGGV?' MD%*A648= 1W-$59(SR0@:,(IN@0ZX3EAMP4_]&S/LT?!;XF#6\W?#]S!3&'< MTG6'NF[PSS=X2$D)8;4LD^^:T_==\M7V30HCU&?!+*V2_L%[+^'CG?-HOZ9E M#[]K_GBL^<]S_"'M&QFAW#GWP)<,JY\9VT(T_-MV?LR9L>EZ=6_#:\W_SQAS M5IJ2E=0;C0VUH=W(]6 PR'#N'9A=8ZR9I/U&^[YGO%!R-QA@HH25DCP;1\_> MA[\&;7Y:B HDB)9#M35P4"O/.4\^+X;=-QL,Y_NA;:VG?*OU,GR4Y5SA;:(Y MXOO1A2 KS2]PQ26/U*1C'"7AP]RW^IA+^9$>H)VSUL&L S#Y 5L,LA+CSO!% MXYQ%(IJEA[\-#!>@3-#O*!%C0/I#S7H&N\%%ODY,S?6(PSQ4N5C[8GH$+NT7 MF.E[[9D2!=FZNM_73PU9-UY('Y;5_>WD_N;K'S..5VXHA<1@TH$W31Z.\3SD M/YW@KO=T:]>/#R=+%-^X+782[9F'CP\')<=^Y;_/7D CD=S?=)Z^G[#M]\G^ M>WP#/OPT^3!TPN[W>_!+8I,@:DV:E9&%(^ M6G7\]@7XNVG#;3_)[#]X3NO_>'; 4W MC+A88VJB?Y,9[!R5S5K5Q4@H M*N,WXMJFH1/GN?=)E@C^__D+F=E)(+B5$(*Z4CZM_AR26,*%0&V\SHTX)<) M;TKYSHA:95@$;?U?4'B.^E*;5I3T:P1QW/;O_0R)_ET\5F8PUA[QH MID]QMXNXPT2'Z.$).0^S'E N)]R44_YTLZ_9Y&2\'EL,5-4\3WH(]7; ))!S MS+O2D(6LYT5K=:]:V#I\4#E3;?+\V^ _<=W/6/POFB7OEP+^?2M MI:.['12Q=[!Z:?\':K$_@$M3YOQ'W="9;*I]4CZ3H>:"O6R"5JF!WLW-8E0V M__(-5#5!P^S1X 9H,](VR[A5P(,: ITSIJJ&:X]Z*%[&> :BPU40HWCKV*%] MRH2JHA(6)>223] >H(2X/L@3=VCCSEZXH>\--6^V[Z_:="^QB_SA8 R?N4O@ MD\K'V .LP?7>?V $>#^[%1["7@3M8 R+RSK!.HEN@J9,=#"I3DG@1MH@3$S\ MG39H+D,G6-QJ"XB$,"J9,N08.PU^XT C/*X)98JG>;Z;DG?]F[KS MSO_ +S8[X=W&F6R'O'Y#MG8JD7:@)4AB0-UCPS/ WY 3:!RQ[90 M]IKOA((W*,4P9?(+)5>:IQ&,,YGE=),VXD;V@P]W5N1J$)3@\U,6I%MZ M))]"SE#'=51!J@?W@9!VT?,XQA"%77,_WNV(J5'WLV!9XN^C9,4Q,D8J#CCS MD;/B7*J/P-\T8D*;E&C]/O!/@75DQ*=#@R+A8&R7>;)ME\?%W5!+R=W MZ7B7-/O8V@\L',/<@ZB;SCR\8'PSCV+T&Y-'BMHKJ:'V'5>Y3XOD^CU 0!R# M^K=D1(0#BY/^PI@RUE K;1-Q7U@*/H?:B7,)S3[;SGN"!E-Z:3 M2'"6+\X.0XEF@FU,+ +ZY+$5XV,M?/5=PZ*NN^MC4W/S'W9S,J)V,O6E'D_X M_ U[_)(_O>LC$ <\&A!(C8^DL7 9.5@BBR3@SC,BE$E08Y!DL# S!>C/LIF5 MX;N4W07OY6>V$HXV@"3$5YGO^.Y7 ]X,;R46C-=&8GPQ7$;/05U!-#=\$HL^N1[0,YI#?::%X;G+ MX$Q.\:9]\@82_JF5$T^DM=@<=.P7?E14X2=%)38K#W$FJ_/IU9F^'5^$@&RN M'5Y$:][CQ^:<;;UUV1+>31X&#;:OX7A!E\6"S8Q>V%TG0/]] \;B_G9RV[F> M/A,+H-!M+[AAFM@,3F$*$MO)146J-BM266F&)!;V\B*"TX#,; XNV!LDGT[B M-YY\/CTT+G**O?3A;NJAP]U$B)T(L?M@(79KY"OB ]X3C2PX2#E>UHML&> > M!XM*3N>J_7]XJOWZMM/J7-ZVOI'N8^NQ_;W=>>Q.M(XL.Y5%IH[>!4G1N>P7 M)H=!D8S: Q<9^TS0)<(_D<69%'BD2_"V1OVT\7-LN)Z^N@$2M!!RK>9I[><% M6P#I#R,P>=RQ)T>7HYYPK\BV ]Q5Y@B-#!U4^WZZ5Z(U1WNL!*-%5>^G,9H#U?+NX7OK,4J&IL7"E-8;*EN'A*7<<@(;I_5U$3+=P(+G ML^G6@G7-VH<4_2F7YQQ*I2!=2QP+MRO1<.O1$5%(";1_; >=/=>1LX<=8.1! M+)]\2_-U YU+OF7BR;O0+P56$'HS7@T74XEMCIO=+E"Q<).-J5N>-77G(3)9 MX3_MP9]X=!N#ZY9#)H:*X+CWB * 'J%)RJSB#C!3\IW'(7"_XWP.)G8CIMW, M #([T5>X\$B85;6&["O:#^[@GB29? JO%P7P6\Q>N501^-X[)[?[/X:V"QZHZYN<9=^-*7?D%1/.::9-J99482_N"<3E5" N XC_@8%. M!G!3//Z!J(0?S/ [@MJT71^WUEL]V_>"$X4$ZZT4%:DKYR8O,)VDL"Z>7C [ MZ954@*QP#Z[GV*;+P'COV'VJ(_[61-OD6*\@F?L &2M="AK M/RR8JE-6/53=%*#-S6L8P2J",]N93G MCV5\KYB07#DS H[9PS&]D7A%!QIS53R-,6*:6H;MQ&!82,BM-@,%Y#*'7'HS M\#ON6W2U 06&%W-#%!)JJ\U ;7,H59-!;4J0(T7@+BU^)D4P[8*";*5XQ4@ MRQYDM50@JP'(VORG8C*PE<-4<[(]=338ZL*K-0\E7@I_UN3F+/Q7!XA&23W8 ME3@+S_O_C7\.SOSCE_!\3.*1GCV=?)@^DI/=P;'9]M8^.D86GY&:NQ0[/K;L M'2IN=]C6/I:T]Z=-'T^)(3C%5 ML4\'R 1/EA]0R\.QM#VQ@'6'VMCX4!HP6$,'7"HGQ,/LROQCP'-/F)Q(<80F MUY.SJ$CDPJFXC4_&[>QT #J^$^5T9<31JGG9[:'C#.G(;&0+Y#=W?=V4"+506;ZZ:G3>KI"ZOP\>RIQ3]";L,RU3R<&;'I@6(_X M:+(L7RX/E\:#3!V0DD%2Q9-Y+5#KPG.%)_$<79N'H$QITKMI$40LGE;\[:2V M6J_8+(QF3IW:;[$ _O_C[P_M-OE^UWG\O4O:G:OV58P,4)EOWP.E?&T_8'@N MIX/P3T+"=;&BAU_1SFTG84&G5FW?73H,B,),)VDMG[I7)T%R3-\M M/6O:^/R!OE#+I]>./6*'&. U_S*\X:7O0K^H7!W TL4E9U2S#&=PA600F[H00E@1+D"27(N:($ M52J7:U*Y)@M*$)20-26HZ1)_YX,2%%E2:PVIVE0%*0A2R)H4RLE"0/SI$W\88YL!LUO," M["]&9>BXD?V1&Q:3*R:WF V+R4UL.'OY?PP":UIKXD5N4'ZQ$D+X&-[:MNRU+[U+GQ>A3MVN;^H8FKE169:DJSY?_V9.Y M5US3->]PJV;@=,P:;LUZ1:K7R@)LQP:V6@9^O:S!5I&4ABPUE7UY[P3<]@:W M>@:^LZSA5I9JY8I45??E(MNM[^M(G35)NF^0*-1ZCOENA *\ ZIM9* 1XO% M/&Y N.U@S3:4$=6&5&T("7%T6&MFH/UFC;5F60*^*K!V9%BK+PAT6DOYS1AK MBE11&U(=XX4%VHX+;0N"B=;2?3-'6U65)47)"6\3;M^TJN\#=:GF](=LYU*G M+]2TQWCHN* *\)8G&(H50%)?$$NU9GPM!P"P@*O)\@?<8$-F4):E>D6$3 F0 M9P'R!5%2:X;.9@]RI2(URB)87( \"Y OV!E<,RHV>W F2P<'4VY"8J?D(D"V5D@>\$^]MHQ.IFX\!JJU) %L@6RLT#V@KW>M0." MMD=V56I6&U*M(8QU@>PLD+U@9WGMV*,LD%UI5*5ZO5C(%KLSJXT7M1X:+SSS M*QDX]HC8L8K&PG0I K-H9)$#)=JLY5CX9KL;ZWAJK2DU%:'C"7!G >XLTIID M!NYZM2Q5JW4!;0'M#*"=19Z2S*!=D '=>P9U%YI',P%V6%+4A M*04+&,E^!R87&3X.]578A LSBX25%)'*S@M2L^ HD@>(R06+*?( MAXB]X,'EM]8+=3T,T"$&$U\%]5@>7NM?KLYGD5=DLE9FV6)KDDVF[[F?RK!D6 8C!73\HKW/JTK[O&)Y1V$PBQ^\:)"Y/VVTGIY$*M2HI\,!:1>HH_"YP?'N?+8)Y% M3I3,87ZA*&5)K10KL;S >$XQWLPB%TOV&*_(4D795XY5 ?'CAG@6"6!VP,8K M9:FQ-Z=,7G?QC\_>F3U':;/]Z-"A+\*0"\$RLD@5T[$M>SKH9\LT,5*M+$2B MP'<6^,XB2TS6^*ZJF']: %P / . 9Y$A)FN URI2M29BD@7 LP!X%MEA,@:X M6J]*2K58'#S;'1S2-S47IN/F^G__72E=W7;@YE')T9]+WA >I8X.L^!%]*0V]DEJA)<:NL- 3PF0A JA^IM31W<+-' 7"4C!W[ MQ7 1]/ UL)Z(I[T5.@O-X5G/G3D F/"CCBV:3+6Y%$@EDTWC"6U@2?=1/C+T>$UBVPP MN<-K4ZY*];((HSDZM&:1X25W:*U(E3K^$=SUZ/":1=Z6W.&U+%7DLJ0V1L\B-$S':P-/SE5IT8&S(3-5:79(KPJ,IX)T% MO+/(CI,IO)5&0U+EJH"W@'<&\,XB0TZF\&Z654FM%,M=+^"=5WAGD2,G4WC7 MY8;4^/!9M7(M-&GP3-%MX>/J5I)C&;"DVSZ>D^J9L/#0G[_GAUDD M]&X9F\CB[#VL^_:9/66E)E7WEB%NDVDLK-S[6(C.XJ!_!HBN*W6I>K@S_@+/ MQX+G+'(*9(#GLE2M@'TB$)V7P187T5GD+\@ T:I4:U:DRMX"Y+9%=/:;*;G8 M(RKHWM21VG;,D&MKCF58SRX94P=(=30" G:'FD/)IZ^::_19%;HKP_0]JG\6 MMEY1^.XF62+NJ=/%E9_EOR%$PNL,%UC5DJ-B,XXLGZI"O&JYLBR]LQQ_UJ',W8/?>^9[KP6("C\V$M5:D:K,BE?>6>.J(@EWR#L:U M$UX(, HP[@J,:R>G$& 48-P5&-=.)"' F&3EG'D]6W_';Y@D\(+\C8!*J1LO M_%.BBOS+3 =^^3)Y-7OSE%(?I^])W)%MG(?', NKD@K^+J,0>@'$9O#D"_]3G^,=A9,G>MV[: MI:\/[=8?I=;U8_OAG&CFJ_;NA@X'M @M.C7X+V1(^4RJX[/:_W92.]F^]20-GW=< M13S%Q*9 [:=);PNR?QB:5G70:G*REWCI.P[6X 4UC'HL.\JY*"%?I(;%Y.ZB M$/>1)D=**E9XJ;E#%B30QP_T+]]XTE6 7J52R0?T\JA"YE.&?#^BZK:K&C\TW:KRIB(CJ:Q;H/]O1JT- MJ=$L2Y5J3NA5H"Q#E"F;2H?,45:74"J4&SE12(1ED58JM/I]&+[G$H?V*:@) M F)6-3#G7/--.U7MJ^'&5HQK-X;^";1PD?@EK]/;8&50+"4C+?2T-!U:IUS MF-: &5ZH=4EMUH+M+Z)YI$O''L60'+93@-R1V3>IVE.P5J4D*_58>U?0?=Z< MPIJ3A63;#<]1-Y5L(=(>(J!UJ+<5TP$+","C-,KY8#H"9AG"K+RI:-L%S,J- MNE1K[JO N;!X,I)MM]8+++KM&!AW!#)-B(3=T&IE4Y$0+M [D.CFM91 M2@+ MZ^;X8%7=5 1D :N*4I7J]9QH%L*<2,CL+F=OE8 MG*&\\?Y]%DJD*C5KJJ14]^5]$'+NR-&\<9Q %F@&BZA2DVK*OBSP7 B[O-;! M%3)\X2D++-XT=NPQS,B[1,8FM"(Q]R&&6X\Q>80X>5&XAL7D[N+DQ0=R#7T# M#E!0E3T'VLMRM63C4")XPI-:EQ7XP+^?& MH4?ANB,#N(TM^Q8\0)4:U;)45_85"B)<^$<.[HUCG78#[DI#JC;V)>!RX='_ M$";2[/;U:G]X045C#MC";14@>F@WI-ED#4%(H.A%66M546''4OK&GVP;C-QD$0"]G'QJ>>:[6R5"V+ MJ&.![$R0O7%(Q@Z072]+M=J'DHPB KFX K]-ON MDE;G*E93->CK6JUU@<#_^/WNVU7[H3O=E"HKS34;(^U_/-T^_EN4>4U0-T29 MUTSB$_)0BE.4>=T1:$29UQR6>14+ONL%EWE1^-X%R=/*AVPFHRY,U14M&,+2 M5'J-5Z;-VCV=7-<2G5RL8G:L+5NN>+M5TUQKJD5'.2'UQ ;5=0 MV_A,3990*RM2XTC2TWR@@S2 ,>G2PN8Q!36@@J.'$0X+B7@ZC9'87#YODV6 M:,O2<]6*BG']^2!C@;$,,;;-,9-L,5:N88'H?26C%P=",BMO.*E64G!+(O?$ MNDW56R16OE:L7L16Q%JM2S5%)"\K*, .5BKN:;2/ MQ2DVSHN9G8>A+MN-DF-DANJ)4)+5@VIPX4?Z!!#J3WE=T M0 'FLY6-A>0N!I_;.&0A7/?([1AC?!LGT5!5$.*R2 \CP)T)N#<.DM@)N)6J M(M4:^_*L"WDNY/E&,\-;0?F4O^29IB5/=.G8HZ,>=5BJ O2?L+NN:#_X56&_PC5H9TS!Z'NAYOOG@OK' M1O-L;!*7D$9_\?R'=EO]AHL8PT7%Q]8"/5="CEL4I@):E9\9#1;$:@>VL ML)W%>8 LL2W*V/SWN,O8\%ZO^_?^:P&(:C?1='Z)*KA41+6;(ZUV@Z__6[S7 MJWHTBY$4%'>$E7#4S8:*Z=LU)H?C@O//4')ZAH=]B%\CX;6A@P+Y)VCC3 -S MH_78_M[N/';)W36Y_+W5N0%[Y+9#XG;(+[,61WZGVTR?>[SN/O7=+N7+6OR'1Y#EY0012DF5,5%A?4L"EB/+9=BP'7^)PLU,L[_$M M[P%G8C>E7XHM!1;O0J1RES6S=G$D 7-E%]&[S4*&IPH.186'#N*<67,B\PR1 MK,>Z%P:4!C2M$>9E%R#)XUAS Y)V%$,J8)*_L>9& +$@J]QB)(_;Z=,*U*&W MUGD-:,W4K#Z5R/]JEJ\Y[T0)/2V%W1%?D\WN^XA'?C/<4NR,QW=V["NV*\C4P;E((:8CWDV.DFUX*F1RABT/YT**!,9U"OX< M')E)QQ&V1^8.(]AR=5Q)P')'L%QRA& %+&?/$.P3F_L^9R#0>1AT)D6F'W<8 MKSBVN9&VW:%>D+^RH(IU-O'Y>R#8].'YAZID(@YW"/ (\'QD\"S1*&;"@/4@ MQ!W_#SZ6=Z/Z@H3BR4B_V:Z[:49QI:%(T,M"'2D2M)!76FBDH@4!:W%H?$._ M]W?-Z0_#]%G"[;T[.SDI3W8Z42;PM8;@7+I'W" MW>G^&1X:E.LU^),3;Z2 YX[@N2!WV6IU/$.D5MYB'<4Z?LAU7")UJ\G^L,K$'U8KE>6\ M^H;+%;"IU7WE%A6PW!LL:ZE@^=$0)OROR5I;5+H=U\_4'%[R@,_<6#-T\NGO M*ZHK .AJY?+)A7Q::42U**C#ZR@<:=4#H4.(=13K^,'6\=,RJ=M,IPQ&[)8I M?^&W>V"T7/';@;88O7+#$KT2"K^:"5KPR!H:;_W(--XCC&420:$"/ (\ CQ[!\]2[:B\C79T%8BK MO%H+M>K!8@U2KXXP)SXR^56R(S]!2;FW8([6;S^5+\2W:"POJPB;WLW.6C.I M2E"Z75X1-ETX,!8I +"YH!++EL@48=,"EEO!,JF(RN["8C),XJ J5:FL-@0\ MCQJ>C<7PW!O2:O6*5*_)^4":V"XXTM#FX[/QA7]6@&=3\.SV/(< I@!F]ND7 M5%E)=ES6)X[+9H[#S66E)E5E4;!;T$(6M*"FH@4!:Q$*OZ%+O4O''F.-Q^!7 M3U,*MQ=U8&$2^0,PA^2>+N,,20EJTXG&//KH#Y;0_Z-7K@:4_;WHI)"4#7=[ M4CC(IH"@ T$'&]/!@FW;'5E+&:;44,N*U"@G': 4]"#H86-Z6+!9O-IBRA#: MM2; NY9D-^45VMQJ.@NJ^9ZQTL,+2Y0'X4PSQM=LE>3X74FEGW9:P%E>6L!Y MZ0!$ 6;L:[%+;XH"S!]X1_[PM0]% >:\+.].HBY$G>5\@:0 U5 7>J'7J[]\ MZ CYX[>*C@T\H@YS?L>:>_"(^LQY'FONX2/J-F^GD.5KTWBZ;K-EFJ M)&X4"7@>#3R5A+(_(3SW=Q*KK$J-9D[._(F36.(D5E'BM,6!%P$> 1X!GCR= M$%&2LJS)DV*U;LE26]Y7^25#"<5-"4L*S>4H0H!8GI;8OVBQ\WKNS MD9/"V-.),>'S+AP8"^6]20HHWQZ9PN=3P3,H^EDH9S_ 83D4M2U6YF@^D"9_WD?J\365%:JH-J5D[X,:(*()6+%JH M94,+ M9;PUJX*7=54[E2/3*-]P@#C42\I@"/ (\ S][!LU0[:FZC'>6^IG+E M8!NT>:H$*\@OK^17EK,C/T%)N;=@CM9EOZBFLHAJWMFF6EE)CH(2-96/T>-< MI/B\LKH39(JH9@'+K6"95.!F=Q$Q6=945F6I7L])I5L!SQW!,ZGH3*K(F"PS M>30 ;7).&*'8+CC2J.;CL_&%?U: 1X!'@"=7^0O*]63G8GWB7,QOW>.Z4I>J M>S/)!"4<-R4T4E&" +6(4L^FYG&1_=X?J.9Q.2&Y:TJQF$EX+ !8*_1^T MMF4E(9%L!J0@:AX+.B@6'2S85LU[S6-9:H*654[TW0IZ$/2P,3TLV,S=:\WC MM>C:Y MM+&.L$MU3Y]0Y^833)?CH) M*C=/M7?]^! UF%0O*_:2X/FI!H:#DF._AE=F+V$):')_TWGZOO0=R69MB/O9 MI3ZYX.\B56(/P"H/WAS!!)=.R%G2M/]^E3SMN'Y93/KC MW>4WP_H1S16'5,JI6D7B9 [B$E\EB;C4,08+V5%"O7,<<&*5\;_%>[VJ1]FS M@Z?.[6/[JG3SU'JXNFUU)'+;N3S=,^&O.U1ULZ&B_-28R+S4W.&?UZ;]ZIX0 MS_#PU?@3"7X:.B@I?X(GSK2+[F/KL?V]W7GLDKMKKG >/^^?91:R3/T*'V5FWL=D/3/#%J.2\K63+%K?O;VTR?>[SN/O7=+N7+6ON/*VP$V:U5RF]%X+9!P0&=WV/;#"K^T'])X+ M5&R%"C4#5&Q[X&*OX %K5-D19K;<(A7+F\WRRGE:WCSNAH;V3EW.36%?IO8. M4.TE \<>$7M,'RJ2 D;*GL*>R5*VHDBH.6!T[WE87S-H+WE2I MUJQ(E6I.3DSE46?,IWAHZ?_Q78]M$N$VDD,!37W#I,2*Y ;^CM_ZH&'R21X[ M-J8VT$GO?9&>F7L=4[3X,5L4FN-JUJ T6*>NZ!CX@:$QH8/YH+61#9/U7_9# M0;7)58T?7* GY9%=5X&,+QQ\-BE^:%EZ*[9^FP8]U3!O9CZDO,!=AKA;D+-U M+45RA[A3%:EVR%RM0KO<2(2@]^%9,RP":(/K/RC?W79IWW>8JBC$R.:87);F MK))T$G%=.?(]6K%NM& /%(;T7ZK?P*IN;B]69*ERR*1$(@5@P>"\X#CA6N)I M=W!6*F6I<4AG6_X3\7TDP^DFD'@N( E#/C77I9Y@#3MB#4GY=->5="'YWUE7 MACNV70/?]QW\*%EJ]MYRI8N%:P;AOR^+*DUG/BEA!P MRU"KJ"XHH+F6P9$YWH@+L_';2>GDHMD4UH:P-H)MF@%UL&1GN%VKO0F_VJ[$ M4!;Q/>&"\:"+1^VM_3;&LYM?J44'AK=AHJ.J5!5IO@N*N*62*(L0GUU ;B*, M%."TBEH7 NF#6T@\I.@3@,RAFDL_(V#8)X+^L$F@$/.JB" AT6)>6Q3:9WIW M2&#/8.@@-5YP=T7HGCO2!+*(#0J9\U7 FF^M< 4?H@7<3 .M N+KM:24,<>C M!0@\9VA+91%RM#,X3[3;AE*5&G).8MZ$&II:,MU:+]3R;$=$&>V,@K,(,IJG MX-C";6N8J@VI6A9>D6(B;ZDNE$5 4/;0NRBK=3QZ=]1*D+".4LN@>X>.-4,G ME+O;7':,PO:&U"%]WW$ :X$W1$BHW4BH+(*#YME$L*RA5S5PIK8L_0Z7ED<- M;2NZI$;E@!Y5(;AV \C:@O+36\JM/0"R(BF-@U6D%D;0E@)([ WOGK2S"%%: M2-J/N');!XU(BBR$RO$A+XM@I9TB#[AM\TB.[WT(\Z49>-""[=M/X4;NY^F= M7-/0>H8I\ M(3Q*'1T,_U+?-"ATT:&N[3M]ZI8N7?B.S1$U6*Z8T!%B:"$VJ'[VH ME,IR60C#H\/=SH*/,L&=VI34 M*L7E.T HB-I*- MCTM1*U*M>K"-^&W+4>7(%S9C7 A?V+IR4JUS5:?'4K5BBG^R*KO_PB)2@A$> M0HPNX8-9!"0!++"TV'T BJ_O3RZ:1WN2VI8+]05=4F+WK"8 M7%&7=+O"<_V_?(/GV<84Z6!T@G+EO4MD;&IX*M+2"84[QFB'%]3:S(%&O<)1 MED44XKWVSLH'/MIL21UZ'RSE/2YDR]+;X3)NIBLW%*G9/.[<<@+468(ZBRC' M78-:K4J5\GNC$:44A8*M/J1XHR&'1$%$N:W_!)/4LHA##9;R&5>S"(@*7 M^*YYN'#O=X.DVD,;AB1BI2&IH>;D-)V 888PS"(H<4\P+$L-6954^3A2 GP@ MP^O>=_I##>/=CTS('.$^QU(]-XL R#D]-TL&(3P*Y<*4NUJB+XEJ"J'%-5(XN,?'ND*BRVTVS4!%6)@"31HFA1!"1M M&9 T,"S-ZL_KQ$5(:'84,3-B>*$M!=450BJRB(>>F]4);0!46AMDT1/@39@)%S^?1-7P>>U7[K#S7KF3YH'FT/!K2_X5D.19:E2EV4U2DF@I>*SBSB ML0L X9CXK94E]7 A&T60J@DV]@R.#_-5* O)6WZ7BV0_T3S2H_" A0X#/(/, MB*V@ZL 16C7+./-,\+O!V;&BELK*#MEQQ'BO#'=LNYIY X0TAB?@.W;'L'RJ M!UF";&M#AVBUJ4@5D0]+4$HVE-*8IQ2E>1R4HDARI2&5E7WI*[M)HR5\_//H M+]>FPG46B6^*%5LF@KNPMOQJTB\#UG3;QX-Z/1. ?WY>XXX4T+WEO&D9H+T MWKT_8"\\J=9$%V9N@MX3%J:PC$L#C/!-XG@3EQQP\T_F$J>1;CY5&DY0^_0#;>=Z[(LR7)1=&B!ZORB.HMP\*Q0 MW5"K!4*UT'\WT7]A74M,!S8\.A+)WXO7L)A0L+Y"S.1&P+Y,K!4N<*+7=7#AU'TVG)L(A#^]1XH?IT2G?-=6E1 MBYE\- ZQU>F%YW.&!,-Z"' 0)N.^&[00 QOF%V@6R#06V#XPM@]57CT;:7/F M]6S]';^A>7!!_D: 9^K&"_^4R/E_F>GA+VN?$@B[,5[RE@U.(L3 T*? 4ISI MMW8I)1W;@U8]FUS:%N@4>)P].%NIF:3K:1[SI+C[[MK,A,#\AQ6V[V^^_G$R M"QQ9_CEI_8-?&!VPGTY8A@_K63_#LF7;1N7ML=P%EY/*N<]7N=-M7Y/JVT^I< MWK:^D>YCZ[']O=UY[!+FINLY2 2?GCJMIRN<\<_+1YNY1$$T_RU.!#& T/7KG/&N6\5\630)BA$6FLR\M2[]WJ(NN>/QZ-XAF=")9KB(/ M/=S=A<4R!F#B65ZKWP=>@BEL[Z&]OD'=1^C65]/N_SCA^K+2;"C-6NV$4-!I MQ\A%')^&''Y'T[I$N5%.F6[#9Y@D_=/!:CC,'OOJNX9%W4BL[@D&.Z'H__BN M9PS>8^\EX9\@80-*4Z,*BO]+Y?V:*Q9[_RK M_N4S,5RBD2MJ:J\:3%G?=L8V#_PDWE#S)/@;1,TS[N2X)&R8?--Z>)?M %H( MX-MPX0$)(:W[?;@1L:@Y_:&$53_Q)S!T7JAILWIZ$G!HRQ^ ;>,[+)&/I0=5 M:H)3>GW;'<&7/JSYLT-U ]$++0TUF)$^]9EG GX8P27X%+["90UAE5'HE:85JFIJ/Y9=)SUEBLT_!YK#D>^SBR=: =%$' MIA!>$B]F^@9-Z:#C0;L^5M\!NP]^-'@Z_JB7^*NFZZPN*O2'W3F9 NC7K0)!8")'D= /P-?@,F#I]E[K1?#L2V^$6>^DP&,W]+A@Z.]0JO CPTV M7Z]# \8%ZVV,8(T]K,$*ZBBLQ3M.NC>9C5_KK\']=DOF[%8#;0COO!1FREK,+=65W)(-'"$0%R$?@V'> MHK9BC!CCXC;9(%)%W$ARSI '048Y=I ?\)QD&D#&T>$Q"MJT-R2<#7.C#I@F MM:C#"!.@1<=X98(QF',#7CD?C,$\T&??Y#*A6UKR MU/]QJ('485VPQX85U'Z&M=.>*6?^,!7 _W!M1IRQ&^%YA, YBZY5W^&BH=]W M?,:\8(5< \PEF#V+]D&B(X/'<>&;!IKAX(I$Z,5W)JYD^$0XF_Q.9AG' M@/9.)EUGSP\,Q_76&D6*=TC\ 9AC$-2> =+N_3,CKF7OL3W^5(@"8!,HWD$3 MP!;PM>&:H?Y"X).!,A#N6C:C(PVN8[L]"J ;&I1Y]E%2HW2$*7!F($/@6@B# M=] 8<-40L<@5=YJNF\%4[Y>]\C '2MS2@!602*W@2+HW%?4KP @IK[0YM MW]0!Q3 #&F-,T,1_?(M[OAEGPMZ&[:=L%26I!HO+&K1]A[0L"T@2F +RDW68 MR1]S$[8"YK/S)9\&3LTC542>SV]!P/2]N\&E#0J=!FJ=[UYB/C:EF6R3-0ZH ME2Q7.\J!+%BB=_#!(L7&ADL^7=[]\_9JF9A1FJSIS\>NHO"T9_\:&B9E5-./ MS1):&G0$^(J4AO"7B=80GN5C7F>#3[:79/-,))O$;G#]GHOF 5,R)L]%[QP" M=P&Z#]4AW/MTD3LLY_><"[!$1('G 7@R/ E"FS.7%1*5B2#>1K9R*$ J&];C@I> W'X8(A-FO4@7D[#.QS>*N; M2G1.+X'&LDI1+NBUGF$:WJQ!B "R>R@&IE_/;%5XJT2&]BN(3$>:&C3K;S1" MG9K:NTMTGX8Z*@@L,$.?F= &]M7_070'9+@S;9NS83'5C!6Q92:KP612:!1S M9P5S4]C^-%9//P:3Z#(2G%ZT"7UC-.ZT]V3>=Q+QD=DK$WZ"9,\43+88%GW6 MN,X64 NL>>]]FE&LY@F!"MACRV:[-&@K4,@C[@ (>,6MAJRX1$P[#W3B-1C% M\LF>F>AH@E]I2L5VB]GD#3!C\<#<]&.0W2/JR--R%K1OQO9 [:8.,BGF?02V M^*PY>LCX!C[S3QN1 C2USK:U2DPSXR-2WT-[!V6'AMY<_@-*! .]LP-@]?@] MU+YC3'W,L_W"HVAJ^] \)5C.#CD\O@2N_X=R!JNQX;VB3;5Z"*\&$"M,Q:*A M!$^O&-&T&-!MFDZ\T3O2CH8X[PCT!-XHB MYH^:!C?)C* I?&0FUP13/YZQ)XN>XV_2F5#GDGJA\\\!,X[I,L&.)GH@T6AC MLS3I+[.)F2/TE+3ZGA]30_K,"XEJ!W6XMAINQ?8\MN$*K.2%!CLBT%7/=L!:[;DVZ.0@./I4XIL&%+N M6[Y@6J#Z,J#(A\ \U-DK0Q,6&@1-! WWL>VZ!AJ87/ZSE64[%[@KRRQ/%[T1)\'-2" G&K@30P4^W,)#!3PAUR.H)T-0I= IR#1R1M_! M)B%GOF"EV*"W&A@V,<( B,!3E<[0#RU8A[D50J8(/(@Q1>AR?ZBY=,;F &;G MHI&PL+P$[QEVG/0Q5L5#AP)SH<4W:F$J/9_S?VRD1TW<80J% 6XI!\P?1 Y] MPXTM9JM80$N,"YH&B*# 4N)6"CPW,BR#;9<:[H]3LCB+YI":H7_5I6RSFKV* MA?MP?R?;0D.ZC8R>:ZKCIC6YXA- ;J.N7,8BA"*GT?75[>7$4>2/V=8CK-&; M,?)'*Y;H[VJ5I;D(2+"U=)LQ:>N3[WPNWV2=WTN2@N?&8..^A5N$?U]\7J12 M5;=):?ED!3/<8BN]8>H$N99X/H2M^]*^E[=)IIU)WVO5]4#_S/""2. M]@UDZ*ZC1?8I81^X'H:GBB[A:9RM?P&GN0S"L9(%K%+4(*7:2LN%_QW,"GF@ M??O9,O(3J'00\1N75 [%&"0WU-^3PI):W4OR:(\!C\M60JY%JA!C[>&4,TT^ MA&(@]BZCX,"0^9,G6'-T,X)1] Q"7&,:>=0IE_435NZ_0.^O0]S3B2(,@QTF MEU&+8YM,*L-+#=PU>[8Q2@=D-ZK_1I^RL"'FMF0LB0M2APY,VO?0MW'!OTAB#Z)QAK&OK(- MTISL1!T:J)/)8[,BH2X8FL 2TTE$+=O$[ :F*SQ+DQVA!UJ:@&T M>,LF77=W2(JL7\"B\TS1;^B&QC.="2B\FD0BPVO^2<&2U6"4K0&&P44[>8TO M_VQ%*AF28(\]S'T:%IT)"IKK:+@3CJ\R$.-8NO-_0H_NE),,<71I,+>6F=62GAR04F.D)BPO@X8%_,9]+,/OAPM@]@*H6 MJ=\,D_+/O5I/HS96_]CZ\_LVGE@ E<.HQ-!6V'3I"I;0]W II8OV!H M/#""19'-NTT^,#NXXMZD%1N)J8(G8WO(<5-S@D).\=AEVP>1A!X:B\?S._YS M0!43*"\@Y0=J:7U#-RR<4_I%8G ?853&))0^F;)#P$9OB'NYYD@WM+JZ/+RD MVQ\"GJ +GZZ[W<\3IU-$@OQB388(7.,* ME^F!+U,THN]7#_>?PUB;B>]U9F]3@_;CL2[A:@>+&V+"Y5SUE>WE1BM-7C4W MW!YE>)CP,6 #/' YC$H(@FR[ 5-=%A57D;_R66#CNH>YY$'@P<#2/+IRX&P) M)P/A"T@I(FI^':\FX3B((KBGYSL8=XH2UHK.44VM22!+)H!,;IW%.+FNW3?8 MRD:R)M7\!%,R[4$"LE8"/JV#JO@O%0YI;',.+UPE(G8;RI MM1R+3HF/8$*7Z#5\(V&%)N.%V_/)6LS>90Z8P:!>(\-+V*_<:)=YV8[GGO:9 MP[>MMZVWWKM9=Q=NN/WJ MAM(T%J0.AD(%,_ MLL63[#U:$"D:A_N+H6$(^LBV6"R; 7CR 821 ^Y#LR*VB4JZ@+AFT#U-:_=+ M!LO!SN( ; MYE1>%8L"EA*8#.OBD?9[0P@!%:N""C.CB"_G4^\S[')A<&+6I MC<"@XU'TP=I\0>K[U)^[-?*5?,(HZC0!DB.;V7W:4E/%#B-_V6$M;> QMRXU M\$C[V C@8"3L#K$ T 2C9OE"??I[> MB(W'T\Q$ARR,Z0 U!EW'-L;Y&' C&PCP>$Q;T(_=%@C0!5 7;&O-\%L6_Q2H M)A9WPS];P='?@#CGE0*8;=P%=*>4!&1N<\D)XM[W@#Y7R;N@8[% *<9#IZ1T MCS)S-3AAPDQHO,YE&G-%+XTR,!R=OP1EZ/M'QDR+N74" @V/GG-"0Q;H 3JL M,$P]/+R#PH$!!F56HEF[W"\?>Q]7.;BC ,,90A80HWO<"\(4&7V,TD<%=JV- ML:4G$^65MY35E;@TL:^\['I4ZZO@>ECE!YW3?>H]THG3FV4U+$) M1#<#C^A#3OQBK(;S;FVAZ:WD1L[A_\@5'F0FX30[D\WJ^ ;A@)^OF.P01NPQ MIMR!CA;&F*YYLF_!EF4D@(-H):24Z-CB"R95T.DX.,L^PR,EXK!]TG!UX+;=.U]YK 'RXJ#4CG:D['97C&0@,K*S MZTS.H(K QHV#XD8J,OHH81#Z>-U9IA48WM&]^%NHST32BYN^6!>%Y;OT!KYY M2EJKCDEE'L0T'S(;]F82[C49"W-M+XL6JF]FLJ&<8J^Z='8*^%>1K1%RF2< MC>'5?&>".8VC/$U?)F=Q8T=MX\?1 GTJ>@)EYY#L^U](M(_ MM,JS;LABC&RGXW>8[XQH^@LCY)#Y,]=6&E,M= 5&*QOH4H&W#2XO)92D*E$! MV:]3^XP=7@=6Q?Z]M9+"U[X%IQ/>-R0>M2'5RO.\(,S9PS=Q%[@ YK>D##>: M:CSCG$;0,G]GY#I ?3:@JIYFLA>Z0TH]9A_S3NEA4IY0_$]M-<=Z8$1[Q&%N M*7:8(3J*P<(CT,\7A6C$CGI\9"J<59=GHTQX7-DD>"U@B)/[;&>5+X [AF'. M,6TI\W&.F/X1?Q/+ZL##QDKA&F.,R[1^$X;KS87"\',WD;4^SLB9V];7;VK@Q7>W[&A #(&KCEUWN/3$$V.TROTM#H0!44 M"^CME+SC)G9S$;EO%\\>&S5+4!R$%3^B!IT=X&QC68Z"O\QFDX52RP2D5E9>[ MF]32R_3E'333-WQWRBI%:\V8&G5ZIH:%,GXC+,$V*W$$BCO^_WE:+9D9&X]: MG!Y V'H T'CSRKT'(QS (L1++!Y''DE\AOZU4?OYR^/)?)Q>7 M84S-[22FYFB*>RVI;Z3LOK[1LM)<97E!::[ZM([QYSW7F>Z<+C>X6F^&6PH7 M+;9FWYE\6>ZX6''@[C9,4HS5O>!__5%[V]!Y(57K#:E6/5B9KV.JXI5G$->2 M*U#6IRM0%A/$U:HL*?6#U6D5$-X/A.NI2B06%,*27(,_JBI ?-P@;J2J!%Q, M$)>ER$' ?&61D6URNR)8ZLC?'(Q'5E:4!-B5>,')_3F%E;#] KE MB\@5255J4KTBU*VCPZPB;V$DY!RS956J-G(BF 1F,\2LLH55D&?,EJ6JW 3< M5@5FCPZS2;%-:8V ?&.V4BM+]7(C'YC-XZY"'@P GCM!:/X[HN[R%II_L#3Y MHNI*66HT*OF@:8'4#)%:V4+?SR-2JTI=DA-"<052BX[4!7NPJ;3\/")5 6M4 MEFI5X44Y/JPNV&I-I=WG$ZNU1AG^Y&1O2KCUD[7ZV_F$.@75\!?'CDV%J^6 M$:3NZ3)^L6!?.Y6],%GTEJ7?X4F<7+&.BBQ5:OOR8"6&(:ZQ9,G1E8)L;;!?O2J2RIG).-HH":6M^7\UG031'H1LV( M;M0%>^.IK+J\TXU8 M1N)*R)0!,IAZ!@]H!I@Y9%QHBNXMXS\+XASJLR==<\%1RI)2;TKURL%<\2DF MN[!R]X,!?T&PQ(R=EQ/@JU(9C+=R[6#GJ03PCP;X"^((YG(;Y +XBBRIM894 M;1YLET @_VB0OR N0*F MA\W=M<=DKLIX86[\I&H6+"D.K\>.N=MLQ]1A>2DFSUF2@FE@O(0%H-FCK 2; MYG@6=; @?%AKY^FT>UKBV8);[M#$+%S=,<7RS=Y[_/C_I.9QJWL[*7D<)M_G ME:!,K.'G>N3%-F%=3TEKJLCPLA1\*3>F@+PP603/POY@N#^^OG^E5G^(0V3N M#V9J!O38I2R#*O=_)#WZ^#[F3I,;BI60QC A^\[=*X"\6Q7[JF#/VC/5(G81TE-R3]4D)OS)M+/"Y.,>\QRYUF: M@FR*Z1*!_^4#R+"JZ=)4L)-"=Z]8N0-SUD;)&TV[S\L7^AY6,@V[.%4,4L+J M$ #G,)FAEA9IS90'3P32MD!:PMGBGW>$HK!\^G50*&-9$DLCS!LSCN(&MCS*)KOX$EZ2R[$LIE]24>1P7Z\]/ MW9RXG%6I5I>EJB)R QPY9%-F;2P 9!4)5&])%L>(CQVR*;,T%@"R#4E1JI)2 M$5SVR"&;,B=C 2!;DQJ-NE17\L'+&CDR&DD97+,(M&(@B:9I.PM-CX;&LGC-L[AK3=QJ/)X M#AJ4TZ7JS D7$8XN!#T34RF.]?"<93"+Y]$IR^BDY72@C0(YX@>86+0]MW)T?C M\!2EQ!KB4?'\"=:(0\>V@_%WFLMN"^[ PD#P](L/&H9W,2.:/K.V';QC GB M'QJW_># &R!IT3FG M,#/O?HYOSJ%KYHS48MQ4Y4(>R@7'@W&<-:VCJB8\4)2RE8:5S& MRR'P+.07#G6A>\BQTO*'JISD;CT*_G#9V?N)QZ3EC<1!2(P[/;X=P&*SHY#5 MQ%+W1T'T>P:#E+ !RF%+\4RI<\Z?*@1CMZ4 \*2Y/M3[[':4IBNC42$BLHGH42-B_1$VH M?KDI "2T]3:4BXE%1G.?(B#GQ)VH#">O[;.-5+B">,F^T@D$V4:R8!5)^X]' M@:L#L(IR=K)"]QT&./2T<(OL--1ZDMQY^]&W?M6-EPO4N_C/K"_X$[NV=7*% M6^N%NAZNI7MK7=&>U[+T[RQ'&;HRVW_YAO?>I7V8& ]H#2Y>4L?3#.O1T4*' MK^=>&6[?M%U8[N3,"Y7$S L'3_T69-)8P@7J04(C/O5I_I[,'9E,6WZRW05# MSJN_^.0B-G]N-'^P(KC!0.'?"*TH"0;&&T6G"8AW2C!;'F5X)2/?\S63#'Q+ M1_D/%YBS]\9^H8Z%3\?;9OP<6$WX_=FA&II?P 66>F/*<8'"_E;DNK M57YW.(R(.\]\F?H\C,+K[ELW[=+7AW;KCU+K^K']< Y0>M7>W7 K"M?3HE/3 M^84 GEB2&16+* 31=S_)[+^DP+S@T@DY2US)WZ^25Q*WQ;)9Q\>[RV^&]>/D M(IS/@*6N,VE,!$\!,H[0$+QS]^2'OC#)J#Z5MLFB'GD&:>HR)@4B%'>-;.XL M&B5R0H?V[6<+NJ:'3J6 _;FA3I9*(?8P7P^'+;YY3TZ5Y6^*N;<=ZHXI*',O MH$A+:V:PR@7K+$INK1L WS> W9T54P23E;BJ2)\5I7_*(J Y.<0EPQ83$FAE M&2FQCY#L("9C2=ZO^<1CX2RPRPLR@"4$:8NES-PR"99JBH,M2-5VX$5;)_5; ML0"C[@0PJ0_\Y(%%3"?-RQ1%6Q[1$@N^L5(6FG]Q$)PDYK83"U[8!1<4_L$6 MO*@4GLD UNK:.1NT \*V^N5@Z(].,YZ95G_*4+)#P _BJR5%'F@W8$_(X)?I5T M=>X/P?XJ9:E1/MA)6)'9,HUR_XVZ[CGI1-N9&VGV:&<(TS%TB?!PIC!T:TG10":U.N%2N/EX![;N&>18GW MG<)=451):>PK\8[ ^Y'C/8O"[KME[\T])AT1:1KWE:9124A"PE,W/EE. )QT MFQ*QI""KC!@/LWX,J1E&?L>>U36/%M6<.<*T2$6*U9P,-N=87RHXTE5"RX?@J"M2 MO;:O0C!"< AB6E-PI"O1=E#!H;"$E0>K;RD25J8/*4Q[2"]V4'=ATH!DXP^/ MJNG4H\[(L/@1/@:9KID)XV?NN2FU;H/4LY,WD1ZE%F(=,">U%SV6FV$ M"29X1H)7VP>;LH?V9)\:+SQ#I(NG*S5X#1[$)[9#QIK!4TJEA\P8_&0G\Q#5@ O )['W\A=)4QDT?+'G EYO^ M,&4)0!!.Q! ^:DY_^,XRT&".OKYC]'@6T D(V'%Q&("- K?95AC'P;INQQ" M? )9EI')/*<_$)G?!&!)9%BNA:\$_JXNS+/PC;Y0<^D9;GZ2M!1.9I!-%2>/ MY1Z!6?6&MFZ;]O,[(UMD*S#?""88QR??TG3D%U3_S&!CH/L(_6L<8VX<9#Q% M ='8B=4 KRN/^'_,95'7698P[& \/STS/,Q")4(-E'-(-8+P>\$U$@Q5^DWA_II(88T,#'Q@S M9=I-D%-EHN1(L20GH3!%C>5% Y(,:0DS+DT]PU.BE())9RI*;"U0[J->XSM, MSG%IC4N(C[%;4-KCI;2,/Y*A^-"ZO/V(F/FJX'*F[S)%@FUUX *B5C>"FZ#= M9-TWEH:GN,K'JHG!DT9XX&HJ,0K8?C;/778.[ ;5: -SLRP-C4K(AQ&$2F'S M[ S3IR=+\W4# 7FP7%&8&2J^4]9,GOZM4TY,,CQ-;/&9C!-MI7YU?2VW2JK: M;I0J[4NEU+AN7)E6O7%W*(H'%Q"E1:>(9L77@WKO@_I2I+&>]"::Y M[R/%&<:4F^%+3G]>VJXW.0PX[739+,QB+]V^1NGW3Q1M!>Q\;/L^ 060285]4-& E?]I:EW^&B?V=K?HU+OG^%K*;(4K4BCA<):LB$ M&LIYH(;-**&NRE)M;W6/!24<.254]D8)^U,R058HU6(=S1,^O=6Z:%":X]'V M0/6F83 =6YQ7_W5Z#FKE]K;H%:YF![IXJC,.:U M1M(JV'<_;8$$*,)# C2"--I?_Y[0#31 @$E,DE#E()(('4Z??)Y3J^KUC#Z) MATSIA;MQR7)T"J&SEI>#;YN#:?P*.,A:Y3]]#%#,Y@[LD9]DCW(>,VFOP4RP M+BEF);]:8_/._-$N559<5(IVJ6^F7:KR MQ?8K.A+OW];K7G/IR*DU$)4C%:H<*<]4CG3W73>2VSM:5&08D<0LJC**JHQ# M+VPHJC**JHRB*N/59A0WLS**RZ5*M52K''I51E-OE6MZI=PZC/SA@D:W1:-9 MR:H[I=%UZ;-3;NG5UJY2CPKZW!-]9J6/;IX^=Q=-!>6CTCR06K+A*/B-&SD-&0EA^[\-*RI^L%)J%1VA1-B-TG95TNC9=KTO3C4Y%K[4+FBYH>B,TG95-.I^F=Z;BU4#AJ=;> M5>'MNW W%E49J_2,.9"K^^/98N_.H M6\:S]MD>C_E[TW[$;A5FXE'6O%#YL29;I(L&U]0LAUI>8]L-;-3A\R"CI@[I M-F;4G<.? F$/[8'HEH%M5;AS&/;J>*/],=($<>VY \N"+:)EQ]X8U.<$5]2S M3(N[B.%BYG2'HVYNW/SD;_D\KE'-:GNX:@M1.=9S&.HMC!+XG&1Y5\.L)@QK M!C[T=JVJMZNS%66:[*DTI\#! ?KBJ4]*TB.M1U19:V2L42K-N/<$576]':Y MJE?+L^7NNZ+*\D:HLK:!)=\J558[>JE6IB,ZATVI5.JYUJ5+,_\:66)Y5$7',.2;>/ MB7Y%X6'6__B_? 7%9UEDT GDP2V M5N)6*:=KW.@;86"T#Z7(;?/F] :?F%&>M=FZY);\UI:33?^QWYZ6#/OLHMN[2"J^&-Y5O>X[H1AGJMKE=:LY[O @OA3='= MG!+F/=%=I:'#OX=!=X>H%1ZFQ/C#];YIMJ--,?[IOU:9L>CA>S^N:S?@B8XK M;E3/N>9MVL!Y;37T5J5Y&,>U(+4-DMJ<(N8]D5JCHU<;!Z*1%+;$\GB!CNV/ M+!-%@QD.@MJ7\N@B\L)"6+L#DZDL[E4[V"OG$1@MR]L N5BS(6;T! M4)I1 &]8-_D<*RFKM5UAM!5U96^6C-NKEPUOD(S1J]=J[0VC=!\=>5Y]25!K M)NB+95./6"5K:D9 <=^Q^V1Y& 0>N'Y %1F.%8@B ,K^I@J M]&WG@1YB@-)@/%C\C(D5C%Q3U[BNP)B"U?C=QEB4S[\K3^@_+RIT&-H>=FFP M)I]*MJ,O>:4;!MH1K'VU7!G\?-X[O^*_S9\_BL$=:VF;5I7JN#2KU?=P(04N MWDJM4L1ML"=^@#@@M/2P%0:L/ZFA"ZLO7F[C8E=A8.*.R[C+FHM>J>BU#-!+6N6YDU@'Q&9;DRA7 M]59E5K#@&9A:\/>C-7[6B9"FKN_;R)-<\>8HQ T7!Z'G^)+K *.*"IIL1S-X MZ)KU?6HYOO7VBT&9\W=]F=V#J\5_4WWPU/4"7>-#\&B;I7FMTSI<9P9'Q;0F M]@".BS^W,LT-1&&:V)KQLV;#01M0_=Z(Y8DAZ_V4<\@\NO.SKPW3_D;8U61P M2M> &CPEQ4%EW[K6#ZF0&6N3+20$>@W)'GBECT7)ZKUSIP-7/3/+X$EHPQ ( M36%=\7S\=U!2AA7==\;W!25EJ*GNK:1L?LU89V'-F,:SU&":"^O%=L0G-N+U M4&T;N6IJ\F::>=QE'!Z3H(=: @^7]UG#( M')QN]."G8TUYKB;0&F!6@0LG"WE%!%Y 3\3;^I9C#6WD BC6#.)I^](53!N> MH;8[*_G6H&1_+XULT[2;$&X/"4L O!$C&VA(EQ<'(LT1-\8*5>F'Q,:\J#&[JV_60^S=&O^9 M+;-FSH[.!*!K8#_8PURG3T8E 4Y]>RKU_O7V)%=:W'%V&RK3-BK044+!<7$" M'ZO1A>YXQC;89Y9E^47I[EGO[ _:]RUE6!PR_>5 T;56@:+;"OVU*WJM M>B#M70ORVQ;YU3> S[D=\FLT]6:U8']OG/X:&T#BW []-6MZNS(+OUN4_1Q, MNG-:FZ9\I+>E2R]Z^&[.;W[DHE0J4>BBX,J'O9&+<6F+G7Q=.SE'IFX"YE[( MU%MDJ5W'O' '&Y.LNZLU*JANAU37V9PFMQ6J:QP(U1VBEW3_NEQ6"?>1V'!J MP/ QE2F4Z3KEM*+:S[#Y0PM(R7RE:M^&:F)WH!TN/=*C.;RCD],E9"4G[*G8 MF@_+]X\/I0^?6C6]4]L;2M!+L7%?FF>2C859'*<-RMA-U)AW MTX,;\4F4]NC]U9#;^S,E5B0^UL@ M][GJTF;:5^U 7:HT&GJEVGI'^M*BE%55A2J\^BN"F.37BKQ6Q72C8!![,/=6 M X/HY$2;5[+S-BJ9J\V67J[O#4>RP#EY,Z2=$\A>R>;:K)'5;F=VZCR8 K*[8OKI09 MBR+1JWCVOZ+UPHC%HV.D)+7&,&Q:,C("-9E/ *1APFL=CPRO!AQ+_J5F3 MZ=A]MCS$EAF,$.\J\0X!>+,4B)DV![ZID165F#U;_[Z)3@Y.YA(.6O>[[9=. M3_#C5RKK4_CQ-9RG#-<6+I5*>WCOF9CG5S'-Q.^6A\51$<\N59=DVE78I1EF M_0,NFF4,1G)M+07OPGCF?2%8.O;!24@Y>?6Q)L8*N]:WR,O!."./EA\P.-3\ M30.Z&@;PXQ*H'PV8@8O0&(SC\6P9!*S'S\==.!#8J;T?6=AN%Z[]!J\W@94C M@W<=PWM.+7S@)G?^1Q^!O-S0"6+8&4/[ &10"MP2_ ]HSAA:I9'A]3&M 48: MC@TFD;]"&.O0%G C2S(*)'4X'R#%9>ZKUKNYU3SK 9[+D$^SY!43%@%OS9F? M@8P$<4_\G^:>]N4*"Y8Y[?^F=""\Y!;.*&RIRY>H@U3/LO\[0OHX#]W@[LG] M%]"SOPFNX6>QC2XA!HGW"1YB/%BKLY'*AT_567OFAQ6.<>/#I^#)58^QGSS' MC$0T;\N6L_.VN65G<'*ZIFG3)6/[=2ANB1/,LE0\9)[%>PN,P1XGN+\X MDWZ2YR]/":T/GWS[^QQ*2,)929C!>="+C4VDE.;L$F*TWD2046L6:[2R@3R! MG\UP9UQJH2EI2R!,O1 WBK&\]!C,:]XR-[/RH-8([&UKF2M@G+8R\BAWM8[E M8U['\\6O4W72I>##0-9Z<,(6 ;5QX?\2>&.$Q<97KH'%UFPNA\56R<)B0R5% MXY?-U5.4D_#F42!OK#%B_%W#)C_?>8;C,^DNM,IKK\,JK\Q!B!13+]'<-77R MVX2E6CR?PU7[3T-/@H0OQSQ>+AI((]">\#_S!$16DOVJ =29&3*WX("FD$(?7%8BY%4CL#%)T#U& $I9SW:;NB#49BX+WH5 M6(XP#08A!A.R;SN,6?X$"X=/U]'I:(!:R%N4PC)_\SH@!68PY49S'?Z1FQ>NYR%.+Q9'.$, M?,=F-0O?,8_AEAS>I)CQ)GZU#!\HTX>_5P6D41A;)ESN4BC$U=78T.;*'C:X M7%DC5U&))0;I'+CAO8\M"?*ZQ):^L!#I?5%(UHJKW4P.CQC*VR<&61*T/,M; M0;N&6:05;)Z-T*+W18TTLJ-[QPA-&\R.CUEXQ,MFP>YZU-VUQ[PYZ/$=?=PR M<,G<(K2="_+/KA/Z2]:5K9&X[Q^O^NC,'96;P\I-%;!3\1J"1M]S5*L M6G80_X5+N?)^O-(M7+TYYA:VL%+>]A9NN6;VL)C0J>W'>;A#:R?L:-$M6R'? M>CFK3?B2#6K553JW7DC"M695KU56KYH[ "ZTIYVKK,QXMK1SU8;>ZJQ>.7,X MT&V'Q7RNC6?/'8_)ARP#\U9D-KQ5/E1]H29T:XP-[.?[,CD*I%RKM@LFM/2V MU5ZH_6QFV^H-O;$&9'VA_F1S(-&TG4+S,\W3WRX+JJ^O"FV\S7VE MK05BGZ MC6U>8WUM:..;5Z[JK)>&ZT%.2=42W? * MO4C'KE3;>K.V.F!7<;X/YGR_+JE/ 3YTOK[9@UU9W?>:-)ZO/7=H^3[5[+[8 MC==HZ>U6X7]=?O=6][]N<_?*F=GUA\-\7I=RP47JH%I,72]X^][7RNK>U\AZ MYJ6ZH962V2TO(N5Z4Z\WMQI.>&.;M[H/=GN;UZSI]5H1"]H4'[J%'?"!#?6- MX"VSG]4]KTE1^M7POED! 8WXP0L%:46O%Q&@%?9N=[*WS+^W M0#*M=5GG-DBFTM0KC9<%K39#,N](P#>'*W4T'QNK-ZV:9.T4D"+ MT]["T&-LEFO/=>#/ <70_:YCGHP,Y\'R>XYZC>T,["G8Z]G%PLWM@EK,[7]U MN#@7M;GX:5@4IL5+K"7WX3#@)[:[5V"$.7-AC?[7<$($&:SD FH9ICO%!#YE M'6\#PS$-S_2U^RDF/&E'W=O[C_-1%;&/(CRY- ]4H:I'&/6$Q7-K3Z9CF)X$ M=5.&@+F%W,!!N\-&8L<2KD>[&]D^O(%'J$U<$Y&88?BW]_,&V,*V)!(YRN?W M2@!G(_E:M7]9$I)U9" V>&!Y$X)\)RQH>(!OB6$,&,>9P23GH%.Y @%S9#PB M(*0&PP%.C@C4B! TM!T#6 6H>+Y$Z_7?,]AW;P&%AXX%M WV24S;Y]W;SYKM M^R$3QCRBQ#L74VXM2;CGT1;U'!_8->.!_3_9Y?S$LS X?>'ZH)=+PCUFRGT( M;=- K"EC.+0&B"+F/1B._1]!.D13(W=L*F0 _-4*&L0(8%D(/\RMM1QN# M=6&)&PUO/B:?)#Q!\; Z!*\5:$/#]K1'8QQ:#$HU8 &&SU=^XG@7XY'S2/"D M\!F)YN59?X4V,/KTQ%QM B,-883&>$PQLP$^:L!K-::UHN'$$[>5Q>6C)H: M1Y484P3=#DL;N![:@?1HST8\+SV"UP$)S^C5 K++@Z&X#N%P$$,(I_A8^HQ( M70,PV.#L+Z"\2_>1J^*1^Z6I#[0%PIPC!&G::AL..PW:'>*)9WEGQ+T<5+:& MZ^##:1G#T^,I#X@/V9(M.7 4X^VY1*B@BDPIOL6G"R'P-,8JWK.E*)"_TJ# M!$95(/NJ7!#>(99U_*Q92!D&C8[W5E'/ M3EP']1=&!+BQ_6^+8,]:KU1#_%2IYVMQB54@2$7!/'%%#D/H;5N#6P$IX@0> M!AS70WJ+ETWB2Y>D H4AP8%E/Q(_BPX=GM;O4]<76H\\SL"8!S.;(+BR!YN0 M5($F+AB\V""'%*<)]<^(KX=_#.I!P0C[R.@0\E",&GAOZ$M=3WZI=&#Q;&!= M EU3,/1G8L_X$."U'@H.\:8G8(DC6!6?)$NDE('H?-(F(;Q;7 <_THA &FE/ M(XLPUW >XF=_Y(8@:_L@OX"'.BAEX'+@_-0'1EDF99CNV![0LB&,MXMZ(XA& M?V1/65#A&_$%)%AFK#'T74>TI*) _@KQ*8*+/6.M2XB3L(#PW$@]TGL+>Z0 M@)YSPX!$$@D?7C%:3:$XT";+%^O8@N0)H;X,7KDA"T)O)6:*"WK=@'V&F,$W;'Z%V\(A[#AH& M3 (U ]>D,<"RZHF#T+? 2'V4JA01;GP*>)&-C/,%*PLKIBR3=O%A@?L@V$M"N9X# M$-S):BLQBQK^[QE-X?/S9U!O1S@EPO:E-!"1Q7UI!0(<...VN^L1!VVD;+J#T8MLE&:YO@T;I9E&9,H,^&#P1DR269PI+XN"24F@ \+T2]MH]]=A]M.F-QLHIF/!KV MF X9!3XG(%[Y9DRZP8 3W(>\\\GB),22@8''!TN#LXXG#DXP7#22PN?D"SCGZ/GVM$3>'S7D'!M">* MLE(6"(7GU/?:+*O4,+6)2X4Y+:",P*BH*=;(,/E>3NMZ)_&VZXA&^D3S*+K- M-"&1VC6G$V4S#1&T5'M:R607,6$ZC"!V!7VOE]M>/J[.5H5K"_JR-\M9;7=G MO:E[G5=E-D"E+=&6?3-1U+B]_7(=T5%WYW2R\;.^*@U>Z-13S_W3PG1D M3_LKQ!2](2O4,DM9+ *]%1/V,GTKPS# Y'87E&>11XG#BY>9<^T./J]Y5194 M7?C^B'P;G32_:40US;\8Q!ZO*SU0*@([H-@JQ MG ]U@/MJ.&#L( '_Z&N81!T2:AHM?QW1[*LNR% M[][&C')B@"EL.\P7SN%Y\*+2/[6GD3T840XK\!AM"OP K%FE- 5_ 2WMR?#, MTMAUOR$O4]@OE=X(;0GY$O*9!Q?4/EV;(A:SKKG]/UF3@K]MARQFJFGA\RA=LBWXAM1/JDR"0]''3&W,KD[UHL?)Y@U_8F 2+9QC M'!85Y0G'1.B3)$$^C8G;IH]<6]92R;1;62>E1[_ \V:_Q'J2V6\YCWOV>UHC M,^/9M)ZS7V.&-'8RR/@)Y<+ GB9_Q X(%/KP;:!+P\.-\!BU4>'T[^V@S*$1 MVWETQX\62V/*W+;];RPJL63( ZW"07\/"W<0P%B6Y00:YW[[VM$$Y3L04WS4 M^M8S4'FV4"8P>'>,J/#H@1H82(KPJ# 6R)S)/QS")LH>%G!HA=6@(<6 MCJ;MB(;L>=.CDC'I$^,33$^ PXGEH7F3G7V%F,B/4O-22ZZPYQBH7LPM\.+; MLQ.=2@4$+2Q\W'/9 :ILXZ+^Q.K@G ^QR[5-^ UH"Z9X2!0 M7@"GW@_):^C%LTX^[6>UIA"_!TUK3/4 'CD_7=^.2^'4!9!O^UE#- +\G<.8 M&#@!TY0XUIR;DM\S$@-7;_"DJ(HNOOS!&=@#48.O6X>BNB/1L>7/!W&8(2BR:0WS.41L7 @BT2MK"&IE\\RF-$)/A'S26 9!A"[ M Z\QHATGDPS^H*-).DBR7,AT85:H>9 I'AC?+'ZZY#_"N>Z#$6]/Z,UP_/K MUPW)KT*N]\FIAXB&UO$$Y\.I#PQ0 95EQTJEJ4M")9E9X[ MLW[BY+O/OT6Y=XD4OUF8%/&-QZE_\)5TVKPT+7-.-M]NDC)%%F"E@9M3;2Q( M XS_W&\6Y0N3*%=<]70*960Z+[-4B\QK;8;&==XF8E;V,!?&1Y!F>L(O-BU? MZ%=LYYN65[^?W?S>._OC71N2J6IZ0SNUQL83\G000E-1^DNR38]< :*&?B(=-$!P,TICF+BVCT3_'])+ M@.K&< ^A]L#G!PL)-C8K0[P#:!*&:K,6IIP&I(WHE$2$V \9@@5(W^7[X;)9 M>H\?"J\>8>FZ'(@L /<5ZF95#PD:GO?D>F/S":EF2':3& %V"$>J&F+21%82 M.55J@\YOCFGJ0IE%>^[!WQV(9N[>] MA-X9;Y/D.YRGH%B-IH5CX<)UU*LY&(C3(=U2^-13=J9JF:'.:7V?&GF&OMSN M+-9UK'T53H/L@G[YBI"7/>)#"3:)OX!BZUN1QFX)/!:TU,;(B.-]Q?EXZ"($ M&\VSB%X#:R"5;/&)J#;3=GR_AS]BK5KN3K/YF!(J$>L] 5T1@S:VPWQ GFBD MNNA4QAL%+V(&_LRR(,IK)N0>EKS#<#PN$7V97OB @ 1@(!MC3+R*)2>A$/$# M<=3WCHU?D<>8CC2:=^J=>%WH.4 @,]+,E9,C-QC<238["M/0(_B,D3N15,B+ M@= &)43 8'DL!%CD18,GQF:U9CQ8#C\Z7@8#IBNXD,GZ.!7&JL]TM%?XS0!1VDG4^4XADY]#"MRA'H+[ATT[$Q MX%V0IY^@;V+%R$ H[Q 4#^2D2&69ADCBYB31$D-.$2X/BFX*'?NOT$+O)Y(4 MF-8PT8'@DJ9+KC.ZF"DRFHB+1/6K^P3JB:<+Q,?HZ>@;I)N R).WX?S)1YAB M9Q%4'[XOXFN(+3GS6AD%S%=:4.>,AC ,G0&GXPK/NM H;!4@4(:J%CVZ\,L= MB%^N6?CEWI-?;M]: 8%I/3CP"E\VST7H-(>RRV3VF(LP8"@*U2@5LQ>"ZK(M M\R?MR/A(7J/0(.EJH8XFPG5&A/?E822*-%/K._!CH,VC_L>D[H?@:E/+5'1Y M&H\H58CR%I10!N*MR7&P#HPI10S]B6A>, )$'$48MHC'1IAC'*8Z&F#4F&PS MSN:BL*F #45_ "(UFL=:UV%,-(9BHQ >:O9 (XO 21%ASOB&"\L1(YRP<%'Q MXJ I+@0HU6^*N@S&0>6-H=P\L5WF^U5'KAY%C(DA3U6]),*$$WC E$" D3I' M8.J2I8YB6"8=!# M1"V=8'@>_L7X/*$/8CP2MM)"GYYZ%[XN>'+37JI$EH), M(U'<5(QGC:^4/T:F5@QW':D=\&Z#(I327)0>A3E^CVG0UX5:9$^<*" B6-LB85A8S%,&-G.MVGP!,S MJ*1\,!5DD8T6 ?QR/%G&QU,0O\308*ULY)(P>X_!^_FX*JN6M=@D_!!-JE4SOFLSD?HILP('K@5A\M+W0 MCU.VCZ)<._&-Y&D?-0F;2K)7$$JV(TC)X" Q&(.HJO=%[\0J02"!"#^5Q"@, M'*M1@/A 3 [)60%G98S.7(?GQ0GQ'E 8%LC(VAC4N@FW8=;836*%\FLDVFV& MS'^7;0(J/,%TBM:Y!7,-)-\3G.T_Z M#.U $!?M03@5P_HK!#N?'#6]@"9(;AHZQ#3BB&$C=>!X%YC 0J(8B.;K8<$^ M,2PO''S33 \6V8OF@"^;6,@_: JF-09C",<&TR*7D$?UM%-[\ V6*ISJE-^" MS$]61>2/@OQ-:J4NCIQ=JKGCPKV*D/"%LXO@A$$$N(2_KJ<=X7B+24403PQ3 MJP$]$[J^[8! _(^5J%QP%"3=/C(_"K?$WW'4&15.7 _T(Z-+SS),C6&'%6%- M Z>"710R[]CU=2M/>R8]+.%)U8X\:VAY'N\YYL':CIH1G;X^YIO(WN+#DL%$ MI.\RKIMQ!!(,^HE8B/.U0CN(N*#TW2:X(56A1N2_=!?)@ ML4%*P4HW3.JI[YI*,B1'7 WQS,8ANCKDJ10E"VHQID)I>?JG6M;@991A*DK] M?$TVDD?,#B*!.4"0,Y!0Y UD!EF9X7FL\X>.4FF*3E!,_S(P0QI9DJPY$O&: M/P6_,6AQGJ0Y/G\5GMBT6*$X-7M1,K/)64-E4\/P/&K7Q@VA!/L5#:I0.@28 MBO-7:)NB[J#/0T8/A)0J6<9B$6LZD%A3JX@UO:=8T_;*BV=SP-LR!_SDIG?7 M.^E>:-V3DZO[RSLL,;Z^NNB=],[>=X&Q<+>-73]V2\VP\J[C8*[@#=4%(L.7 MY<>_15CFA@*UBKVQ> MG[?8-2/!P:8>)HOR"L!K,'2!PH1,Q_M;[4NW>\V"BB],N:@S<2U$5,%,:YH3 MXULL?WV!)^&'DZG2C%&I+)N5?BSY=)!Y48]G7<;F?#7<( LYY<;F#57F"N8/ M"MT]5&\I2\'I"LP9&5O?=?'!$1 @J'0GJUU9$1;%;$H%6^X+! @#%=.:YJCD0ED$++5)>8]BU:#YZ'&1>VSIOUN];LE;2 /,XR<,GO&;N8 MDT7!60PF92!R"$G&>O/Y&[V64[2!I.+G9/,JR3J#D0V6A_!X29\&/8L<(-(9 MF^O^B"X5[5[SUB%N/.>AMY59W9\B?8MYW8?E@$T\[7IL. GTD@\2K3$M17Y< M2GS,6U<.19+7Q*)"3PF"(9:,0L7T:#@N$3H#6DY11!O>$C6 3OS@C] ;A/[Y MZ ),,D[>'3IH@25+6A7$"<6-R@9]XN[W?3KGY/>0(%@8QM)SBKZ D7HT'V)_"^,D8T3[M_B4Q!!>LVJ:#G5:_^*DEMLT4P9TX\HD0&UG,1DA4K',.[\ M-,D;9)]+6A!K9DE '"LNZ/2T3 MVG3&QQE%@B_%O'5?=%>'&0+=NAG\0&$Q, M&J*])W-V*JF(WOW@8FA?,(Q YH2;ENB87#"#I:(#*CT^VH9$]T5=V(9C&4Y= M<22G 2?V99U>COSH5 ]'BJ-!A53JQDZ-9YG2I3*SD&&>8AB$PR M^"E#\1&$C"PR(N8A>D>$GRTB;&:,05Q41#%C8P+*!"D$C*E/!-!];')!VH]DHJ 3,:?Z1EBI3,V!I5=(.<2H)]9<$?CIOFYNSV_N+N M5KLZUZZNSVZZ=[VKRU?HGZENCF\B3N'RS;J)MXB&*8>R;-O&*V=^.M^8BG.1 M^L_:W]KUFEYK-[6C6O.'CZRNL@ M1I#_L8WLJP'^6*56Z^']G_9+ D6D9;E(2[N(M!21E@TOPE,),/3PTX,&=SU,;$L9BNJ-9#O#'C.@O5]MZO54#T=]NY6L;6>_/ M$/O![#RT)X/SU!1H!1<-E.@^>-K?.NV:7F^BRE-NPRC28GW6,I? 2PFT)7PR M(;%\CD)L68@(R2I?7 >X*6KG+=K FWS2S!Y15Q#]U00A-G-I6- MD1K@"72QR,64)>@SIREV>^JP""G]-\JE99>K[>!&52J M/WR4Y2SSES7SA)Q[$6PV+WM>]\7,%8Z3\64>+'.K5A5&5]:.&L C=NV$*$3M M>J*M?V"B]A+4O1*9F%ER-M<,W8BL;96;>AFE7*.RHF%/@=/YLB8M4BMZO=W4 MF\TZGY=Y0N='++D).#MX+FQ8)& YUP3?_BP".)'78=8-P#>IW?3F6/N&'Z^" MX<]YJF!Y"0XJW:QR@0Y;!&];.!Z"@,ZPJA3G4"XM1#'WC0AS]@R%7KZ@T=,R M$04YGJ)JI:/7RU40X.U, 9YY6M,\9AU)_ILNA&A"BN<)\;]5ZV6]TVZ ITG MN!3##ZB6_A]A"*: M=1K#9XN[?7"* 05++<[.[,=ICC)N2#4,[L!FR$([XF5YI(UH'SD!0UU+@EC& MN(>ZF@VV9)&>%/^4SN6KB5<8],5PPR_V)R6:^A$'ASS+*M&SG5B$L'21?2DS>D\F.7<'C*0R M" *,'5%;STJKK=<;'>VHCI(AV<]TN3B/KRJBF$8BWR@*)6=TT?AWE*&@AK8: M%65$U1J,L5/C;^R9T'-,+$LM3'I.>>O$6JM:64G$(J>(.F,\"45[C*O;'AD8 MAFLM49M>0ZA)\L\T]M. X' E@BTKV4 M33 B6)6B'.M @H2=(DA8! DWIQ.E98(JBUXHETFBH'B@C&QW.,2>9F1=JB], ML7-96C%7,T.IVFKJC29ZEJN16*W6]$X#OZJE)7U2]DE.YR]0 (EW)HV/;-5O M _ #,MG/0@AOZ0<_C:4P%DG *O9#.*D.%;K#"T,O LR.GBWG,M," SWT6&]L M/+-1P/F^4WY]"@+,XBE1>11#RCQ1^;[$@^&:^ A!.96-&V'6T.OD0EBIEEJP M+E>#P%5(IIQX$,>N9(46<4TF29XJ N@A[$(\\UO9Q>OHY.OM1[D344],6DFI MO-!/F?O1!<.4P2HZA9ITR92$!)$@'(I,3_>%?G$0%OIN4ZT%Q^VN;28)74T:L)BM_SP5!2]&2H$4GBYB MIZC<(6:6(!')8F-.%P.YX_F*.AX0^AXQR-^[A)#]8*'$A\_1$13<1A=34ADI MD7-(A)*;?LNZ=9IW'2MQ_W4DCP3D5EAY*I!6URN5)@B*2BP[FGJGAG[.I:Q$ MQ>V9T-'MM!VU#>D1 =9TQ[,P9(S[$'-J0I:4C??D(TJ2!,21%JANR.;Q;I5_ MT\T"&4XI>V133*4@=DC$;U&)(X.B%')"20 $)E@4];#(HY>#X!K;4\EF4Z]K M:WCYOHJ*K*-9X+&X.&KEU*XWS)'G8V3-8+4E>4FE5=,K#> 2PIJ=ZG)I-.5,YV!J6SCU4]PW7R>[:8V)4&O?WIM\8) M#A)&3/$W>98"39SJ"$$3[Y-B2A-/FA("'HY5C2=7RHDK5:6&5U! MW(^%^K0 5\=3+X"'I2<$P3^%]Y)T\R6K 0543:#5JS\<+Y.8.5AN0+'50A(% MGAXIWR![ZA7YL7+H-O8>CH6 T0%-X$Q@=Q5G(^MLQ.LD,D[D6"RN#US.L MZ6MW9NX99K7E67/LZE1@S'CVW#$OC_Q;VH/J\JKV,%N@$:0:HV\\( *Q&\?V MZ5N'@>K4K.3,A3S69C>54J?4)@7,[(2SF=#GQ:YC&$4N.E]D6E$U!":X%LQF MAMG4Q#3PZN9;B,IRB.&@9CAX)**GU*$CYB@[60M-D.\AE>$WK/VV1Z/_920'[M/Y+VFWIEFXF8_< ?? MF%VYV-(O)*#7(6R7@FDBFZ5D,:-#H/O#XA*7H"1)#8KK54A=\ZU!Z!&Z[ROB M&CL4QPN7+7W\:VV]UD!Y7*VNKGA:T>)C"S;Y.XI5-6%F+>9[T,KT"]G*KNGS!WUU^.6SB MP!$E+%$'FTP$5& 50R=](JEJOP9J>3W.1YN"4$4O/#O?PND3@@D*TC1,7&Y2 M0P2!1;T4D0[=5$59-IEG4_;,Q%2P4JKF/ "2+N(N.7&72A%W*>(N^U(RK[%L MU9?=CM5N!EJA7F9)/R67!M$;HM3K>.DTZJ1%:MX4&/QW@H8=/\-!_V$)JT_% M[,_*V93/3W5K%8Y0D KJ:V0W7J4)RT%H,IL^ TSV%[U_WO=.>W?_TKJ7I]I) M][IWU[W0;LYNK^YO3MYM.Y\\0D80=\*U-J9V0"#'B3#=WSIZNU;5:]4F$M5, M80'2'.@_>K51USLUNB:[@'$&&Z5:U9L50=Z2/HDUI0.%[6-Z2R7W_:WC9G1! M7M6IZJU\2LUXF5R8;,V5 D?<<,47/0#PDMFLQV!FDIDO3?AOJ)60G6PM(RI! M$ZUG4B.%\7CAH?E=#X36\Q,@T;1,TX4MDL%G4M+[%M8K8$-P@E-!Q/!P2@U& M\#%Q'"[150)Y<80LP8;1=_CCR1H_2N:_H->AS(7GCC-*UR Q7MIQL!M"3RF= M2P2]#B:Z?H#TP,%@%*,#PQ^)K#>E-^40$P*;];;>JM=%R8;>J2*F5#V10"T% M>6Y5(MX[\W4YJUQ0/=:9@UJ&<\4E4,7.*TDTN)RAZ&G'C;TH*P#7GWG[ZDGQ MM!T@VFIU()0&")XMO*0L7U)I-/1.NYDBE&4(@HQ_T0F#^TP@](T7@#B9C@U1 M=HBZB@+5ED(H,\V"*/_9009C/$4'7D'I8/JY7E2^5C"[\J3WS4R%_75^KGWN7G0O3\Y*M[^>G=UIW9N;[N67LZ]GEW>%N9E/\B,NZ7>'0ZUOC+&, ML^2/+-!7 L]P?&.@=#S%EIDZM=;R9$B-.I8)3!D@:[["B,PL;";.'=#8.9/? MAWRVOZ.N@MID_A[U4W4])1\G%Q= MWMUT3^[NNQ?:U>>+WA=NX\/>FJNO7WMWQ<')/C@JFCHWV(HZ^"J(&C8(?^Y? M%\1=AC'U%;&>X2*^AWN9X5DXE!:Q:U!;AON[T4D7J-$W[! W--O\QX?K2J_V M@;LJR@\CSQK^X\-_PU5_-S[U< %KQ]H_[[N7=[T[(,_?SX@ZX8L+^?FT=WMR M<75[?W,&E/OYZOY.^]J]^0V8_TWO]K?C@GC?+O$6$Q:/KQQHI$U<7K#UV-=3.(T-/_*:3A6IA,J$AD[E,"T,O>FS?L5\E M2@!P+#\?R041J<:NSVVYGD@)BQ>%'?ICJ^0G;JY:ZT H+8=_--!=-8)6*#" MY.84L9E)4>3IV4?6"Y\6ST;=!W([NW[4'1D>, IARS3+\UPOZD,YL+U!.'D4 MB'G8.1<(P+--4;['T B9+TNA^Z&!KN1E++'T ^HE/'Z6C:IB/X/%G=&Y43LL MPP#HY5%,RO;D S6W_R>_S9<=L*@3-2TE$Q&UP>*N[YSNF WXLWE"%@"**5Q% MZM,@5E7@/M(V<0B"$FWE,$$E%PFRXV>AA.>T9%EBI:D:0<8 MK6) 1*:!Z#/-[XRS>WF$Z-P9H_T BF;8!_K&4ZR>,+PT<8A$$VV0X:;.(_9] M_-,/)QA4^8]ERJ;;PG3!O%29QFPK]0SH;;>'MC*B<"SB]]QG6JSU[=F);#L/ M4R04/'6>V*]Z R%U/.WJ][,;[;QWV;T\Z5%"V?75S5WO\DN4 M(%FH>=M3\WY#^$JRVOX5$2@[.5]HU48\](->47N>[> MW&F]GE;2KNY^!7[5NSR_NOE*$99#\4EO+_-]F:7K593%PP])M]+=V5>M0NY[ MGLJJ_\7\X[,O(![(&7!V"O+A8")96^T'U5&&H6WA?Y=7EV<'OH@[H=YN@GR[ MF?3;79J X=D8K]+.NR=W5S?O@U*595T!J^'K-2R1=G4.ZN#OO=-2I?.*ZF*V M!-:0"O75$6_S!0 -72R(3F*5RR)%73;=0UB?<((-(-0,QJBKGPJ1/"9E3U%6 MJ&>C2(?+Z!R066"Y=D-!O'C,J=X(#YHN+I8MIOFQOM)"G2&:"'\=C'[4/AET M5X$!)M!0!G)RO70]9R(3"]L\J-/BS@>,$Y]JFV!]1U]'7%P ]XF^3(GWXK+Y M%BK*ZL@4Z/08EYA#N+X[?J00;V"/54?3/M >BLAM3N2V5D1NWU/D=B=9(5G2 M062")%#$(\:5EZ#'##C)R!&GQW*L"%)"X:>4+3N'*W/-91H2@]BN/T:ZQ,<3 MP@WA ,VYJZSUXX:>\3Q,VW3DZ FZPJ:$EY0DXC580[C$G'1L!#@8M;CS&Z)']!67 M52;I8$D0J6/M#^HH;5.( D8/C"EP@:A D'61L.X!=KZ(3%U<^RW3>G/G8 M!"M%$.E1V0L#4873*2[O",NA3=OWPJD(3[""0KXN506*-PA>],UXD""A41<% MT:-&[<49[7D$@8LKXQE/D8O.3_10"YV!Y04PH@#4*Y@8"CGIA#1#+]'L*IJB MS*87*R#>B/3MACA[X >>S4/AJ25@>["(L!_Z-H9PY2Z;-GI&4D9P@J,64EYV&S7>K)7=)7R6E5J=Z#D5/ M)T4WARSI^V6;J] :C83VFM1OHU8@V>VQWCNKS*Q=C7O,14PE11+LP::%-41J M +9WZ@<$Z*H>)3H)6,U*/XEECS(PDF8/;"R0BSW%$AA.J"=:G^"O8AM3Q_17 M$/F/&.><2R[) 1$3P51^.(!PM#'&;0\4+$W);."0CDU)F@QKY81#^, QB 3W MR&W*%C>I4$Y;LF08ZW5HEL^T^'#:)++O%%1:T,Q=P=0PQAU.(],S-6C3HN($ MS+@0Y8*B!6_B94K!DO*BC/T!'O]HP6JE2J:Q(9QH,8&\1$:'^X9O1XT"+?EM MQ(47+@]./B6OHF,L$BZD3/%'KB=KH (O''S33,]^?,7%2FM[%=6 0B\=4B"? M8O58>Y%3_/[RYNQ+[Q8LQ+-3[;9[<7:+OK2S?]XC3L?MV^N=\9Y=/>W M9_!C_#JX77C3WZR#,K]\(<.O7KC"B4YK*M'.U' @T=9>2+2G9^?=^XN[6^W^ M^NH2J/2R=W6C$&M!C 4Q2F*LJ\0XDZR.Q%A_(3%^[5V> ><\/P.&J10?%43X MAHDP364-E"&5O<:L@9?15[-]$/14Q"9R8A/U(C;QGF(3+S)[TORR MJ?++9A:_;+XLU^?L_W[M?>XM4ZS^TGEEIB0OF8>\L3R!59E1=B[SIH?U86$Z MJ8;YI'+TU1]2O.=%KUXAJ34QBM9&1[&[I!#UB'_ H\9GROK^[UJY5NXTCT?! M)"*\DF\-2L &/&,0_&1]']E]&^^J58XK_X-'/%.<&$P?B2C M!;]9CO9E[/9#&,ZU9_D(#<0H7O,RII..-#U1%G,K'/RU[[P7"F]E)LO6#JZRY=@JE'.5/K M%C8NP^NQQ>A"7G]<,/N"V1?[OIM]KY0KQ[W+V__9^\[W'"IQ^;_/-Q=:S_$# M0MHX=0( M-&E,NZ+7!<:#:.(]Z5NFF<31L)5QR?=E5@47!+HU KT]^?6P"/3.^([-\9Y! M1 :60YVJ;@+[N>#IY<+HV^-"U+9-ZEC,K'7,HJ".%5N&#VMTTB M3:X$S_])(Q+TW;%MIG$[,E=QX&(BDO./#]4/FN<^\=^5#[O>XR6G\#]TY$P- M2U[QM*V%09;(A^HD=G;_Z;/+%P96EW.!:QDYGFKVW2W\8%!_FR@'3_TJD8EW MV_MRV;U[Y=GLB7?TJ'H6:(^\9E%M=Z(CJ'3+S\=SUF%VU]5OZZ*K M9L=MUF ::E;C2N"K6H/N )D-8[@$@4Y-]SKW=G MIZ4O]]V;TU[W4M=ZER?'V<))OK[6ICN7%2"+677VR-:$;-..;JP'V\=N7L'' M YK(^QI*\IGU*CWR\_-/B:U*?)C[@$JK3D]8 3OM[[=_UWX[N]2^7%Q]OK^- M<-/V,_,5IA@G5KZ"P4:9G^^1Q@]H*'G';1N'JGMY>G/6U?YU=:^@4!\\I:J) M;*]@N#G9%R\<^7X1C952HHON[5TIKI3*+1\[M+*PQDIE8=%?8�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end